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The genus Flavivirus in the family Flaviviridae consists of many medically important vector-
borne viruses, including West Nile, yellow fever (YFV), dengue, and Zika viruses. In the recent 
decade, these viruses have emerged beyond their historical geographical boundaries, causing 
outbreaks and posing a threat to public health systems. Despite their medical importance, 
licensed, effective drugs and/or vaccines against these viruses are lacking, with the exception of 
the YFV. The live attenuated vaccine for YFV, strain 17D, is among the most effective viral 
vaccines ever developed. While this vaccine is relatively avirulent and highly immunogenic, its 
attenuated phenotype was derived by blind passage of a virulent strain, leaving the mechanisms 
of attenuation unknown. Moreover, 17D has been engineered as a delivery vector for 
heterologous antigens. Importantly, the successful and safe use of 17D as a vaccine vector and 
the development of live attenuated vaccines (LAVs) to related flaviviruses requires an 
understanding of the molecular mechanisms leading to 17D attenuation.  
Using subcutaneous infection of interferon signaling-deficient mouse models of wild type 
yellow fever virus (WT YFV) pathogenesis and 17D-mediated immunity, we have investigate 
the role of type II interferon (IFN-) in attenuation of 17D in vivo. We found that in the absence 
of type I IFN (IFN-/), IFN- restricted replication of 17D but not WT YFV by 2 days post-
infection. In this context, IFN- responses protected 17D-infected animals from mortality, 
largely restricted the virus to lymphoid organs, and eliminated viscerotropic disease signs such as 
steatosis in the liver and inflammatory cell infiltration into the spleen. In contrast, WT YFV 
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caused a disseminated infection, gross liver pathology, and rapid death of the animals. We also 
uncovered a mechanism by which IFN- can restrict 17D in human vacinees. IFN- treatment of 
myeloid cells suppressed the replication of 17D significantly more than that of WT YFV in vitro, 
suggesting a direct differential effect on 17D virus replication. Overall, our results indicate that 
an important mechanism of 17D attenuation in vivo is enhanced sensitivity to IFN--stimulated 
responses elicited early after infection.  
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1.0  INTRODUCTION 
 
1.1 FLAVIVIRUSES 
1.1.1 Classification of flaviviruses 
The genus Flavivirus belongs to the family Flaviviridae and consists of over 50 types of 
enveloped viruses with a positive-sense single-stranded RNA genome (1). Members of 
Flavivirus have a wide range of vertebrate hosts including rodents (2), birds (3), primates (4, 5), 
bats (6–8), and ungulates (9). The Flavivirus genus includes many important pathogenic viruses 
that have shaped our history and offered valuable tools to study biology. Many flaviviruses are 
transmitted between vertebrate hosts by specific arthropod vectors such as mosquitoes or ticks, 
which likely limits the geographical distribution of individual viruses. Ecology of the vector, 
such as feeding preferences for specific vertebrate hosts, and constraints of the vertebrate-
arthropod transmission cycle limits the propensity of these viruses for mutation and altered 
virulence (10–12).  
Historically, flaviviruses have been classified based on their vector competency, 
vertebrate host, antigenicity, disease inflicted on host, and nucleotide sequence. Flaviviruses can 
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be broadly classified into mosquito-borne, tick-borne, zoonotic without known vector, and 
insect-specific viruses with no known vertebrate host based on their host and vector specificities. 
In support of this, a comprehensive phylogenetic analysis of the nonstructural protein 5 (NS5, the 
virus replicase) sequences from 73 flaviviruses has been used to construct a tree that clusters the 
viruses according to vector competence (1). However, classification based on vector-competency 
is inadequate because mosquito-borne viruses can be isolated from ticks (13), and vice versa 
(14–16). A more functional approach to classification is cross-reactivity to neutralizing 
antibodies, which is able to predict relatedness of flaviviruses similar to genetic phylogeny (17). 
However, antibody escape mutants, lack of cross-reactivity, and low resolution of the assay may 
complicate the analysis (18). 
 Flaviviruses can also be separated into two groups by the disease they cause in the 
vertebrate host. Hemorrhagic flaviviruses include yellow fever virus (YFV) and dengue virus 
(DENV), which cause viscerotropic disease (tissue damage in visceral organs such as the liver 
and the spleen) and potentially hemorrhagic fever in primates. The encephalitic flaviviruses, 
including Japanese encephalitis virus (JEV), West Nile virus (WNV), and Murray Valley 
encephalitis virus (MVEV) cause encephalitic disease in humans. Interestingly, among these 
mosquito-borne flaviviruses, disease manifestations are also reflective of the virus’ natural 
transmission cycle. For example, the hemorrhagic YFV and DENV have a forest cycle that 
involves non-human primates as vertebrate hosts and Aedes mosquitoes as a principle vector 
whereas the encephalitic JEV, WNV, and MVEV are transmitted between birds and Culex 
mosquitoes. While both YFV and DENV are transmitted in an urban cycle between humans and 
Aedes aegypti, it should be noted that DENV is adapted to humans and does not require a forest 
cycle for maintenance.  
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1.1.2 Virion Structure and genome organization 
The flavivirus virion is a 50nm-diameter particle with icosahedral (T=p3) symmetry and 
composed of nucleocapsid encased in a lipid membrane studded with envelope (E) and 
membrane (M) proteins. The nucleocapsid consists of capsid (C) proteins and one copy of the 
RNA genome. The lipid envelope, derived from the ER of the host cell, is embedded with 180 
copies of E and M protein (19, 20). In immature particles, E and precursor-membrane (PrM) 
proteins form heterodimers. As the virus particle matures in the secretory pathway, the PrM 
protein is cleaved and E proteins form homodimers, which lie approximately parallel to the virus 
membrane. It should be noted that expression of PrM and E proteins results in production of 
31.5nm-diameter sub-viral particles with T=1 symmetry (21).  
The flavivirus genome consists of a single positive-sense RNA molecule of ~11kb in 
length that has a type I cap at the 5’ terminus that is immediately followed by a conserved stem-
loop structure (22). Most flavivirus genomes lack a poly-A tail at the 3’ genome terminus except 
several variants of tick-borne flaviviruses (23, 24). The 3’ terminal dinucleotides of flavivirus 
genomes are conserved 5’-AG…CU-3’. The flavivirus genome encodes a single polyprotein 
ORF consisting of 3 structural proteins followed by 7 major non-structural (NS) proteins 
arranged in C-PrM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5 sequential order. The 
polyprotein is cleaved by host and viral proteases during of the viral replication cycle. 
1.1.3 Virus replication cycle 
The replication cycle of flaviviruses begins with attachment of viral particles to susceptible host 
cells. The entry receptor(s) for flaviviruses is/are currently unknown; however, integrins, C-type 
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lectins, and heparan sulfate have been implicated as attachment factors for various flaviviruses 
(25–27). After attachment, virus particles enter the cell through clathrin-mediated endocytosis 
and undergo membrane fusion as the pH of the endosome drops. Membrane fusion delivers the 
viral genome into the cytoplasm where the flavivirus polyprotein is translated by host ribosomes 
and then is processed by host and viral proteases in an ordered manner. The NS5 viral 
polymerase synthesizes negative-strand RNA, which is used as a template to synthesize positive-
sense genome progeny. The capsid-bound viral genome buds into E and PrM-studded ER 
membranes to generate an immature virus particle, which goes through the secretory pathway. 
PrM proteins on immature particles are cleaved by host furin as they mature and are secreted 
outside the cells, which completes the replication cycle.  
1.1.3.1 Attachment and Entry 
Flaviviruses, as with most arboviruses, have a wide host range and are capable of infecting a 
wide range of cells from different species in vitro; thus the surface glycoprotein E uses multiple 
receptors for different cell types and species, receptors common to many cell types, or a 
combination of both. The glycoprotein E is responsible for receptor binding and entry into target 
cells. C-type lectins such as DC-SIGN (25, 26) and CLEC5A (28, 29), and phosatidylserine 
(PtdSer) receptors such as TIM/TAM (30, 31) and human Axl (32) have been implicated as 
mammalian entry factors for flaviviruses. 
Upon binding to the receptor, flaviviruses are endocytosed into clathrin-coated pits, 
followed by membrane fusion in pre-lysosomal endosomes that release the nucleocapsid into the 
host cytoplasm. In the endosome, pH reduction triggers conformational changes in the dimeric E 
protein that re-configures them into monomers and then trimers. Changes in E protein 
conformation expose a fusion loop and provide energy for membrane fusion. In contrast to other 
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enveloped virus genera such as Alphavirus (33), the pH threshold of membrane fusion by 
flavivirus occurs at a relatively high pH of 6.6-6.8 (34, 35), suggesting fusion at the early 
endosome. Furthermore, membrane fusion does not require cholesterol or sphingomyelin but its 
efficiency is enhanced by cholesterol (35–37). In addition to using the conventional entry 
pathway involving direct binding of virion to the receptor, antibody-bound flaviviruses can enter 
susceptible host cells using the Fc receptor in vitro through antibody-mediated enhancement 
(ADE); however, in vivo, ADE does not appear to be a major pathway involved in flavivirus 
infection or pathogenesis with the exception of DENV (38, 39). After membrane fusion, the 
nucleocapsid is released to the cytoplasm and translation of the viral polyprotein is initiated.  
1.1.3.2 Expression and functions of viral proteins 
In this section, the function of flavivirus proteins will be discussed. The flavivirus genome 
mimics host messenger RNA in that, upon release of the nucleocapsid to cytoplasm, it is 
translated. The viral genome contains a single ORF encoding a polyprotein that is co- and post-
translationally processed into more than 10 proteins. The three structural proteins are capsid (C), 
precursor membrane (PrM), and envelope (E), which are necessary for packaging viral genomes 
and forming infectious particles. The nonstructural (NS) proteins are ordered as follows: NS1, 
NS2A, NS2B, NS3, NS4A, 2K, NS4B, and NS5. During translation, nascent polypeptide is 
inserted into the ER and cleaved by signal peptidase at the junctions between C/PrM, PrM/E, 
E/NS1, and 2K/NS4b, whereas the viral protease NS2B3 complex cleaves NS2A/NS2B, 
NS2B/NS3, NS3/NS4A, NS4A/2K, and NS4B/NS5 junctions at a conserved basic motif. The 
enzyme that cleaves NS1/NS2A is unknown. Genome architecture and the topology of the viral 
polyprotein are presented in figure 1.  
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Figure 1: Topology of flavivirus polyprotein organization and processing.  
Image adapted from (40). 
Capsid 
 The capsid protein forms the viral nucleocapsid, which consists of multiple copies of 
capsid and one copy of viral genomic RNA. The capsid is a dimeric protein in solution that has a 
basic interface formed by the N- and C-termini and an internal hydrophobic domain (41, 42). 
The basic interface interacts with the 3’untranslated region (UTR) of the viral RNA and hence is 
responsible for packaging the genome whereas the hydrophobic interface interacts with the viral 
lipid membrane. Nascent, immature capsid peptide also contains a hydrophobic anchor sequence 
at the C-terminus that is necessary for peptide translocation of PrM into the ER. This anchor 
peptide is cleaved from capsid by NS2B3 at the late stage of the replication cycle to release 
capsid into the cytoplasm. The nucleotide sequence of capsid contains a conserved hairpin 
structure that directs ribosomes to the correct start codon. The capsid suppresses RNA 
interference in mosquito cells (43); however, its role in virulence in mammalian host remains 
unclear. 
Precursor Membrane/Membrane 
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The M protein is translated as a precursor protein that functions as a chaperone to protect 
the E protein from undergoing conformational changes to the fusogenic form in the secretory 
pathway during virion egress. PrM is cleaved by a furin-like protease to M protein during 
migration through the secretory pathway. The C-terminus of M also mediates apoptosis in vitro 
(44).  
Envelope 
  The E protein of flaviviruses is the major surface protein responsible for binding to target 
cells and fusing with endosomal membranes. Crystal structure and biochemical studies reveal 
that E protein is dimeric on the mature virion surface and contains three domains. Domain III has 
an immunoglobulin-like fold and protrudes from the virion surface, properties that corroborate 
its function as the receptor-binding domain (45–47). Domain II has an elongated structure that 
lies parallel to virus membrane and contains the fusion loop (nt 98-110) (48). Domain I is 
situated between domain II and III and has a β-barrel structure stabilized by disulfide bonds (48). 
In many flaviviruses, N-linked glycosylation in domain I masks the fusion peptide (49–51). 
Many neutralizing antibodies against flaviviruses are mapped to domain III; however, antibodies 
against other domains can be neutralizing, especially those that bind near or at the fusion peptide 
(52–54). 
 Multiple virulence determinants are located in the E protein. Mutations in domain III (E-
303 and E-326) are associated with enhanced neurovirulence for YFV (55, 56). Residue 380 at 
domain III is relatively conserved among virulent flaviviruses. It forms the RGD motif that is 
implicated in binding to integrins (57). A synthetic peptide of residues 380-389 in DENV E 
protein blocked virus entry into mosquito cells (C6/36) but not mammalian baby hamster kidney 
(BHK) cells (58). Despite conservation of the RGD motif among many flaviviruses, mutagenesis 
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or blocking peptide fails to inhibit entry of other flaviviruses (57, 59). There are eight amino acid 
changes between Asibi and 17D substrains in the YFV E protein and the mutation at position 380 
is implicated in virus attenuation. Detailed discussion of these amino acid changes and their 
implications for attenuation is presented in section 1.2. Nevertheless, these findings suggest E 
protein is an important virulence determinant of flaviviruses.  
NS1  
The first nonstructural protein, NS1, is a ~46kDa protein that is retained within, secreted 
from, and surface-associated with mammalian cells. Intracellular NS1 resides in vesicle packets 
that are thought to be site of virus replication and is necessary for synthesis of negative strand 
RNA in a virus species-specific manner (60). Trans-complementation of NS1-deficient YFV 
replicon with DENV NS1 did not rescue virus replication. Interestingly, a single mutation in 
NS4A permits YFV to use NS1 from both DENV and YFV, suggesting a genetic linkage of NS1 
and NS4A (61). Two conserved N-linked glycosylation sites in NS1 have been shown to be 
important for RNA replication and subsequent virus production (62). Secretion of NS1 is 
regulated by the short peptide immediately after the signal peptide at residue 10-11 (63). 
Secreted NS1 activates complement with NS1 from DENV, YFV, and WNV binding C1s and 
C4, resulting in degradation of C4 and suppression of complement-mediated neutralization of 
virus (64). In addition, secreted NS1 from WNV also binds factor H, a regulatory factor for 
complement, and inhibits complement fixation (65). Association of NS1 with the endothelial cell 
surface and its ability to alter endothelial barrier integrity through modification of glycocalyx 
suggest that cell-associated NS1 is a virulence factor (66). In fact, flavivirus-infected humans 
and laboratory animals generate antibody against NS1, and some of these antibodies are 
protective (67–69).  
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NS2A 
NS2A is a hydrophobic integral membrane protein that interacts with NS3 and is critical 
for packaging the nucleocapsid and forming the replicative complex (70). NS2A can be cleaved 
at the C-terminus, forming the NS2Aα protein with no known function. However, a basic residue 
at the cleavage site is necessary for packaging nucleocapsid in YFV particles (71). NS2A is also 
implicated in inhibition of interferon (IFN) responses (72, 73).  
NS2B 
NS2B is a cofactor for protease activity of the NS3. Ectopic expression of NS2B in E. 
coli enhanced penetration of impermeable antibiotics (74), and trimeric NS2B lysed red blood 
cells (75). These data suggest that NS2B can alter membrane permeability, but whether such a 
function occurs in more physiologically-relevant systems remains to be investigated. NS2B from 
DENV interacts with the innate DNA sensor cGAS, leading to its degradation and inhibition of 
apoptosis (76). 
NS3 
The NS3 is a 70kDa polyfunctional protein. The N-terminus of NS3 possesses serine 
protease activity that is activated by NS2B and is necessary for cleaving the viral polyprotein. 
Similar to other serine proteases, NS3 contains a catalytic triad and possesses strong substrate 
preference for consecutive basic residues (77). The protease complex NS2B3 also cleaves the 
host innate sensor STING to suppress interferon induction (78). The C-terminus of NS3 contains 
helicase and nucleoside triphosphatase (NTPase) activities important for replication.  NS3 is also 
implicated in caspase recruitment and induction of apoptosis (79).  
NS4A-2K-NS4B 
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NS4A and NS4B are small hydrophobic proteins (16 and 27kDa, respectively) connected 
by the short peptide 2K. NS4A is located in vesicle packets and convoluted membranes 
important for viral replication and polyprotein processing (80). NS4A also forms a stable 
complex with NS3 (81) and stimulates the helicase activity of NS3 (82). NS4B is an integral 
membrane protein that may play a role in viral replication as it co-localizes with dsRNA and 
NS3 (83). Both NS4A and NS4B can inhibit interferon signaling (72, 84) and induce autophagy 
(85–87). The connector peptide 2K is necessary for generating functional NS4B. Abolishing the 
2K/NS4B cleavage site renders NS4B non-functional. Studies using lycorine, a flavivirus-
specific inhibitor revealed that the 2K peptide may play an important role in virus replication 
(88). 
NS5 
NS5 is the largest protein encoded by the flavivirus ORF. NS5 can be detected in both 
cytoplasm and nucleus of infected cells. The N-terminus of NS5 has S-adenosyl 
methyltransferase (MTase) and GTP binding activity important for capping the viral genome 
(89). The C-terminus of NS5 contains the RNA-dependent RNA polymerase (RDRP), which 
replicates the viral RNA genome and contains the conserved Gly-Asp-Asp active site motif (90). 
This protein is also a virulence factor by targeting STAT2 for degradation via a ubiquitin-
proteasome pathway (91, 92). Interestingly, NS5 from DENV can degrade the human STAT2 but 
not the murine homolog (91), suggesting host-specific subversion of antiviral mechanisms. 
5’ and 3’ untranslated regions 
The UTR of flaviviruses are important for regulating virus replication, virion packaging, 
and suppression of host IFN responses. The 5’ end of the positive-sense RNA is capped, 
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allowing host translation machinery to recognize the RNA for translation. During replication, the 
virus genome circularizes due to complementary sequences in the UTR, which is described in 
more detail in the next section. The 3’UTR interacts with NS3 in the replicative complex (93). 
Despite only possessing one putative transcriptional promoter, flaviviruses generate 
subgenomic RNA in host cells.  The host exonuclease XRN1 participates in recycling 
nucleotides and controlling gene expression by degrading de-capped cellular mRNA (94). 
During replication, some copies of flavivirus genome are not capped and hence are susceptible to 
XRN1 degradation. However, two stem loop structures at the 3’UTR prevent complete 
degradation of the genome by stalling XRN1 (95, 96), forming a ~500nt fragment called 
subgenomic flavivirus RNA (sfRNA), which antagonizes IFN responses. Expression of sfRNA 
from JEV has been shown to suppress phosphorylation and nuclear translocation of IRF3. While 
sfRNA-deficient YFV and WNV replicate poorly in IFN-competent cells, they are able to 
replicate in cells deficient in IFN induction or response and when IFN is neutralized (97–99). 
DENV and ZIKV sfRNAs suppress IFN responses by antagonizing RIG-I and to some degree 
MDA5 (100). Studies with DENV reveal that sfRNA binds to and interferes with 
deubiquitination of TRIM25 and subsequent RIG-I activation, leading to suppression of IFN 
induction (101). In addition, dengue virus serotype 2 (DENV-2), but not YFV, Kunjin virus 
(KUNV), or DENV-3 modulate ISG induction through interaction with the stress granule 
proteins G3BP1, G3BP2, and CAPRIN1 (102), indicative of virus-specific functions of sfRNA.  
1.1.3.3 Genome Synthesis 
Upon translation and accumulation of nonstructural proteins, virus replication occurs. The 
negative strand is synthesized first, followed by the positive strand. RNA synthesis is performed 
by the replicative complex (RC) located in the invagination of ER membrane, composed of the 
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nonstructural proteins. NS2A, 2B, 4A, and 4B are involved in modification of ER membrane. 
Both NS3 and NS5 lack membrane-association regions (103). NS3 is likely anchored to the RC 
through interaction with NS4B via its helicase domain (104), whereas NS3-NS5 interaction aids 
retention of NS5 within the RC (105, 106). NS5 synthesizes and NS3 modifies the nascent 
strand. The current model for RNA synthesis by flaviviruses is that upon recognition of the 
positive strand by the RC, RDRP activity of NS5 synthesizes the negative strand, forming an 
RNase-resistant dsRNA replicative intermediate (RI). The RI is then re-used to synthesize the 
positive- or negative-strand RNA. During replication, the amount of positive strand is between 
10- to 100-fold higher than negative strand (107). The mechanism controlling this ratio is 
unknown, but inhibition of genome circularization and sequestration of NS5 by sfRNA have 
been postulated as possible explanations (108).   
Circularization of the flavivirus genome is important for efficient replication. The 5’UAR 
(upstream ATG region) and 5’CS (circularization sequence) base pair with the 3’UAR and 3’CS, 
respectively. These two pairs of complementary sequence elements are required for 
circularization and replication as mutations that abolish sequence complementarity in either one 
pair are lethal to virus replication (109). Circularization of the genome brings the conserved 5’ 
stem loop, which binds to NS5, in close proximity to the 3’ end, allowing genome synthesis to 
occur (110, 111).  
  RNA synthesis by flavivirus NS5 is initiated by de novo priming (110). A conserved 
histidine residue in the priming loop near the protein active site has been implicated in selecting 
ATP as the first nucleotide, as deletion of the priming loop led to incorporation of GTP instead 
(110). In the absence of an RNA template, NS5 only synthesizes the dinucleotide AG when Mg2+ 
is present, whereas NS5 coordinating with Mn2+ can synthesize other dinucleotides with a 
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preference for AG. These observations explain conservation of the end nucleotides 5’-AG…CU-
3’ for flaviviruses. After priming, the polymerase changes from the initiation conformation to the 
elongation conformation, allowing processive synthesis of nascent RNA. The MTase domain is 
important for this conformational change (89).  
Following synthesis of the RNA, the 5’ end of the positive strand is capped. Capping of 
flaviviruses follows the conventional capping mechanism similar to host mRNA, which begins 
with removal of a phosphate group from 5’ triphosphate of the RNA by NTPase activity of NS3, 
followed by ligation of GMP by the guanylyl transferase in NS5. Finally, MTase methylates the 
guanosine cap at N7 position and the 2’OH of the first nucleotide (106, 111). No evidence for 
capping the negative strand exists.   
1.1.3.4 Virion Assembly and Egress  
Accumulation of viral genomes from replication eventually leads to packaging and egress of 
virions. Translation of the polyprotein results in ER-embedded PrM and E proteins. Capsid in the 
cytoplasm interacts with virus genome through its positively charged surface, forming 
nucleocapsid (42). No evidence for direct interaction of capsid with either PrM or E exists, and 
the mechanism by which nucleocapsid buds through the PrM and E coated membrane is 
unknown. NS2A may play a role in packing nucleocapsid in virions (112). Upon budding into 
the ER, immature virions are trafficked through the secretory pathways, where glycosylation of 
E and cleavage of PrM to M occur, resulting in mature infectious virions. It should be noted that 
cleavage of the chaperone protein PrM and protection of E protein by PrM is not uniform across 
a newly made virion, often resulting in mosaic virus particles that still retain some PrM proteins 
and/or contain copies of E proteins that adopt the acid-exposed conformation (113). These 
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differences in structure and composition of the virions have potentially important impacts on 
humoral immunity against flaviviruses (39).   
1.1.4 Innate immunity against flaviviruses 
The innate immune response is a relatively non-specific antimicrobial system that works with the 
adaptive immune response to restrain and resolve acute infection or protect vertebrate hosts from 
repeated infection. Flaviviruses are controlled by various innate pathogen sensors, inflammatory 
and cytokine responses, and immune cells. In particular, the interferon (IFN) system is important 
for resistance, control, and clearance of flaviviruses from infected vertebrate host. Defects in IFN 
induction and/or signaling can alter the outcomes of flavivirus infection. In addition to IFN and 
its downstream genes, NK cells are also important in controlling virus infection before the more 
specific and robust adaptive immunity is activated.  
1.1.4.1  Interferon induction by flaviviruses  
The RIG-I-like receptor (RLR) and Toll-like receptor (TLR) family pathogen recognition 
receptors (PRRs) are implicated in detection of pathogen-associated molecular patterns (PAMPs) 
associated with flaviviruses. In cell culture and animal studies, deficiency in PRRs leads to 
reduction in IFN and antiviral gene expression in a virus species-dependent manner. The RLR 
family members such as RIG-I and MDA5 detect dsRNA in the cytoplasm. Upon binding to the 
dsRNA substrate, ATP hydrolysis and oligomerization (114) of these sensors occur, allowing the 
sensors to interact with the adaptor protein MAVS on mitochondria or peroxisomes (115). The 
substrates of RIG-I are dsRNA bearing 5’-triphosphate or the absence of type I cap on dsRNA 
(116) whereas MDA5 detects long dsRNA (>300bp) (117–119). Activation of RLRs leads to 
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activation of TBK1 and initiates a signaling cascade that phosphorylates and activates 
transcription factor IRF3, which activates transcription of antiviral genes including type I IFNs 
(subtypes IFN-α4 and -β). Alternatively, PRR-mediated activation of IRF7, which is 
constitutively expressed in myeloid cells such as dendritic cells and macrophages, can also lead 
to rapid production of IFN-α/β (120). Upon secretion, IFN-α/β acts in an autocrine and paracrine 
manner to induce expression of various antiviral genes, PRRs, and transcription factors that lead 
to production of additional IFN. 
Both RIG-I and MDA5 are implicated in sensing flaviviruses. WNV and DENV have 
been reported to replicate more efficiently in RIG-I-deficient mouse embryonic fibroblasts 
(MEFs). Correspondingly, these cells also had delayed IFN production and ISG upregulation 
(121–123). Similarly, MDA5-deficient MEFs have been shown to support greater WNV 
replication than WT MEFs; however, a delay in ISG induction is not observed. In addition, mice 
lacking either RIG-I or MDA5 are more susceptible to WNV infection (124). These results 
suggest that RIG-I and MDA5 are important for sensing WNV and DENV. In contrast, while 
JEV is more virulent in RIG-I-deficient mice and resulted in less IFN production, MDA5-
deficient mice do not display enhanced susceptibility to the virus (117). RIG-I has also been 
shown to detect YFV in plasmacytoid dendritic cells (pDC). Interestingly, depending on the 
route of entry into pDC, RIG-I or TLR were differentially involved (125). 
Members of the TLR family are transmembrane molecules expressed on the cell surface 
and in endosomal compartments in a cell type-dependent manner. The leucine rich repeats 
located in the ectodomain of TLRs mediate sensing of PAMPs. Binding of ligands to TLRs 
initiates a signaling cascade through the adaptor protein MyD88 for all TLRs except TLR3, 
which activates TRIF instead (126). Similar to RLRs, activation of TLRs results in activation of 
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transcription factors such as IRF3, IRF7, and NF-κB, leading to expression of antiviral molecules 
including IFNs. 
Various TLRs are implicated in detection of flavivirus RNA. In human monocytes and 
fibroblasts, TLR3-mediated sensing of DENV are important for secretion of type I IFN and the 
proinflammatory cytokine IL-8 (127), whereas inhibition of TLR7 in human pDCs suppresses 
IFN induction upon DENV infection (128). Similarly, shRNA silencing of TLR-2, -7, -8, -9, and 
MyD88 suppresses IFN-β and cytokine production in human monocyte-derived dendritic cells 
(MoDCs) infected with YFV (129). In addition, pDCs secretes IFN-α/β upon ligation with YFV-
infected cells in TLR7-dependent manner (125). In WNV infection, the role of TLR-3 and -7 
remains controversial (130, 131). However, MyD88-deficiency renders mice more susceptible to 
WNV infection, suggesting a protective role for TLR signaling in WNV infection (132). On the 
contrary, MyD88-deficient mice do not display enhanced sensitivity to JEV (117). 
Since RLR- and TLR-mediated sensing of viruses leads to robust antiviral responses, 
pathogenic flaviviruses have evolved to evade host recognition. While RNA fragments from 
WNV activate RIG-I and trigger the IFN response, WNV genomes and anti-genomes are poor 
activators for RIG-I (133), suggesting that potential secondary structures or genome modification 
may aid evasion of innate sensing. In addition, DENV also inhibits RIG-I activation by 
preventing its interaction with MAVS (134) and deubiquitination by TRIM25 (101), which is 
necessary for RIG-I activation. Overall, detection of flaviviruses by RLRs and TLRs is virus 
species- and cell type-dependent, and pathogenic flaviviruses deploy various means to suppress 
host virus sensing mechanisms.  
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1.1.4.2 Interferon antiviral activities against flaviviruses 
IFNs are a group of broadly antiviral cytokines important for restricting pathogens and 
modulating other immune responses. Cells or animals lacking components of IFN induction or 
signaling are often defective in viral control and highly susceptible to infection with many 
different viruses including flaviviruses. There are three types of IFNs, and they have a similar 
overall signaling scheme (Fig. 2). Upon IFN ligation to its receptor, type I and III IFN utilize 
JAK1 and Tyk2 to phosphorylate STAT1 and STAT2, whereas type II IFN utilizes JAK1 and 
JAK2 to activate STAT1. These events lead to formation of STAT1/STAT2 heterodimers or 
STAT1 homodimers, which translocate to the nucleus and transcriptionally activate target genes. 
In addition, type I and type II IFN activate NF-κB and p38 MAPK, further regulating antiviral 
gene induction and fine-tuning the immune response (135).   
Type I IFN (IFN-α/β) are broadly antiviral against flaviviruses in vitro and in vivo. IFN 
prophylaxis and treatment has been reported to suppress replication and delay death of mice 
infected with Modoc virus (a flavivirus) (136). This cytokine is also important in the 
pathogenesis of many flaviviruses, as animals lacking components of the IFN response, either 
pharmacologically (137, 138) or genetically (139–141), are more susceptible to flavivirus 
infection and disease than their immunocompetent counterparts. Many of the antiviral roles for 
IFN-α/β can be attributed to its direct antiviral effects due to induction of a large ensemble of 
antiviral gene products. While IFN-α/β serves as a major innate barrier for flaviviruses, it is also 
important for activation of T cells in WNV-infected mice (142).  
Type II IFN (IFN-γ) also possesses moderate innate antiviral activities through induction 
of antiviral genes regulated by the gamma-activated sequence (GAS) promoter elements. Cells 
treated with IFN-γ are resistant to flavivirus infections in vitro (143–146); concomitantly, 
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prophylactic treatment of non-human primates with IFN-γ suppressed YFV load and disease 
(147). In addition, IFN-γ is a signature cytokine involved in differentiation of T cells to a TH1 
phenotype. Details of IFN-γ induction and signaling of IFN-γ will be discussed in section 1.3.   
 
Figure 2: General interferon signaling pathways. 
 
Similar to type I IFN, Type III IFN (IFN-λ) signals through STAT1 and STAT2, leading 
to a similar profile of antiviral gene induction. Despite activating similar transcription factors, 
direct antiviral activities of IFN-λ tend to be less robust than IFN-α/β (148, 149); however, IFN-λ 
has unique antiviral activities at the epithelial barrier. Neutralizing IFN-λ in placental organoids, 
 19 
which produce IFN-λ constitutively, have been reported to enhance ZIKV replication (150). 
While IFN-λ does not inhibit WNV replication in vitro, mice lacking its receptor, IFNLR1, have 
enhanced vascular leakage and virus titer in the brain, suggesting IFN-λ is critical for restricting 
viral access through the blood-brain barrier (149). Similar barrier function is also observed in an 
encephalitic model for YFV (151).  
1.1.4.3 Other innate immunity against flaviviruses 
In addition to the IFN system, several other innate immune mechanisms play important roles in 
restricting flavivirus infection. The murine 2’-5’ oligoadenylate synthetase 1b (OAS1b) is of 
particular importance for anti-flavivirus immunity. Mice have eight isoforms of OAS, which are 
involved in sensing dsRNA. Upon detection of dsRNA, OAS synthesizes 2’-5’ oligoadenylate, 
which activates RNaseL to degrade cellular RNA, resulting in substrates for RIG-I and/or MDA5 
activation (152). Genetic studies of mouse strains that are differentially resistant to flaviviruses 
but not other RNA and DNA viruses have revealed that a nonsense mutation leading to 
truncation of OAS1b is responsible for enhanced flavivirus susceptibility (153). One potential 
antiviral function of OAS1b is to inhibit viral replication as escape mutants insensitive to OAS1b 
frequently have mutations in the helicase domain of NS3 (154). However, the mechanism for 
OAS1b-mediated resistance remains elusive. In contrast to other OAS gene products, OAS1b 
does not have any apparent enzymatic activity. Overexpression of functional OAS1b or OAS1a 
only slightly restores anti-flavivirus activities. Thus, OAS1b is postulated to be a regulator for 
other OAS1 molecules and the truncated OAS1b is believed to work as a dominant negative 
inhibitor. It should be noted that humans have five OAS1 isoforms that are catalytically active 
and may be important for innate immune response against flaviviruses (155). 
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Natural killer (NK) cells are innate lymphoid cells that play crucial defense roles against 
many intracellular pathogens, including flaviviruses. NK cells can lyse virus-infected cells (156) 
and promote inflammation by producing cytokines such as IFN-α/β and -γ, TNFα, and RANTES 
(157, 158). Early activation of NK cells has been reported after YFV, DENV, and TBEV 
infection (159–162). NK cells can be activated by proinflammatory cytokines, ligation to cells 
lacking MHC-I, and antibody-bound cells (details discussed in section 1.3). To suppress NK cell 
activation and subsequent lysis of infected cells, surface MHC-I is upregulated in flavivirus-
infected cells in a NF-κB-dependent and IFN-α/β-independent manner (163, 164). Expression of 
MVEV capsid and PrM enhanced surface MHC-I expression (165); however, DENV replicon 
expressing only nonstructural proteins also induced MHC-I expression (166), suggesting that 
flaviviruses may employ multiple mechanisms to enhance MHC-I expression and/or it is a virus-
dependent process. Nevertheless, NK cell activation and differentiation are still observed in vivo. 
In addition to potential cytokine-mediated activation, direct ligation of domain III of E protein 
from WNV and DENV with the NK cell surface receptor NKp44 has been shown to trigger NK 
cell degranulation, lysis of infected cells, and induction of IFN-γ in vitro (167). In secondary 
infection, where anti-flavivirus antibody is present, antibody-mediated cellular cytotoxicity has 
been proposed to be a mechanism for NK cell-mediated control of DENV (156, 168). 
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1.2 YELLOW FEVER VIRUS 
1.2.1 Transmission and Epidemiology 
Transmission of YFV from its enzootic habitat to humans can be described in three main cycles 
– sylvatic, intermediate, and urban cycles. In the sylvatic cycle, YFV is circulated in the jungle 
between mosquitoes and non-human primates. In South America, the sylvatic cycle is primarily 
maintained by mosquitoes in the genus Haemagogus and Sabethes, whereas in Africa, the 
sylvatic cycle is primarily maintained by Aedes africanus. YFV replicates and seeds serum 
viremia in the non-human primate (NHP) host, allowing the subsequent blood-feeding 
mosquitoes to pick up the virus (169, 170).  
In the intermediate cycle, YFV transmission to humans occurs when various tree-hole 
dwelling Aedes mosquitoes indiscriminately feed on humans rather than NHPs. The intermediate 
cycle primarily occurs in Africa where human activities and settlement tends to be proximal to 
jungles in contrast with South America. Human activities in forests such as logging and tourism, 
encroachment of human habitats into jungles (169), and environmental factors boosting mosquito 
populations such as rain or flood (171, 172) can enhance the risk of YFV spillover to humans. 
Human infections in the intermediate cycle can lead to outbreaks in urban areas when Ae. 
aegypti, an urban-dwelling mosquito that bites humans aggressively (173), feeds on YFV-
infected individuals. This can occur when infected humans travel to urban areas to seek 
hospitalization. In this urban cycle, Ae. aegypti propagates YFV to a human host and 
subsequently to other Ae. aegypti, potentially leading to large-scale outbreaks.  
  Historically, the geographical range of YFV spanned North and South America, Europe, 
and sub-Saharan Africa, with outbreaks occurring in these regions during the 17th-19th centuries. 
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Due to active vaccination and mosquito abatement programs in the 19th century, YFV is 
currently only found in South America and sub-Saharan Africa; however, in recent decades, 
YFV has been re-emerging (169, 174–178). One prominent example is an outbreak in Uganda in 
2011, which led to at least 58 deaths. This is the largest recorded YF outbreak in Uganda, and the 
last documented outbreak was in 1972 (175). The upsurge of YF cases has led the World Health 
Organization (WHO) to expand the definition of geographical regions that are considered to be at 
risk for YFV (178). The reason for YFV re-emergence is unknown. However, human 
encroachment to the sylvatic regions (175, 177) and lack of vaccination (179) are the likely 
contributing factors. In addition, an increase in traveler-associated cases has raised concern for 
potential expansion of YFV beyond its current boundary (180). Interestingly, local transmission 
of YFV has never been documented in Asia. This phenomenon may be explained by factors of 
vector competency and/or pre-existing cross-protective immunity from endemic circulation of 
DENV and JEV (181).  
1.2.2 Pathogenesis and pathophysiology in human infection 
Most YFV infections in humans are abortive or subclinical (182, 183); however, in symptomatic 
cases, the disease ranges from mild disease to fulminant pan-systemic disease. Disease severity 
and pathogenesis are influenced by the virus strain, host development and genetics, and 
environmental factors. 
After a three to six day of incubation period, patients generally develop abrupt fever and 
chills. Three phases of disease have been described in human YF. In the initial phase, known as 
the “period of infection,” patients experience general malaise, headache, and nausea. Viremia 
peaks 2-3 days after the onset of illness. More severe signs including liver tenderness, 
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leukopenia, hyperemia of skin, and Faget’s sign (fever with low pulse) are also commonly 
reported. The “period of infection” is followed by the “period of remission,” where patients 
recover and symptoms disappear, lasting for up to 48hr. Most patients recover from YF at this 
point; however, 1 in 7 patients will progress to the severe disease phase known as the “period of 
intoxication” (169, 182, 184). 
In the “period of intoxication,” which occurs in three to six days after the onset of illness, 
patients experience moderate to severe hemorrhagic fever and multi-organ failure. Typical signs 
include high fever, black vomit, jaundice, enlarged liver, and renal dysfunction.  Serum 
antibodies appears while viremia declines at this stage. In addition, both serum aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) levels are elevated, with AST 
surpassing ALT, indicative of muscle and liver damage. Serum transaminase and bilirubin levels 
directly correlate to disease severity. Proteinuria (excess protein in urine) and metabolic acidosis 
can be detected from patients’ urine. Perivascular hemorrhage and edema in the brain indicates 
involvement of the central nervous system (CNS). In rare cases, neuroinvasion of virus and 
immune infiltration is possible. Jaundiced patients have an approximately 20% mortality rate. 
Survivors of YF have neutralizing antibodies against YFV and are considered to be protected 
from future infections.  
1.2.3 Live attenuated vaccines for yellow fever 
1.2.3.1 History of yellow fever vaccines 
Historically, there have been two live attenuated vaccines used for YF, known as 17D and the 
French neurotropic vaccine (FNV). Both were developed independently during the late 1920s 
when researchers from the west were investigating YF outbreaks in West Africa. In the summer 
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of 1927, while studying YF in Ghana, Adrian Stokes and colleagues inoculated the blood from a 
28-year-old patient, named Asibi, experiencing mild febrile illness, into rhesus macaques. Some 
of the infected animals showed signs of illness and histology similar to human yellow fever. 
Furthermore, blood from the sick monkeys was infectious and the infectious agent could be 
propagated in mosquitoes and/or monkeys. Importantly, Stokes also discovered that the 
infectious agent was filterable, suggesting bacteria were not involved. The virus, which was 
maintained by passaging in rhesus monkeys, was named Asibi (185). Tragically, Stokes 
contracted YF and passed away soon after the discovery. At the same time in Senegal, Sellards, 
Mathis, and Laigret isolated another YFV strain using a similar approach and named it Mayali, 
now known as French viscerotropic virus (FVV). In addition, the Sellards team found that the 
virus survived freezing in tissues (186), allowing storage and transport of the virus when 
monkeys were not available.  
Vaccine development started when the Asibi virus eventually arrived at the Rockefeller 
Institute. Interest in vaccine development stemmed from the need to protect researchers and field 
workers from contracting yellow fever, which had led to at least 32 laboratory-acquired cases 
and 5 deaths between 1927-1931 (187). When Max Theiler and his colleagues attempted to 
culture the Asibi virus in small animal models via various routes of infection, only intracerebral 
inoculation led to disease and death of infected mice. After passage in mouse brain, the resulting 
virus lost viscerotropic virulence in rhesus monkeys but became more neurovirulent. In contrast, 
intrahepatic inoculation of rhesus macaques restored viscerotropism. The ability to alter virus 
virulence and tropism founded the basis for developing a vaccine for YFV. To attenuate YFV, 
the researchers serially passaged the Asibi virus 18 times in mouse embryos and 50 times in 
chicken embryos. To eliminate concern about enhanced neurovirulence, the virus was further 
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passaged 108 times in chicken embryos with neurologic tissues removed (188). Eventually, by 
passage 176, the resulting virus had lost viscerotropism and neurotropism in macaques, and 
infected macaques developed immunity against Asibi infection. This resultant attenuated virus 
strain was designated 17D and became parental material of the present vaccine for YFV. Since 
its derivation in 1937, new lots of the 17D vaccine have been generated by continued passaging 
of 17D in chicken embryos. Subsequent clinical trials demonstrated the safety of the vaccine for 
human use, and 17D was further passaged to generate sub-cultures for vaccine manufacturing. 
Today, two vaccine substrains exist; the sub-strain 17DD, maintained in Brazil and the 17D-213 
line that is maintained by the WHO. The substrain 17D-204, which is commonly used in 
laboratory research, is the parent strain of 17D-213. 
 The second independent live-attenuated vaccine, the French neurotropic virus (FNV), 
was developed at the Pasteur Institute. FVV was attenuated by serially passaging through 
intracerebral (i.c.) inoculation of mice. Similar to Theiler’s observation, the resultant virus lost 
the ability to cause viscerotropic disease in macaques but acquired enhanced neurovirulence in 
monkeys and mice at passage 128. Subsequently, the virus was named FNV for its neurotropism. 
At passage 237, the virulence of FNV remained stable and could induce protective immunity in 
humans upon skin scarification with viral inoculum. It was thus used as a vaccine in French-
speaking colonies in Africa between 1939-1980. However, because FNV was associated with 
high rates of encephalitis, the WHO prohibited its usage in children less than 14 years of age. 
With the availability of 17D, the FNV lost popularity and was discontinued in 1980 (189). 
 While 17D is relatively safe and effective, achieving its widespread application was not 
without complications. In 1943, vaccination with the sub-strain 17DD, which was passaged more 
than 300 times, failed to elicit immunity due to the loss of infectivity in humans. Protective 
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immunity was restored by using vaccine stocks at lower passage. Moreover, hepatitis in 
vaccinees occurred because human serum was used as a vaccine stabilizer. This was resolved by 
replacing human serum with egg protein. In Brazil, cases of viral encephalitis in children were 
reported and led to the suspicion of residual neurovirulence in the vaccine. Due to such issues 
with the 17D vaccine, in 1945, the WHO generated guidelines and standards for YF vaccine 
manufacturing that employs a seed lot system to control passage level and a monkey 
neurovirulence test, which stated that i.c. infection with the vaccine stock in monkeys should 
lead to no more than one case of lesion in the brain and no serum viremia higher than 104 
PFU/mL (190).  
1.2.3.2 Innate Immunity to Yellow Fever Vaccination 
17D vaccination triggers robust innate and adaptive immunity. In the first few days after 17D 
vaccination, local reactions such as redness and swelling often occur at the injection site, and low 
levels of circulating viral RNA and infectious particles are detectable in the blood. Elevated 
serum cytokines, including IFN-α, IFN-γ, IP-10, and MCP-1 can be detected early after 
vaccination (191). Early cytokine induction by 17D is likely due to activation of NK cells and 
DCs, as ex vivo stimulation of these cells led to activation and production of proinflammatory 
cytokines. However, the role of these cells and cytokines in controlling 17D remain unclear in 
vivo. Peripheral NK cells rapidly mature and differentiate in vaccinees as indicated by expression 
of CD57 and enhanced responsiveness to IL-12 and IL-18 (159). Elevated levels of TLR-3 and -
9 have also been detected, suggestive of enhanced viral sensing capability. Differentiation of NK 
cells is independent of expression of NK cell inhibitory receptors, but the NK cell response is 
correlated to serum type I and/or type III IFN concentration. Interestingly, 17D infection in mice 
lacking the receptors for both type I and III IFN led to elevated numbers of NK cells in the 
 27 
spleen and liver (151), whether this phenotype is linked to a failure in NK cell activation remains 
to be investigated. In vaccinated mice, NK cells in lymphoid tissues rapidly produced IFN-γ 
(160). Stimulation of monocyte-derived dendritic cells (moDC) from human vaccinees leads to 
production of IL-6, MCP-1, IL-10, IP-10, and IL-12 (p40 and p70) and upregulation of activation 
markers CD80 and CD86 (129). Similarly, in vitro infection of human DCs with 17D leads to 
upregulation of activation markers such as MHC-II, CD80, and CD83 and results in enhanced 
capability to present antigens to T cells (192). In mice, 17D-mediated DC activation, cytokine 
secretion, and enhanced antigen presentation are dependent on TLR and MyD88 signaling (129). 
Investigation of the transcriptome of PBMCs from human vaccinees has demonstrated the 
importance of innate immunity. Signature genes for the IFN response including STAT1, IRF7, 
OAS1, IFIT1, ISG15, and IP-10 are strongly upregulated and likely shape downstream responses 
for activating adaptive immunity (193). 
1.2.3.3 Adaptive Immunity to Yellow Fever Vaccination 
The goal of yellow fever vaccination is to induce of long-term protective immunity. The 
primary immune component involved in protection in humans is believed to be neutralizing 
antibody. Vaccination triggers a robust humoral response in humans, and >90% of vaccinees 
seroconvert within two weeks. Neutralizing IgM can be detected as early as six days post-
vaccination, and the number of plasmablasts in circulation also increases and peaks at 14 days 
post vaccination (194). Persistent levels of serum IgM lasting for at least four years have been 
documented (195). Convalescent sera from human patients or vaccinees protect mice and 
monkeys from lethal YFV infection. Thus, serum antibody has been used as a correlate for 
protection. Detection of circulatory IgG, which can last more than 35 years (196–198), and 
increases in antibody titer upon booster doses (199), suggest the presence of a long-lived 
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memory response. In fact, vaccinees receiving hematopoietic stem cell transplantations for 
leukemia treatment have been reported to remain seropositive for YFV for at least one year after 
transplantation (200, 201), indicating that memory cells persist and remain functional in non-
hematopoietic compartment. The mechanisms leading to a long-lived adaptive immune response 
are currently unknown. Antibody response to vaccination is correlated to expression of 
TNFRSF17, a receptor for B cell growth factor, in PBMCs, while detection of viral RNA up to 6 
months post-vaccination suggests viral antigens may persist in vaccinees, potentially 
contributing to long-term protection (202).  
In addition to neutralizing antibody, 17D vaccination elicits robust, polyfunctional, and 
long-term T cells responses. Activation of CD8+ T cells can be observed as early as three days 
post-vaccination (193). Peak CD4+ T cell responses occur between 7-14 days, whereas the CD8+ 
responses peak between 14-28 days (194, 203, 204). Activation of CD8+ cells appears to be 
antigen-driven (204). Around 5% of virus-specific CD8+ T cells differentiate into either central 
memory (TCM) or effector memory (TEM or TEMRA) T cells that persist for years (198). At the 
peak response, 17D-specific CD8+ T cells express granzyme B and cytokines including IFN-γ 
and TNFα (203, 205), suggestive of cytolytic, polyfunctional T cells. For CD4+ T cells, both 
TH1 and TH2 T cells are present, as are their signature cytokines (IL-2, IFN-γ, TNFα, and IL-12 
for TH1 and IL-4, IL-5, IL-10, and IL-13 for TH2) in the serum of vaccinees (194, 206–209). 
However, one study suggested the response is polarized towards a TH1 phenotype as indicated 
by the typical CXCR3+ IFN-γ+ phenotype of CD4+ T cells (208). After the peak response, YFV-
specific CD4+ T cells gradually gain expression of CCR7, indicative of a shift to TCM phenotype. 
Since human experimentation is not feasible, the role of T cells in humans is unclear, but CD4+ T 
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cells and antibodies protect mice from viscerotropic infection by WT virus (210) whereas CD8+ 
T cells and antibodies protect mice from i.c. challenge (211).  
1.2.4 Attenuation of Yellow Fever Vaccine strains  
Despite a long history of 17D vaccination and numerous potential applications of 17D as 
a vector for other vaccines, very little is known about its attenuation mechanisms. Between 17D 
substrains and their parent Asibi strain, there are an average of 48 nucleic acid changes leading 
to 20 amino acid changes and 4 mutations in the 3’UTR (summarized in Table 1). The roles of 
these mutations in attenuation or pathogenesis of 17D have remained largely uncharacterized; 
however, two conserved mutations, M-L36F and NS4B-I95M, are consistently different between 
WT YFV strains (Asibi and FVV) and their corresponding attenuated strains (17D substrains and 
FNV) (212). For M-L36F, substitution of the analogous amino acid in JEV leads to a mutant 
virus defective in virion maturation. This residue is located at the perimembrane helix that 
interacts with the E protein. Of note, WT strains of JEV, DENV, WNV, and YFV have a 
nonaromatic aliphatic residue at M36 and alanine substitution does not alter virion production 
(213). It is possible that the aromatic property of phenylalanine or its bulky side chain can 
interfere with E protein interaction, resulting in altered kinetics of virus maturation and/or 
sensitivity to the antiviral response. NS4B is important for formation of the virus replication 
machinery and resistance to host immunity. I95M is located at the end of the helix α2 where IFN 
antagonism and interaction with NS1 occurs (214). Attenuation of Asibi can also be achieved by 
serial passage of Asibi in HeLa cells six times. This strain, HeLa-p6, is attenuated in mice and 
has three amino acid changes, I95M, V98I, and E155K in NS4B (215), suggesting I95M is likely 
involved in attenuation in vivo. Interestingly, the V98I mutation was also observed in hamster-
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adapted Asibi, which gained virulence in hamsters (216). While V98I is not likely to be involved 
in attenuation, development of mutations in NS4B during passaging or adaptation suggests 
mutations in NS4B are important for viral fitness in different hosts. It should be mentioned that 
the mutation NS5-P901L, which is observed in 17D substrains and HeLa-p6, might also 
contribute to attenuation (212, 215); however, little is currently known about this residue at this 
point. 
There are eight amino acid differences in the E protein. E-M299I, E-S305F, E-T380R, 
and E-A407V are located in domain III, the putative receptor-binding domain. A positive-charge 
mutation, E-T380R is implicated in enhanced binding to glycosaminoglycans (GAGs). This 
mutation leads to enhanced virus clearance from circulation and hence attenuation in vivo (27). 
The role of other mutations has not been well characterized individually; however, one recent 
study suggested that 17D can enter susceptible mammalian cells through a clathrin-independent 
pathway whereas entry of Asibi requires clathrin-coated pits. The usage of this alternative entry 
pathway is mediated by mutations in the E protein and the mutation at position 380 alone is 
insufficient to generate this phenotype. Moreover, this clathrin-independent pathway triggers 
more robust innate immune responses, which may contribute to attenuation (217). E-G52R is 
located at the hinge region between domains I and II, which participates in fusion. Mutations in 
the hinge region can have inhibitory effects on virus entry. Cell culture-adapted JEV bearing a 
mutation at position 52 has reduced peripheral virulence (218) and possesses different antibody-
binding activity than its parent strain (219). Substitution of the analogous residue in DENV-2 
have no effects on virus growth or fusion activity in vitro (220). E-A170V, E-T173I, and E-
K200T are located at the dimerization interface between M and E proteins. Reversion of position 
173 to the WT residue leads to enhanced neurovirulence. In addition, reversion of both E-G52R 
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and E-T173I have been observed in neuroadaptated 17D, suggesting their potential role of 
neurovirulence in vivo (55).   
 
Table 1: Sequence Comparison between YFV Asibi and its derivative strains. 
Rows in grey are the 20 conserved amino acid differences between Asibi and substrains of 17D. 
Empty cells indicate that the amino acid or nucleotide is identical to Asibi. 
Gene Codon 
WT Attenuated strains Adapted WT 
Asibi 17D-204 17D-213 17DD HeLa-p6 Hamster-p7 
M 36 L F F F     
E 27 Q       H H 
E 28 D       G   
E 52 G R R R     
E 155 D       A A 
E 170 A V V V     
E 173 T I I I     
E 200 K T T T     
E 288 M       K   
E 299 M I I I     
E 323 K         R 
E 331 K       R R 
E 305 S F F F     
E 380 T R R R     
E 390 H       P   
E 407 A V V V     
NS1 307 I V V V     
NS2A 48 T       A A 
NS2A 118 M V V V     
NS2A 167 T A A A     
NS2A 172 T A A A     
NS2A 183 S F F F     
NS2B 109 I L L L     
NS3 485 D N N N     
NS4A 146 V A A A     
NS4B 95 I M M M M   
NS4B 98 V       I I 
NS4B 144 E       K   
NS5 836 E K K K     
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NS5 901 P L L L L   
3′UTR - T C C C     
3′UTR - T C C C     
3′UTR - G A A A     
3′UTR - A C C C     
1.2.5 Severe adverse events associated with 17D vaccination  
Yellow fever vaccination is associated with mild adverse events such as myalgia, headache, and 
local reactions at the site of injection and severe adverse events (SAEs) including anaphylaxis 
and hypersensitivity and rare but potentially lethal neurotropic (YEL-AND) and viscerotropic 
(YEL-AVD) manifestations. Anaphylaxis and hypersensitivity due to 17D infection are not well 
studied. Some cases are linked to patient histories of allergy to known allergens in the vaccine; 
however, the absence of gelatin or egg allergy in some patients suggests the antigens and/or other 
ingredients may serve as allergens (221). Similar negative consequences have also been reported 
for other vaccines. YEL-AND and YEL-AVD are unique to YF vaccination. Currently, 
documented or suspected cases of YEL-AND and YEL-AVD number at least 200 and 70, 
respectively. Most cases have occurred after primary vaccination, and at least four cases have 
occurred after a booster dose (1 for YEL-AVD; 3 for YEL-AND) (184, 212). YEL-AND 
includes several typically self-limiting neurotropic syndromes such as Guillain-Barré syndrome, 
meningitis, encephalitis, and disseminated myeloencephalitis, followed by complete recovery. 
However, residual ataxia has been reported for 11 months in one case (222) and at least one 
death occurred in an HIV-positive patient with a low CD4 count (223). YEL-AND is more 
common among infants, especially before 1950, when infants younger than 4 months old were 
commonly vaccinated. Post-vaccination encephalitis has been associated with regain of 
neurovirulence through manufacturing, leading to the implementation of the seed-lot system and 
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monkey neurovirulence test, described above, to ensure efficacy and safety. Today, despite 
stricter safety standards, YEL-AND still occurs, suggesting additional, unknown underlying 
causes exist. Age-dependence of blood-brain barrier integrity and immune maturity has been 
hypothesized for increased risk for neurologic disease in infants (224). The incidence of YEL-
AND is higher in males. The overall fatality rate for YEL-AND is 5% (184). 
In YEL-AVD, patients experience a syndrome resembling WT virus infection – 
pansystemic disease with high virus titer in visceral organs and cytokine storms, with 60% 
lethality (169). Patients who survive YEL-AVD tend to have higher than expected antibody titers 
(≥1:10,240), which are likely due to overwhelming infection and high antigen levels (225–228). 
Advanced age and history of thymic disorder are considered potential risk factors (229), but no 
single factor has been identified as the cause of these SAEs, although host genetics and virus 
mutations are hypothesized to contribute. In one case, a patient, who had enhanced and 
prolonged serum viremia and T cell response, was found to possess single nucleotide 
polymorphisms (SNPs) in the CCR5 and RANTES genes (230). While virus isolated in another 
YEL-AVD case had amino acid changes compared to the parent virus from the vaccine stock 
(231), virus mutations are not always found in YEL-AVD patients (232). Some YEL-AVD cases 
have occurred concurrently with additional traveler vaccinations (228) and immune interference 
has been documented (233), raising the possibility that multiple vaccinations with 17D may 
increase the risk for SAEs. Together, the data on 17D-associated SAEs highlight not only the 
very limited understanding we have of this vaccine and its mechanisms of attenuation and 
immune response elicitation, but also the critical need to address these gaps in knowledge. 
Before 17D can be used extensively for other applications, such as heterologous vaccine 
development, the molecular mechanisms conferring its attenuation phenotypes must be 
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delineated because these vaccine candidates may retain the ability to cause SAEs. This 
knowledge will facilitate further studies into the mechanisms underlying SAEs and what can be 
done to improve the safety profile of 17D-based therapeutics in the future. 
1.3 GAMMA-INTERFERON AND ITS ANTI-FLAVIVIRUS ACTIVITIES 
Type II interferon (IFN-γ) is an important cytokine in both innate and adaptive immunity against 
many pathogens. IFN-γ is mainly produced by NK, NKT, T, and innate lymphoid cells (234–
236). Macrophages (237), dendritic cells (238, 239), neutrophils (240), and B cells (241) have 
been implicated to produce IFN-γ in certain experimental systems. The immune-modulatory 
functions of IFN-γ are important for suppressing intracellular pathogens in responsive cells. In 
addition to inducing antiviral states, similar to other IFNs, IFN-γ strongly induces nitric oxide, 
GTPases that modulate intracellular membranes, and proteins involved in antigen presentation 
(145, 242, 243). In fact, deficiency in IFN-γ induction or response enhances susceptibility to 
intracellular pathogens ranging from bacteria, parasites, and viruses, highlighting its broad role 
in antimicrobial immunity (244–247). 
1.3.1 Induction and transcription regulation of IFN-γ 
1.3.1.1 Transcription regulation of IFN-γ 
The Ifng gene is composed of four exons spanning 5.5kb and a 600bp upstream promoter 
element located on chromosome 12 in humans and chromosome 10 in mice. Gene sequences and 
regulatory elements at this locus are highly conserved between humans and mice. The Ifng 
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promoter contains binding sites for various transactivation factors such as STAT4, NF-κB, and 
T-bet and repressors such as STAT6, SMAD3, and GATA3 (248). Within the intronic regions of 
Ifng, hotspots of DNA methylation and histone modification sites also regulate its expression. 
Downstream of Ifng is the non-coding RNA Tmevpg1 that can enhance Ifng transcription (249). 
In addition, Ifng is flanked by multiple distal conserved noncoding sequences (IfngCNS) 
containing CpG sites and hot spots for histone modification located at least kilobases away from 
Ifng (248, 250). These IfngCNS are important for fine-tuning transcriptional regulation of Ifng in 
T cells.  
 Naïve CD4 T cells are capable of differentiating into various lineages of helper T cells to 
exert specific immune functions, and IFN-γ is a signature cytokine of differentiation into the 
TH1 phenotype. In naïve CD4 T cells, the Ifng promoter site is unmethylated; however, 
methylation at CpG sites of intronic regulatory elements and the absence of histone 
modifications that favors transcription (H3-K4Me and AcH4) at the promoter, and intronic 
regulatory elements suppress Ifng transcription. TH1 signals such as IL-12 trigger epigenetic 
changes to the Ifng locus, leading to demethylation of the intronic regulatory elements and 
acetylation of histones H3/H4 around the Ifng loci, including IfngCNS (250). Chromatin 
remodeling enhances DNase sensitivity of this locus, indicating increased accessibility of the 
gene and active transcription. In contrast, TH2 stimuli such as IL-4 lead to hypermethylation of 
the Ifng promoter, suppressing expression of Ifng and differentiation towards the TH1 phenotype 
(250, 251); however, ectopic overexpression of T-bet in terminally differentiated TH2 overrides 
the repression and results in IFN-γ expression (252).  
 The NF-κB family transcription factors are activated by multiple pathways and are 
important in IFN-γ expression in T and NK cells. The NF-κB family proteins such as RelA 
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(p65), RelB, c-Rel, p50 (NF-κB1), and p52 (NF-κB2) have been shown to play important roles in 
T cell differentiation. Active NF-κB complexes are composed of heterodimers of RelA/p50 or 
RelB/p52. Both RelA and RelB contain a transactivation domain and a DNA-binding domain, 
whereas p50 and p52, which contain only the latter, are implicated in gene repression; however, 
Bcl-3, which has a transactivation domain, can associate with p50 dimers, resulting in gene 
induction (253). NF-κB in cytoplasm is normally sequestered by the inhibitor IκB. Upon 
stimulation, IKK phosphorylates IκB, leading to its degradation and release of the active NF-κB 
complex, which enters the nucleus and activates transcription of many genes, including 
proinflammatory cytokines (254). Expression of degradation-resistant IκB in naïve T cells 
suppresses TH1 polarization and IFN-γ expression (255). In addition, RelB-deficient T cells fail 
to express STAT4, T-bet, and IFN-γ upon IL-12 treatment (256, 257). On the contrary, while 
p50- or Bcl-3-deficiency suppresses TH2 differentiation upon IL-4 treatment, enhanced 
proliferation and IFN-γ secretion is detected in p50-deficient mice (257). Interestingly, 
deficiency in c-Rel does not affect T cell polarization, but c-Rel knockout mice are deficient in 
IFN-γ secretion by NK cells, indicating the influence of lymphocyte differentiation and IFN-γ 
production by NF-κB family members is cell type-dependent (253, 257). The long non-coding 
RNA located downstream of Ifng, Tmevpg1, also regulates Ifng expression (249). Tmevpg1 
opens up the chromatin by recruiting WDR5, a subunit in H3K4 methyltransferase to the Ifng 
loci (258). Tmevpg1 overexpression is insufficient for inducing IFN-γ and T-bet is required to 
stimulate IFN-γ transcription in CD4 T cells; concomitantly, expression of Tmevpg1 is controlled 
by STAT4 and T-bet (259).  
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1.3.1.2 Regulation of IFN-γ in NK cells 
Constitutive expression of Ifng positions NK cells to produce IFN-γ rapidly upon activation 
(235). NK cells can be activated by two major pathways – surface receptors and cytokines. NK 
cells express multiple surface receptors that regulate their activities. Activation receptors 
recognize the presence of stress signals such as MICA, specific C-type lectins, and antibodies on 
the target cells (234). These receptors are associated with ITAM-containing proteins, which upon 
activation, lead to phosphorylation of src family phosphotyrosine kinases (PTKs), Syk family 
kinases, and eventual activation of MAPK pathways (234). Activation of MAPK kinase and 
subsequent calcium ion influx are critical for IFN-γ secretion for both murine and human NK 
cells, despite possessing different activating receptors. On the contrary, inhibitory receptors, 
which contain ITIMs, recognize MHC-I and deactivate NK cells through activating SHP family 
phosphatases that dephosphorylate kinases downstream of src (260). Thus, the balance of 
activation and inhibitory signals is an important fulcrum for IFN-γ production versus inhibition 
through this pathway.  
NK cells can also be activated by cytokines. IL-12p70, an active heterodimeric cytokine 
composed of p35 and p40 chains, is a prominent IFN-γ inducer that signals through STAT4. 
While the source for IL-12 is debatable and is likely immune context-dependent, macrophages 
(261–263), dendritic cells (264, 265), and PMNs (266, 267) have been implicated as IL-12 
secretors. IL-12 also indirectly enhances IFN-γ expression through induction of CD28. Ligation 
of CD28 with CD80/86 enhances NK cell cytotoxicity and IFN-γ production (268, 269). IL-12 
induces T-bet expression, which is the signature transcription factor for TH1 polarization. In 
murine NK cells, while T-bet deficiency does not influence the capability to produce IFN-γ, T-
bet is needed for sustained IFN-γ production; correspondingly, T-bet binds to Ifng upstream of 
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the promoter site (252). IL-2 primarily signals through STAT3 and STAT5, but it also activates 
STAT4 and MAPK in NK cells and leads to IFN-γ production (270); it also enhances IFN-γ 
production independent of STAT4. Other proinflammatory cytokines cannot induce IFN-γ 
secretion alone but augment Ifng transcription in IL-12- and IL-2-responding cells. Type I IFN 
primarily signals through STAT1 and STAT2 but can also activate STAT4 to enhance Ifng 
induction (271). IL-1 (272) and IL-18 (273), which activate NF-κB, have also been shown to 
augment Ifng transcription. IL-15 may work in synergy with IL-18 to stimulate IFN-γ 
expression; moreover, IL-15 is a proliferation and maintenance signal for mature NK cells. 
Deficiency in IL-15 or its receptor led to loss of NK cells in mice (274, 275). On the other hand, 
IL-10 and TGFβ negatively regulate induction of IFN-γ. IL-10 has been shown to both stimulate 
and inhibit IFN-γ production by NK cells through distinct mechanisms. While IL-10 augments 
IFN-γ production by activated NK cells (276), it also inhibits IL-12 production by myeloid cells, 
indirectly suppressing IFN-γ induction (277). TGFβ is an important negative regulator for IFN-γ. 
TGFβ signals through SMAD3 complexes, which occupy the Ifng promoter, subsequently 
suppressing transcription (278, 279). It also inhibits expression of STAT4, IL-12Rβ2, and T-bet, 
which are important for IFN-γ expression, but such inhibition can be countered by IL-12, IL-15, 
and IL-18.  
1.3.1.3 Regulation of IFN-γ in T cells  
Production of IFN-γ by T cells is contingent upon T cell maturation and differentiation. 
Thus, Ifng gene expression is tightly regulated in T cells. Activation signals from the TCR and 
ligation of CD28 to the co-stimulatory molecules CD80 or CD86 on antigen-presenting cells 
drive maturation of naïve T cells. While naïve CD8+ T cells have a strong tendency to mature 
into cytolytic lymphocytes that secrete IFN-γ, differentiation of CD4+ T cells requires additional 
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cytokine signals. Similar to NK cells, IL-12 also promotes TH1 development and Ifng expression 
in T cells; however, STAT4-deficient cells are capable of producing a low level of IFN-γ in 
response to TCR ligation, suggesting IL-12/STAT4 signaling is needed for amplification but not 
initiation of IFN-γ transcription in CD4+ T cells. Sustained TH1 response and IFN-γ production 
requires STAT4 and T-bet (280). 
Activation signals and costimulation combined with IL-12 drive expression of T-bet and 
subsequent Hlx and Runx3 transcription. HLX is a homeobox transcription factor that increases 
chromatin accessibility for Ifng (281). Sustained HLX expression in mature TH1 suggest its role 
in genetic imprinting and/or maintenance of the TH1 phenotype (282). T-bet and RUNX3 bind to 
and activate the Ifng promoter while silencing IL-4 expression, further polarizing immune 
response towards the type I phenotype (283). Secretion of IFN-γ by memory T cells (TMEM) is 
more rapid and has a lower threshold than naïve T cells. TMEM, especially CD8+ TMEM, are 
capable of producing IFN-γ within hours of stimulation by cytokine or antigen in the absence of 
costimulation (284). This can be attributed to the higher levels of IL-12β2 and IL-18 receptors in 
memory cells. 
1.3.2 Signaling of IFN-γ 
Upon ligation of IFN-γ to the receptor complex IFNGR1/IFNGR2, JAK1 and JAK2 
trans-phosphorylate each other and the receptor, creating docking sites for STAT1 and leading to 
STAT1 phosphorylation at Y701 (pSTAT1). Active pSTAT1 dimerizes and translocates to the 
nucleus. Active pSTAT1 dimers induce expression of target genes regulated by the gamma-
activated sequence (GAS) element. In the nucleus, acetylation of pSTAT1 by CBP 
acetyltransferase lead to recruitment of phosphatases and inactivation of STAT1, which is 
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shuttled back to cytoplasm for re-activation (285). Maximum transactivation by STAT1 also 
requires activation of PI3K by the JAK kinases phosphorylating and activating PKC, which in 
turn phosphorylates STAT1 at S727 (286–288).   
In addition to STAT1, IFN-γ also activates other signaling pathways, including STAT3, 
MAPK, and mTOR pathways in a cell type- and stimulus-dependent manner. IFN-γ treatment 
results in transient activation and phosphorylation of STAT3 at Y705 in a GSK3β- and src 
kinase- dependent manner, resulting in transcription of survival genes (289). MAPK is a 
signaling pathway that involves cascades of kinases and results in activation of many genes. 
IFN-γ activates the MAPKs JNK-1, p38, and ERK1/2, which play distinct functions in 
macrophages. JNK-1 activates genes associated with antigen presentation (CIITA, MHC-II) 
whereas p38 activates primarily transcription of chemokines (CCL5 and IP-10) and 
proinflammatory molecules (nitric oxide and TNFα). While Erk1/2 is also phosphorylated in 
IFN-γ-treated cells, modest effects are observed on inflammation and antigen presentation (290). 
Downstream of PI3K, Akt and mTOR are activated, which regulate mRNA translation. In 
macrophages, suppression of mTORC1 and translation upon IFN-γ treatment inhibits non-
opsonized phagocytosis (291) and promotes autophagy (292). In fibroblasts and monocytes, 
mTORC2 is activated and necessary for induction of antiviral responses (293). Activation of 
additional signaling molecules such as STAT5 and CrkL/C3G has been reported also (294); 
however, their effects on immune modulation remain unclear.  
Termination of IFN-γ signaling is important as sustained interferon signaling results in 
chronic inflammation that could be pathological. IFN-γ responses can be halted by inactivation 
of downstream signaling molecules and by abolishing IFN-γ-receptor interaction. The suppressor 
of cytokine signaling (SOCS) molecules SOCS-1 and SOCS-3 (295, 296), which are downstream 
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of STAT1, inactivate JAK1/2 and provide negative feedback to inhibit signaling. Mice lacking 
SOCS-1 rapidly succumb to autoimmunity and inflammation (297). Conversely, overexpression 
of SOCS proteins can reverse IFN-γ-mediated chronic inflammation (298). The SOCS family 
molecules inhibit JAK-STAT signaling by binding and sequestering JAKs (299–302) and/or 
targeting them for proteasome degradation (303). Tyrosine phosphatases such as TC-PTP and the 
SHP family phosphatases inactivate IFN-γ signaling by dephosphorylating the receptor, JAK, 
and STAT1. Receptor endocytosis has also been hypothesized to influence IFN-γ signaling. 
Upon ligation to the receptor, IFN-γ/IFNGR complexes are aggregated on lipid rafts and 
endocytosed in clathrin-coated pits, leading to degradation of IFN-γ by fusion with lysosomes. 
Alternatively, IFNGR has been reported to localize in cav-1-containing caveolae (304). While 
IFNGR is not endocytosed by caveolae, cav-1 acts like a SOCS protein by interacting with and 
inhibiting JAK2, and deficiency of cav-1 results in hyperactivation of JAK-STAT signaling and 
pathology in vivo. 
1.3.3 Control of flaviviruses by IFN-γ 
Because IFN-γ signals through STAT1, establishment of innate antiviral state through induction 
of ISGs is likely one mechanism for IFN-γ control of flaviviruses. Treatment of various cell 
types with IFN-γ inhibits replication of JEV, TBEV, WNV, and DENV in vitro (143–146). In 
mice lacking IFN-γ response, defects in viral control as early as one day has been reported (146). 
IFN-γ-activated macrophages possess enhanced phagocytic activity and capacity to eliminate 
pathogens (305). One effector downstream to IFN-γ is induced nitric oxide synthase (iNOS), 
which generates nitric oxide, a potent radical that can modify macromolecules (306). Inhibition 
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of JEV by IFN-γ treated macrophages is dependent on nitric oxide induction, as pharmacological 
inhibition of iNOS abolished the effects of IFN-γ (145).  
IFN-γ also influences the pathogenesis of various flaviviruses differently. IFN-γ-
deficiency resulted in increased viral load in the spleen and the CNS of mice infected with WNV 
(146) and DENV (246), whereas in MVEV (140) and JEV (307) infection, only the CNS viral 
load was increased. Prophylactic treatment of NHPs with IFN-γ suppressed WT YFV replication 
and delayed death (147).  In addition, the sources of IFN-γ are also dependent on the virus and/or 
the model. IFN-γ, which regulates T cell differentiation and class switching, is also important in 
formation of memory response as 17D vaccinated IFN-γ-deficient mice exhibited poor virus 
control upon intracerebral challenge (308). 
1.4 MAMMALIAN MODELS FOR YELLOW FEVER VIRUS  
Animal models are valuable for understanding host-pathogen interactions. Historically, YFV has 
been studied in multiple mammalian models that recapitulate various aspect of YFV biology, 
each with its own benefits and drawbacks. A good animal model should recapitulate important 
aspects of human-pathogen interactions despite potential genetic and physiological 
discrepancies. Technical aspects including cost-effectiveness and availability of reagents are also 
critical. To model YFV, considerations such as route and dose of infection, disease course and 
pathology, and immune response should be made. One major challenge for developing a small 
animal model for YFV is resistance to disease by non-primates. One possible explanation is that, 
because YFV is transmitted between primates and mosquitoes in nature, the virus may have 
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evolved to overcome the primate immune system but not necessarily the murine immune system. 
In this section, common animal models for studying YFV will be briefly discussed.  
1.4.1 Non-human primate 
Genetic and physiological similarities between human and non-human primates (NHPs) make 
NHPs valuable for studying YFV biology. In NHPs, subcutaneous (s.c.) infection with virulent 
wild-type YFV leads to viscerotropic disease similar to human YF, and vaccination with 17D 
leads to protection from wild-type virus challenge. The NHPs are valuable tools for studying 
immunity, pharmaceuticals efficacy, vaccinology, pathogenesis, and ecology with respect to 
YFV; however, the cost, availability of molecular tools, and genetic variations among individual 
NHPs hinder their extensive use as a model (185, 309). Furthermore, different species of NHPs, 
particularly old world versus new world monkeys, respond differently to YFV infection. 
Specifically, with the exception of rhesus and cynomologous macaques, old world NHPs such as 
baboons experience milder disease than new world NHPs such as marmosets, which are highly 
susceptible to YFV infection (310). This is largely consistent with the fact that YFV originated in 
the old world and spread to other continents through slave trade; hence, old world NHPs likely 
co-evolved with YFV and are more resistant to it.  
In rhesus macaques, infection with WT YFV usually leads to a more rapid and severe 
disease than in humans. Upon s.c. infection, serum viremia is detectable at 3dpi and continues to 
increase until the host succumbs to disease, which often occurs within a week. In deceased 
monkeys, cytokine storm, lymphopenia, and necrosis in visceral organs like spleen, liver, and 
kidney are observed. Decline in liver and kidney functions are detected within 24hr before death. 
Interestingly, YFV antigen is only detectable in liver but not spleen or kidney, suggesting soluble 
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mediators rather than viral replication may contribute to YFV pathogenesis in this model (224, 
309). In addition, expression of zinc-binding proteins is disrupted in WT infection but not 17D 
vaccination in circulatory monocytes, which may explain the differential pathogenesis between 
virus strains. 
1.4.2 Golden Syrian Hamster 
The Golden Syrian hamster (Mesocricetus auratus) is a susceptible host for YFV. Intraperitoneal 
(i.p.) infection with WT strains of YFV results in viremia without obvious signs of disease in 
hamster; however, hamster-adapted WT virus strains of Asibi (216) and Jimenez (311, 312) lead 
to viscerotropic disease similar to human YF in this model. When compared to the parent Asibi 
strain, the hamster-adapted Asibi strain has 11 nucleotide changes, leading to seven amino acid 
changes. No nucleotide change occurs in the UTRs. Among these amino acid differences, five 
occur in the E protein, one in NS2A, and one in NS4A. While the contribution of these mutations 
to pathogenesis remains to be studied, it is likely that changes in E protein aid receptor binding 
or entry processes because most of these mutations are located at the exposed surface of domain 
III of E protein, which binds the receptor (216). The need to adapt the virus in hamster and the 
lack of immunological reagents renders direct comparison of 17D to Asibi difficult in the 
hamster model; however, this system has been useful in evaluating drug candidates against YFV. 
Two antiviral compounds, Flavipiravir (an RDRP inhibitor, also known as T-705) (313) and 
BCX-4430 (a nucleoside analog) (314), have been shown to have potent antiviral activities 
against YFV in hamsters. It remains to be investigated if such results can translate to humans 
clinically. Prophylactic treatment with IFN delivered by an adenovirus vector also protects 
hamsters from YFV infection (315). 
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1.4.3 House mouse 
The house mouse (Mus musculus) from various backgrounds such as 129, BALB/c, Swiss, and 
C57BL/6 has been used for studying YFV. Immunocompetent adult mice are highly resistant to 
peripheral infection with both WT and 17D viruses but are susceptible to i.c. infection that leads 
to encephalitic disease. However, this model does not readily distinguish 17D and WT strains. 
One way to circumvent the need for i.c. infection is neuroadaptation of YFV. Serial passaging of 
17D in mouse brain suspension led to enhanced neuroinvasiveness and neurovirulence and adult 
mice were susceptible to i.p. infection of the neuroadapted 17D (55). In contrast to adult mice, 
suckling mice are susceptible to peripheral infection with YFV through the i.p. route. While 17D 
and WT strains can be differentiated based on relative virulence, infection still results in lethal 
encephalitic disease and susceptibility to both viruses is age-dependent.  
Mice lacking various innate immune components have proven to be extremely valuable 
in studying YFV. From an evolutionary perspective, YFV circulates between mosquitoes and 
NHPs but not rodents; thus, it is rational to reason that YFV has adapted to overcome antiviral 
mechanisms in primates more efficiently than in rodents. This is corroborated with reports that 
multiple flaviviruses antagonize human IFN response proteins more efficiently than the murine 
homologs (78, 91, 92). Intraperitoneal infection with WT YFV strain Asibi in rhesus macaques is 
uniformly lethal whereas nude-athymic mice are protected (316), suggesting that murine innate 
immunity exerts a strong blockade against YFV infection (317). Mice that lack the type I IFN 
receptor (IFNAR-/-) are highly susceptible to WT YFV infection and s.c. infection leads to 
viscerotropic disease similar to human YF, including midzonal necrosis in liver, elevated 
cytokines, splenomegaly, and death (139). In contrast, while 17D vaccination in IFNAR-/- mice 
leads to serum viremia and viral replication in various tissues, 17D is avirulent and confers 
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protection to WT virus challenge afterwards, similar to human vaccination. Despite the lack of 
type I IFN responses, IFNAR-/- mice vaccinated with 17D have robust, functional, and long-term 
protective immunity (210). Neutralizing antibody is the main protective factor against WT virus 
infection, and different lineages of T cells likely have different protective roles. In the peripheral 
challenge model, which leads to viscerotropic disease in IFNAR-/- mice, CD4+ T cells and 
antibodies are important for protection, and some immune CD4+ T cells are cytolytic (210). 
However, in an intracerebral challenge model in immunocompetent mice, CD8+ T cells and 
antibodies are needed instead (211). While the latter model uses a non-physiological route of 
infection, these data overall suggest that 17D elicits a diverse T cell response that plays distinct 
roles in protection in different anatomical regions.  
Interestingly, mice that lack both type I and type II IFN (IFNAGR-/-) are susceptible to 
17D infection and disease (139, 318). Intraperitoneal and s.c. infections with 17D are uniformly 
lethal in IFNAGR-/- mice. High 17D viral titer can be detected in both visceral and neuronal 
tissues at late stages of infection. These reports indicate that type II IFN is an attenuation factor 
for 17D, and IFNAGR-/- mice can serve as a potential model for severe adverse events associated 
with 17D vaccination. 
1.5 HYPOTHESIS 
Despite the long history of 17D vaccination and current efforts to utilize 17D as a vector for 
other vaccines or as a template for generation of LAVs for other flaviviruses, our understanding 
of 17D attenuation and YFV pathogenesis is limited. One major obstacle for understanding 
attenuation of YFV vaccine strain 17D is the lack of a small animal model that recapitulates 
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important aspects of YFV biology, i.e., differential virulence of WT strains and 17D upon s.c. 
infection where WT virus infection causes viscerotropic disease, and 17D vaccination confers 
immunity. Most previous mouse studies on YFV were performed by i.c. infection, which led to 
neurologic disease. These studies have highlighted the importance of envelope glycoprotein and 
NS1 glycosylation as virulence determinants. However, the lack of differential virulence 
between 17D and Asibi in i.c. infection models suggests the need for a more stringent animal 
model to study human-YFV interactions. 
The mechanisms of 17D attenuation remain elusive. As described above, regarding viral 
attenuation factors, Lee et al. reported that enhanced glycosaminoglycan binding of 17D due to 
genetic changes in E-380 led to enhanced viral clearance from serum and attenuation; however, 
reversion of this mutation alone was insufficient to restore virulence to WT level, suggesting 
multiple mutations are involved in attenuation (27). In addition, one report suggested that 17D 
enters susceptible human cells through a clathrin-independent pathway whereas Asibi uses 
clathrin-coated pits (217). This phenomenon is due to genetic changes in the E protein but E-380 
alone cannot confer the phenotype. On the host side, we and others have reported that mice that 
lack both type I and II IFN systems are highly susceptible to 17D infection while mice that lack 
only the type I IFN receptor are resistant to peripheral infection, indicating that type II IFN is an 
attenuation factor in vivo (139, 210, 318). A recent study also suggested the potential 
neuroprotective role of type III IFN in 17D infection (151); however this study used the 
intravenous route of infection with a non-physiological high dose (107 PFU) of virus, which 
renders relevance of the data to human vaccinees questionable. 
Previous studies from our lab have developed a mouse model that recapitulates the 
important aspects of YFV infection in humans (139, 210). In this model, mice lacking the type I 
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IFN receptor (IFNAR-/-) are resistant to 17D infection and disease but susceptible to WT YFV 
infection and disease through the s.c. route. WT virus infection leads to viscerotropic disease 
signs, including mid-zonal necrosis of liver and loss of lymphoid follicles in the spleen, whereas 
17D vaccination in IFNAR-/- mice confers protective immunity against WT virus challenge for 
more than 18 months post-vaccination. Upon challenge, vaccinated IFNAR-/- mice has no sign of 
disease and the virus titer is almost undetectable. In addition, we and others have reported that 
additional deletion of the type II IFN receptor renders the animal susceptible to 17D disease, 
indicating IFN-γ is an important attenuation factor for 17D (139, 318). Based on these results, I 
propose the following hypotheses for my studies: 
1. IFN-γ restricts 17D viral replication and dissemination in vivo.  
2. IFN-γ is directly antiviral to 17D but not wild-type YFV. 
The results of this study will advance our understanding of one mechanism of attenuation 
of YFV vaccine strain 17D and will provide insights on generating live attenuated flaviviruses as 
vaccine candidates.  
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2.0  PATHOGENESIS OF 17D IN THE ABSENCE OF GAMMA-INTERFERON 
SIGNALING 
2.1 PREFACE 
Most of the work described in this chapter are adapted from a published study (LK Metthew 
Lam, Alan M. Watson, Kate D. Ryman, William B. Klimstra, 2018, NPJ Vaccines 3, article 
number 5). 
2.2 INTRODUCTION 
YFV is the prototypical member of the Flavivirus genus of the Flaviviridae family, which 
includes many important arthropod-borne pathogens such as dengue, Zika, West Nile, and 
Japanese encephalitis viruses. YFV is estimated to cause 200,000 cases of disease and 30,000 
mortalities annually (184). Historically, YFV has caused devastating outbreaks in North 
America, South America, Africa, and Europe but is currently endemic to sub-Saharan Africa and 
South America. However, a recent YF outbreak in Angola led to at least 300 deaths (319) and 10 
symptomatic traveler-associated cases in China (180). In addition, outbreaks that occurred in 
Espírito Santo in 2017, which is not considered at risk for YFV historically, and Uganda in 2011, 
which has not experience YFV outbreak since 1972, suggest that YFV remains a problem in the 
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modern world and threatens to expand geographically (320, 321). Mosquito abatement programs 
and vaccination with the live-attenuated YFV vaccine strain 17D remain the primary strategies 
for controlling YF outbreaks (169, 322). 
The YFV vaccine strain, 17D, is arguably one of the most effective vaccines ever 
developed. A single dose of 17D results in seroconversion in >90% of vaccinees within a week 
and can offer essentially life-long immunity against YFV infections (196, 323). While the safety 
record of 17D is exemplary, potentially lethal severe adverse events occur with low frequency 
and these can involve both viscerotropic and neurotropic manifestations of virus disease (221, 
227, 230, 324, 325). Regardless, due to the overall safety and effectiveness of 17D, multiple 
candidate vaccine vectors have been created using its genetic backbone, and these are currently 
being tested as a delivery system for antigens of other flaviviruses or other pathogens (326–329).   
Despite being safe and effective, the mechanisms for attenuation and immunogenicity of 
17D remain elusive. The 17D vaccine strain was derived by Max Theiler in 1930s through serial 
passaging of wild-type YFV strain Asibi in tissue culture, resulting in loss of viscerotropism and 
neurovirulence in non-human primates (330). Multiple substrains of 17D, including 17D-204, 
17D-213, and 17DD have been generated and used for vaccination (331), with similar efficacy 
(207, 332). An average of 48 nucleotide and 20 amino acid changes distinguish 17D substrains 
from the parent Asibi strain (333, 334). The attenuation of 17D is attributed to genetic 
differences in both structural and non-structural proteins, but the role of specific mutations in the 
attenuation phenotype is not well characterized. Lee et al. suggested that a positive-charge 
mutation in the 17D E protein that leads to enhanced glycosaminoglycan binding, contributes to 
attenuation, but attenuation likely involves multiple 17D loci (27). It was recently demonstrated 
that E protein mutations allow 17D to enter susceptible cells through clathrin-independent 
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pathways, leading to an enhanced antiviral response in vitro (217). We recently reported that 
both neutralizing antibody and CD4+ T cells are important in 17D-mediated protection from 
lethal wild-type YFV infection in a viscerotropic disease model (210). However, questions 
remain regarding the specific virus-host interactions that are modified by the 17D attenuating 
mutations and the mechanisms through which 17D induces highly protective immune responses. 
Understanding of the mechanisms of 17D attenuation will promote informed design of live 
attenuated versions of other flaviviruses and vaccines derived from other virus types.  
To assess the specific host interactions affected by 17D attenuating mutations, we have 
used a pathophysiologically relevant mouse model to study host-pathogen interactions of YFV. 
Many WT flaviviruses, including YFV, replicate extremely poorly in mice with a functioning 
type I IFN system, precluding study of the roles of other host factors in their pathogenesis.  
Flaviviruses are more effective at antagonism of human type I IFN signaling than the analogous 
mouse responses (78, 91). Indeed, mice deficient in the type I interferon (IFN-/) receptor 
(AB6) are susceptible to viscerotropic disease and lethality after s.c. infection with wild-type 
YFV strains Asibi and Angola71 (139). Interestingly, s.c. infection of 17D in AB6 mice, which 
mimics vaccination, does not cause discernable disease and results in life-long immunity against 
challenge with a WT virus strain Angola71 (210). However, mice lacking both type I and type II 
IFN receptors (AGB6) are susceptible to lethal infection by 17D by either subcutaneous or 
intraperitoneal routes (27, 139, 318). The fact that the additional deficiency of the type II IFN 
(IFN-) receptor renders 17D infection lethal in AB6 mice suggests that the type II IFN system 
plays a critical role in attenuation of 17D in vivo.  
To begin to understand the effects of IFN- on 17D, we have compared infection of AB6 
and AGB6 mice. IFN-γ restricted 17D virus replication and dissemination early during infection 
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and enhanced clearance later after infection. Antiviral gene induction and cytokine production 
was also influenced by the presence or absence of type II IFN signaling. Finally, 17D infection 
resulted in liver stress and histological abnormalities in the spleen and brain of AGB6 but not 
AB6 mice, demonstrating that both viscerotropic and neurotropic diseases occurred in the 
absence of IFN-γ signaling and revealing a possible application for the AB6 model in 
understanding vaccine-associated viscerotropic and neurotropic adverse events. 
2.3 RESULTS 
2.3.1 IFN-γ attenuates 17D but not virulent YFV in vivo 
To investigate the role of IFN-γ in 17D attenuation, we compared pathogenesis of 17D in AB6 
and AGB6 mice. Groups of 6-week-old mice were infected subcutaneously with 104 PFU of 
YFV strains 17D-204 or Angola71 in both of the hind limb footpads. The virulent WT strain 
Angola71 was used as control. Similar to our previous reports (139, 210), Angola71-infected 
mice experienced severe weight loss and disease, requiring euthanasia (AST 7.5 +/- 0.6dpi), 
whereas 17D-204 was uniformly non-lethal in AB6 mice. In contrast, 17D-204-infected AGB6 
mice experienced severe weight loss and eventually succumbed to disease (AST 10.75 +/- 
0.5dpi) (Fig. 3A-B). Both 17D-204-infected AB6 and AGB6 mice exhibited footpad swelling, 
which peaked between 7-8dpi (Fig. 3C). In addition to footpad swelling, 17D-204-infected 
AGB6 mice displayed signs of brain infection and neurologic disease including hind limb 
paralysis, paresis, and/or seizures at late stages of infection, before euthanasia (Fig. 3D).  
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Figure 3: IFN-γ attenuates YFV-17D in vivo.  
Groups of 6-week-old AB6 or AGB6 mice were infected s.c. with 104 PFU YFV 17D-204 or Angola71. (A) 
Survival, (B) weight loss, (C) footpad swelling, and (D) symptoms of diseases were measured daily. Data in (A) are 
analyzed with log-rank test. Data in (B) and (C) are presented as mean ± SD. (17D-204 infections, n >6; Angola71 
infections, n = 4.) 
2.3.2 IFN-γ restricts 17D replication and replication in vivo 
Because IFN-γ influenced survival of mice after 17D-204 infection, we hypothesized that virus 
replication is reduced and restricted in its presence. Thus, we compared 17D virus replication 
kinetics in different tissues of the AB6 and AGB6 mice. In parallel, tissues from 17D-204-
infected wild-type (C57BL/6) mice were harvested, but no infectious virus was recovered from 
any sampled tissue (Fig 4A-F). 
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The regional lymph node draining the site of infection (DLN) is one of the earliest sites 
for flavivirus replication and important for seeding viremia and dissemination (139). At 1dpi, 
17D-204 virus was recovered from the DLN in both AB6 and AGB6 mice. In the absence of the 
IFN-γ response, 17D-204 virions were more abundant as early as at 1dpi (Fig. 4A). Serum 
viremia was first observed at 2dpi; however, no significant difference was observed in AB6 
versus AGB6 at this time point. 17D-204 virions were detectable in bone marrow aspirate and 
spleen at 2dpi only in the absence of IFN-γ response. However, by 4dpi, high virus titers were 
observed in the spleen, bone aspirate, non-draining lymph nodes (mesenteric LN), and adrenal 
glands in both types of mice (Fig. 4C-G), although, higher virus titers were observed in AGB6 
mice in most of these tissues. Interestingly, infectious virus particles were recovered from 
kidney, liver, and brain in AGB6 mice but not with AB6 mice (Fig. 4F, H-I). In the presence of 
IFN-γ responses, virus clearance was observed from most organs by 8dpi, but virions were still 
detected in all sampled organs in AGB6 mice at this time. Despite lacking both type I and type II 
IFN, virus clearance was observed in most the non-CNS tissues of AGB6 mice by 12dpi, before 
they succumbed to disease. In contrast, virus replication in the brain increased through 12 dpi (up 
to 106 PFU/g) in the AGB6 mice (Fig. 4F), through the times when neurological signs were 
observed (Fig. 3D). Overall, in the presence of IFN-γ, 17D-204 replication was controlled as 
early as 1dpi. Some dissemination of virus still occurred in AB6 mice, but the peak viral load 
was significantly lower than that of AGB6 mice. Virus tropism was also restricted by IFN-γ, 
most notably absent from liver and brain, and virus clearance was observed in most tissues by 
8dpi. In the absence of IFN-γ responses, virus clearance occurred later and replication in the 
CNS tissues was poorly controlled. 
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Figure 4: IFN-γ restricts 17D-204 replication and dissemination in vivo. 
Tissues from 17D-204-infected mice were harvested at various days post-infection (B6 = C56BL/6). Tissues were 
homogenized, and virus titers were determined by standard plaque assay on Huh7 cells. (A) Draining (popliteal) 
lymph node, (B) serum, (C) non-DLN (mesenteric), (D) 1mL bone marrow aspirate, (E) spleen, (F) liver, (G) 
adrenal gland, (H) kidney, and (I) brain titers were measured. Data are presented as geometric mean ± 95% CI. (* p 
< 0.05; ** p < 0.01; *** p < 0.005; **** p < 0.001; multiple t-test, corrected by Holm-Sidak method.)  
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2.3.3 IFN-γ protects mice from 17D-induced viscerotropic and neurotropic diseases  
Because 17D is known to cause viscerotropic and neurotropic infection in vaccine-associated 
SAE cases, we sought to determine if tissue pathology could be detected after 17D infection in 
the absence of an IFN-γ response. We investigated tissue pathology at 4dpi, which is the peak of 
viral replication in most visceral organs in both AB6 and AGB6 mice and 11dpi, when AGB6 
animals displayed neurologic signs before succumbing to disease. At 4dpi, hematoxylin and 
eosin (H&E) stained spleen sections (Fig. 5A) of 17D-204-infected AB6 and AGB6 mice were 
indistinguishable from mock-infected animals. In contrast, spleens of Angola71-infected mice 
displayed loss of splenic architecture and increase in inflammatory infiltrates, similar to our 
previous findings (139). Despite the lack of titerable virus in the spleen at 11dpi (Fig. 4C), 
spleens of 17D-204-infected AGB6 had increased numbers of inflammatory infiltrates and 
exhibited a loss of splenic architecture (Fig. 5A). Immunostaining of spleen sections from 
infected AB6 and AGB6 mice demonstrated the presence of YFV antigens in F4/80+ cells (red 
pulp macrophages) and cells in the outer marginal zone (Fig. 5B) at 4dpi at similar levels. H&E-
stained liver sections revealed microsteatosis occurring only in the liver of 17D-204-infected 
AGB6 mice at 4dpi (Fig. 6A), a time at which virions were detectable in the liver (Fig. 4E), and 
thus, indicative of a viscerotropic phase of 17D infection in the absence of IFN-γ responses. 
Moreover, YFV antigen could be detected in some F4/80+ cells in the liver of infected AGB6 
mice, suggesting that Kupffer cells were infected in these animals (Fig. 6B). Corresponding to 
the time of neurological signs in 17D-204-infected AGB6 mice (11dpi, Fig. 3D), we observed an 
increase in immune infiltration to the cerebral cortex (Fig. 7A) and virus-infected cells in the 
cerebral cortex and cerebellum of the brain (Fig. 7B), indicative of neurotropic disease. No such 
phenomena were detectable in 17D-204 infected AB6 animals. Overall, the histology data  
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Figure 5: 17D infection led to splenic damage in the absence of IFN-γ. 
(A) H&E sections from spleen of 17D-204-infected animals were indistinguishable at 4dpi, whereas Angola71-
infected animals display loss of white pulp and red pulp architecture and increase in infiltrating macrophages and 
neutrophils (inset) at 4dpi. At 11dpi, 17D-204 infected AGB6 has increased immune infiltration and disruption of 
lymphoid follicles but not AB6 mice. (B) YFV antigen can be detected in the spleen at 4dpi in both AB6 and AGB6 
mice in the red pulp and outer marginal zone area. n≥3, original magnification = 40x. 
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Figure 6: 17D infects liver and induces liver stress in the absence of IFN-γ. 
 (A) H&E sections of 17D-204-infected AB6 mice do not display major histological changes but infected AGB6 
mice and Angola71-infected animals had microsteatosis (inset) at 4dpi. In AGB6 mice, microsteatosis only occur 
transiently at 4dpi and resolved by 11dpi. (B) Antibody-stained frozen sections revealed that YFV antigen could 
only be detected in infected AGB6 mice at 4dpi but not AB6 mice, parallel to titer data in Fig. 2. Arrowhead 
indicates YFV-infected F4/80+ cells. n≥3, original magnification = 40x. 
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Figure 7: Inflammation and viral antigens in brains of 17D-infected AGB6 mice. 
In (A) H&E stained brain sections, 17D-204-infected AGB6 mice but not AB6 or mock-infected animals had 
increased cellular infiltration into the cerebral cortex at 11dpi. Concomitantly, YFV antigens can be detected in (B) 
cerebrum and (C) cerebellum. n≥3, original magnification: (A-C) 20x, inset in (B) 40x.  
 60 
demonstrate that IFN-γ restricts 17D-204 dissemination and protects mice from viscerotropic and 
neurotropic diseases. 
2.3.4 Cytokine induction is impaired in the absence of IFN-γ 
IFN- is central to activation of T cells and macrophages, and induces production of other 
proinflammatory cytokines. Therefore, we hypothesized that the absence of IFN- would impact 
cytokine production during 17D infection. To this end, serum cytokine levels in infected mice 
were measured at various times post-infection using the Cytokine 20-plex Mouse Panel (Fig. 8). 
In AB6 mice, serum levels of IFN-, IL-12p40, MIG, MCP-1, and IP-10 were elevated 
transiently versus uninfected controls on day 4pi, corresponding to the peak spleen virus titer 
(Fig. 4D). While AGB6 mice also exhibited a slight increase in serum IL-12 and MCP-1 levels 
on day 4pi, serum IFN- levels were highly elevated in comparison with control or AB6 mice on 
this day and at days 8 and 12pi. Wild-type YFV-infected AB6 mice produced higher levels of 
serum cytokines (IFN-, MIG, MCP-1, IL-4, IL-5, IP-10, and TNF) more rapidly than in 17D-
infected AB6 or AGB6 mice (Fig. 8), possibly associated with the severe viscerotropic disease 
and rapid death of the WT virus-infected animals (139). The cytokines that were more 
significantly upregulated in 17D-204-infected AB6 but not AGB6 mice, i.e. IL-12, MCP-1, MIG, 
and IP-10, are all IFN--inducible, suggestive of a central role for IFN- in protecting AB6 mice 
from 17D-204 infection is through cytokine induction. Similar to our observations, in adult male 
vaccinees receiving YFV vaccine substrain 17DD, serum levels for IFN-, MCP-1, MIG, IP-10, 
and IFN- were reported to be elevated (191). 
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Figure 8: Cytokine response of 17D-infected animal. 
Groups of 6-week-old B6, AB6, or AGB6 mice were infected s.c. with 104 PFU of YFV 17D-204 or Angola71. Sera 
were harvested at the indicated time points post-infection by the bleeding at submandibular vein. Serum cytokines 
(A) IFN-γ, (B) IL-12, (C) MCP-1, (D) MIG, (E), IL-5 (F), IL-6, (G) IP-10, and (H) TNFα were quantified using 
Cytokine 20-Plex panel bead-based assay. Data are presented as in geometric means ± 95% CI. Statistical 
comparison were determined between 17D AB6 and 17D AGB6. (*: p<0.05, ** p <0.01, *** p<0.005; multiple t-
test, corrected by Holm-Sidak method; n=3-5.)  
2.3.5 IFN-γ is secreted by NK cells early during 17D infection 
IFN- has been shown to upregulate and activate cellular and humoral immunity, but it can also 
exhibit direct antiviral activity against YFV in many cell types through upregulation of genes 
that encode antiviral effector proteins, such as IFN-stimulated genes (ISGs). Since IFN- 
inhibition of 17D-204 occurred at early times after infection of AGB6 mice, we attempted to 
determine if differences in tissue-specific IFN- or ISGs expression could be detected in the 
absence of IFN-. Because we observed inhibition of 17D-204 replication and dissemination 
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before 4dpi, we examined IFN- transcript induction from 1dpi to 4dpi. Robust upregulation of 
the IFN- gene was observed as early as 2dpi in lymph nodes but not spleens of both AB6 and 
AGB6 mice (Fig. 9A). Using flow cytometry (Fig. 9B-D), we observed induction of IFN- in 
NK1.1+ cells in the DLN, similar to a previous report that used immunocompetent B6 and 
BALB/c mice (160). Despite the lack of IFN- induction in the spleen, various antiviral genes 
including IGTP, IFIT1, and IFIT2 were upregulated in the spleens of 17D-204-infected AB6 to 
higher levels mice than in spleens of AGB6 mice, indicative of IFN--dependent gene induction 
and likely a systemic antiviral effect of IFN- production (Fig. 10). 
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Figure 9: IFN-γ is produced locally at draining lymph node by NK1.1+ cells  
Tissues from 17D-204-infected animals were harvested in Tri-reagent, followed by RNA isolation, reverse 
transcription, and quantitative PCR. (A) Kinetics of IFN-γ induction from 1-4dpi. (B-D) Flow cytometry analysis 
demonstrating early IFN-γ production at 3dpi in DLN by NK cells. (B) Gating strategy for cell types of interest. (C) 
Representative flow plots for IFN-γ staining for indicated cell types. (D) Proportion of indicated cells type positive 
of IFN-γ. In (A), data are presented as geometric means ± 95% CI. In (D) Data are presented in mean ± SD (*: 
p<0.05, ** p <0.01, *** p<0.005, **** p<0.001; multiple t-test, corrected by Holm-Sidak method.) (A-D) n ≥ 5.  
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Figure 10. IFN-γ induces antiviral genes in tissues.  
Tissues from 17D-204-infected animals were harvested in Tri-reagent, followed by RNA isolation, reverse 
transcription, and quantitative PCR. Expression of (A) Igtp, (B) Ifit1, and (C) Ifit2 at 4dpi is shown here. Data are 
presented as geometric means ± 95% CI. (*: p<0.05, ** p <0.01; multiple t-test, corrected by Holm-Sidak method.) 
n>3. 
To confirm the role of NK cells in IFN- production in vivo, we performed antibody-
mediated depletion of NK1.1+, CD4+, or CD8+ T cells in 17D-infected mice. In both AB6 and 
AGB6 mice, NK1.1+ cell depletion led to a reduction in serum IFN- levels at 4dpi (Fig. 11B), 
supporting the flow cytometry data identifying NK1.1+ cells as a primary source of IFN-. 
Depletion of CD8+ T cells in AGB6, but not AB6, animals also led to reduction in serum IFN- 
levels. NK1.1+ cell depletion also resulted in enhanced 17D replication in AB6 mice (Fig. 11C), 
likely due to less IFN- production. However, depletion of NK1.1+ cells resulted in reduced virus 
titer in AGB6 mice, which may be due to the recently documented replication of 17D in NK1.1+ 
cells in the absence of IFN-α/β and IFN-γ signaling (335).  
 
 
 65 
 
Figure 11: NK cells are important for IFN-γ production. 
AB6 and AGB6 mice were injected with designated antibodies by the i.p. route and infected subcutaneously 
according to the experimental timeline in (A). (B-C) Depletion of NK1.1+ cells was confirmed by flow cytometry. 
(D) ELISA quantification of serum IFN-γ at 4dpi. (E) Serum virus titer at 4dpi. Data are presented as mean ± SD in 
(B) and geometric mean ± 95% CI in (C) (*: p<0.05, ** p <0.01, *** p<0.005, **** p<0.001; multiple t-test, 
corrected by Holm-Sidak method.)  
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2.4 DISCUSSION 
Despite the long-term success and widespread use of the 17D YFV vaccine substrains, the 
molecular mechanisms for attenuation of 17D remain unclear. One major restriction on 
understanding YF pathogenesis has been the lack of pathophysiologically relevant and cost-
effective small animal models for studying YFV pathogenesis and attenuation. Previously, we 
reported that mice lacking type I interferon receptor (IFNAR-/-) are susceptible to subcutaneous 
(s.c.) infection of wild-type YFV and display signs of viscerotropic disease similar to human YF, 
whereas 17D is avirulent in this model system (139). In addition, 17D-infection leads to 
protective immunity against wild-type YFV challenge for the life of the mouse (210). However, 
we and others have reported that 17D is virulent in mice lacking both type I and type II IFN 
receptors (IFNAGR-/-), suggesting that type II IFN is a critical attenuation factor for 17D in vivo. 
In this study, we investigated the role of IFN-γ in controlling replication of 17D in vitro and in 
vivo. Our results indicate that type II IFN restricts 17D replication and spread in vivo. 
By comparing 17D-204 pathogenesis in AB6 and AGB6 mice, we found that 17D-204 
replication was largely restricted to lymphoid compartments by IFN-γ. In the absence of IFN-γ 
response, 17D-204 infection in AGB6 mice rapidly disseminated to tissues beyond DLN, spleen, 
and bone marrow. In addition to higher viral titers, we observed signs of liver stress and 
recovered infectious virus particles in the liver on 4dpi, indicative for a viscerotropic phase of 
17D infection with the additional absence of IFN-γ responses. Despite viral clearance in the 
peripheral tissues, virus accumulated to high titer in the brain and was associated with signs of 
neurological disease including immune cell recruitment to brain and paralysis. Taking together 
our data and those of other reports (139, 318), we propose that 17D-infected AGB6 mice could 
be used to model neurotropic SAEs associated with 17D vaccination. Despite the presence of a 
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brief viscerotropic phase of 17D-204 infection in AGB6 mice, we did not observe cytokine storm 
comparable to Angola71-infected AB6 mice or extensive damage to the visceral organs (which 
can be found in viscerotropic SAE patients (227)), with the exception the spleen late during 
infection. These data indicate involvement of additional or alternative factors, such as host 
genetics (230, 336) and/or 17D genetic variants, both of which have been proposed as sources of 
SAE (231).  
Consistent with other studies of 17D vaccination in mice (160) and non-human primates 
(NHP) (337), we observed an early induction of IFN-γ after 17D-204 vaccination in our mouse 
model. Such early induction of IFN-γ resulted in contemporaneous restriction of 17D-204 in 
AB6 mice. In both AB6 and AGB6 mice, NK1.1+ cells were critical for IFN-γ production; 
however, in AGB6, CD8+ T cells (CTL) were also involved. Lymphocyte activation is driven by 
antigen abundance, and the high virus titers in AGB6 mice may have contributed to more robust 
CTL activation and IFN-γ production than in AB6 mice. In addition, a recent report has shown 
that CTL and NK cells can be infected by 17D in the absence of STAT1 (335). In that report, 
deletion of STAT1 in the hematopoietic compartment rendered mice susceptible to intravenous 
17D infection, and enhanced 17D replication in leukocytes from both myeloid and lymphoid 
lineages was detected in the spleen and the blood. Thus, we speculate that infection of both CTL 
and NK cells leads directly or indirectly to IFN-γ secretion. Whereas in AB6 mice, the presence 
of IFN-γ response partially protects T cells directly through inducing an antiviral state and/or 
indirectly through control of virus titer, leaving NK cells as the major IFN-γ producer.   
Although deficiency in IFN-γ receptor led to early virus dissemination and uncontrolled 
replication, peripheral clearance is also observed in AGB6 mice by 12dpi, which is suggestive of 
a type II IFN-independent viral clearance mechanism. The nature of this response also needs to 
 68 
be investigated, as it may be important in minimizing pathological consequences of 17D 
immunization such as SAEs. It should be noted that despite the lack of both type I and type II 
IFN responses, some antiviral genes were upregulated in our model, especially in the DLN and 
spleen. These genes may be induced directly without type I or type II through RIG-I and MDA5 
(124), toll-like receptors (129, 338), or type III IFN (149, 339), which may aid eventual viral 
clearance from the periphery even in AGB6 mice. However, it was recently reported that mice 
lacking both type I and type III IFN receptors had higher 17D titers in the brain but not other 
tissues when compared to mice lacking IFNAR1 alone, suggestive of a neuroprotective role for 
type III IFN (151). 
One major criticism of the AB6 model is the lack of a type I IFN response. However, 
evidence suggests that infection of these mice recapitulates important aspects of YFV infection 
and vaccination of human, namely, viscerotropic disease during WT virus infection and long-
term protective immunity after 17D vaccination (139, 210). Indeed, robust, protective B and T 
cell responses to 17D are present in these animals (210). In human vaccinees, the presence of 
type I IFN does not prevent 17D replication and establishment of serum viremia or mild 
reactions at the site of vaccination. Whereas in C57BL/6 mice, the presence of type I IFN 
suppressed 17D replication to the point that replicating viruses cannot be detected by 
conventional assays, and infected mice do not have local reactions such as footpad swelling after 
infection. This suggests that YFV is more resistant to, or more capable of suppressing, the human 
type I IFN system than the murine counterpart. In fact, dengue and Zika virus are more effective 
in antagonizing human innate immune signaling molecules (STAT2 and STING) than murine 
homologs (78, 91, 92). Together, these observations suggest that the type I IFN receptor-
deficient mouse is a pathophysiologically relevant model that is valuable in exploring the 
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immunogenicity, pathogenicity, and attenuation mechanisms of different YFV strains. However, 
clearly, type I IFN very likely has a role in controlling YFV in humans (193, 340).  
The cause for the severe adverse events (SAEs) following 17D vaccination is still 
unknown. Despite the adaptation of monkey neurovirulence test to ensure safety of each vaccine 
lot, SAEs still occur, suggesting additional factors are contributing to virulence of 17D in SAE 
patients. In terms of host genetics, single nucleotide polymorphisms (SNPs) in CCR5 and 
RANTES genes were found in one viscerotropic SAE case (230), while SNPs in OAS1 were 
found in another (336). These polymorphisms are implicated in aberrant immune response upon 
17D vaccination. In terms of virus genetics, mutations were found in some clinical isolates from 
SAE patients, and some, but not all of the viruses demonstrated enhanced virulence in animal 
models (341).  
Our data suggest that IFN-γ is an attenuating factor against 17D in vivo, leading us to 
hypothesize that variability of host IFN-γ signaling is one potential underlying causes for SAEs. 
In humans, genetic differences that disturb IFN-γ production or signaling have been shown to 
enhance susceptibility to infections. For instances, heritable mutations in the IL-12 receptors, 
which are critical for IFN-γ induction, and IFN-γ receptors that reduce receptor expression or 
signaling efficacy render individuals susceptible to Salmonella and disseminated Mycobacterium 
infections (342–344); importantly, these individuals are also susceptible to the disease cause by 
the generally safe M. bovis BCG vaccine strain (343). This evidence indicates that primary 
immunodeficiency in IFN-γ signaling efficacy may influence the ability to control some 
pathogens. This may explain some 17D SAEs. NK cells are important early producer for IFN-γ 
(160), and NK cells are robustly activated in vaccines by three days post-vaccination (159). 
Since flaviviruses upregulate MHC-I early during infection to suppress activation of NK cells 
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(166, 345), it is tempting to speculate that defects in NK cell activation of the vaccinees due to 
genetics or environmental factors may delay virus control and increase risk of SAE.     
These studies have revealed that the murine IFN-γ-mediated response protects IFNAR-/- 
mice from disease and promotes the eventual development of robust and long-lived protective 
immunity against wild-type YFV challenge (170) similar to human vaccination. In contrast, the 
lack of an IFN-γ response renders 17D virulent and leads to viscerotropic and neurologic disease 
and eventual death, potentially similar to human SAEs. Enhanced sensitivity to IFN or particular 
ISGs has been documented in several arbovirus LAVs (346–348). Thus, the deliberate creation 
of an IFN-γ sensitive phenotype may be a productive approach to rational design of new live 
attenuated vaccine (LAV) candidates against arboviruses. This will require identification of the 
mutations in 17D that underlie this phenotype.  
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3.0  YELLOW FEVER VIRUS 17D IS MORE SENSITIVE THAN WT YFV TO 
ANTIVIRAL ACTIVITIES INDUCED BY GAMMA-IFN IN MYELOID CELLS 
3.1 PREFACE 
Most of the work described in this chapter is adapted from a published study (LK Metthew Lam, 
Alan M. Watson, Kate D. Ryman, William B. Klimstra, 2018, NPJ Vaccines 3, article number 
5). 
3.2 INTRODUCTION 
Interferons are innate immune cytokines that exert important roles on restriction and clearance of 
invading pathogens. The three types of IFN are critical for controlling various pathogens, 
including flaviviruses. Sensitivity of pathogen to IFN responses can influence the pathologic 
outcome of an infected host, and some attenuated pathogens or live attenuated vaccine 
candidates are more sensitive to IFNs (346–348). Conversely, many pathogenic flaviviruses are 
equipped with multiple mechanisms to subvert the IFN response, by suppressing IFN induction 
and signaling and interfering with downstream antiviral effectors (91, 92, 121, 144). Different 
cell types have different responsiveness to IFN due to such factor as their steady-state gene 
expression, expression of IFN receptor, gene regulation pathways, and local environment, 
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rendering some more susceptible to virus infection (149, 349). Type II IFN has important roles in 
triggering TH1-biased adaptive immunity, and at the innate level, it has been shown to be 
directly antiviral to DENV, WNV, and TBEV (143, 144, 146). In addition, IFN-γ activates and 
enhances the antimicrobial response of macrophages by inducing iNOS, pro-inflammatory 
cytokines, and respiratory burst, which are important for clearance of many intracellular 
pathogens.     
Based on our work on characterizing the role of IFN-γ in the IFNAR-/- mouse model, we 
observed that IFN-γ restricts 17D dissemination and replication as early as 2dpi, prior to 
activation of adaptive immunity. Thus, we hypothesize that 17D is inhibited by the innate 
antiviral activities of IFN-γ. In the current studies, we have compared virus replication of YFV in 
vitro in various cell types treated with IFN-γ or IFN-α/β. We found that both interferons inhibit 
replication of both 17D-204 and Angola71; however, 17D-204 is more sensitive to the antiviral 
activities induced by IFN-γ. In addition, such differential inhibition of YFV by IFN-γ occurs in 
myeloid, but not non-myeloid cells, suggestive of cell type-dependent IFN antiviral activities.  
3.3 RESULTS 
3.3.1 17D-204 is more sensitive to the IFN-γ-induced antiviral state than WT-YFV in 
myeloid cells but not non-myeloid cells 
Based on our observations that 1) AGB6 mice succumbed to 17D-204 infection but not 
AB6 mice (Fig. 3A); 2) 17D-204 replicated to higher titer and disseminated faster in AGB6 mice 
than AB6 (Fig. 4); 3) IFN-γ induction in infected AB6 and AGB6 mice occurred as early as 2dpi 
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(Fig. 9); 4) Angola71-infected AB6 produced higher levels of serum IFN-γ than 17D-infected 
AB6 (Fig. 8), yet virus infection was not controlled in the Angola71-infected mice; 5) Angola71-
related mortality was delayed in AB6 versus AGB6 mice (Fig. 3A); and 6) reports that IFN-γ 
inhibited flavivirus infection in vitro (143, 144, 146), we hypothesized that IFN-γ induces an 
antiviral state that can generally inhibit YFV replication in vitro and in vivo and that enhanced 
sensitivity to the IFN-γ antiviral state is a prominent attenuation mechanism of 17D. To test this 
hypothesis, we compared virus replication of 17D-204 and Angola71 in various relevant cell 
types treated with IFN-γ or IFN-α/β. Consistent with the hypothesis, we observed a dose-
dependent inhibition of 17D-204 and Angola71 virus replication by IFN-γ in bone marrow-
derived macrophages (BMMΦ) and dendritic cells (BMDC) derived from C57BL/6 mice (Fig. 
12). In addition, 17D-204 was significantly more inhibited than Angola71 by an equivalent dose 
of IFN-γ or IFN-α/β. Since basal replication, which may be different between the viruses, can 
potentially induce different levels of IFN-α/β in cultured cells and alter sensitivity measurements, 
we performed the same experiments using cells that lack the ability to produce (IRF3x5x7-/- 
cells, Fig. 12B, E, I, L) or respond to (AB6 cells) IFN-α/β (Fig. 12C, F). Cells derived from 
AGB6 mice, which cannot respond to either type of IFN, were also included as negative controls 
(Fig. 12G, J). While 17D-204 and Angola71 multiply to higher titers in IRF3x5x7-/- and AB6 
BMMΦ than BMMΦ derived from C57BL/6 mice, 17D-204 is still significantly more inhibited 
by IFN-γ than Angola71. To determine if IFN-γ has a broad-spectrum effect on YFV replication, 
we also measured the IFN-γ sensitivity of YFVs in immortalized mouse embryonic fibroblasts 
(MEFs) or a human hepatoma line (Huh7). We did not observe significant differences between 
the viruses to either IFN-α/β or IFN-γ treatment (Fig. 13), suggesting that 17D-204 and 
Angola71 are differentially inhibited by IFN-γ-induced antiviral state in a cell-specific manner. 
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Figure 12: YFV-17D is more sensitive to IFN-γ-induced antiviral states than wild-type strain 
Angola71 in myeloid cells.  
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Indicated cells were treated with IFN 12hrs prior to infection. Cells were infected with 17D-204 or Angola71 at 
MOI=0.1. At 48hpi, supernatants were harvested and infectious virus particles were quantified by focus forming 
assay on Vero cells. (A-C, G-I) Foci data are presented as geometric mean ± 95% CI. (D-F, J-L) Corresponding foci 
data were normalized to untreated cells and presented in percentage, mean ± SD. (*: p<0.05, ** p <0.01, *** 
p<0.005, **** p<0.001; multiple t-test, corrected by Holm-Sidak method. Each dot represent data obtained each 
well. Macrophages from each mice were seeded in two duplicate wells, whereas each well of DCs are derived from 
one mice.) 
 
 
Figure 13: YFV-17D and Angola are similarly sensitive to the IFN-induced antiviral state in non-
myeloid cells.  
Indicated cell types were treated with the indicated IFN 12hrs prior to infection. Cells were infected with 17D-204 
or Angola71 at MOI=0.1. At 48hpi, supernatants were harvested and infectious virus particles were quantified by 
focus forming assay on Vero cells. (A and D) IRF3x5x7-/- mouse embryonic fibroblast (MEFs) and (B and E) AB6 
MEFs, and (C and F) Huh7. (A-C) Foci data are presented as geometric mean ± 95% CI. (B-F) Foci data from (A-C) 
are normalized to untreated cells and are presented as percentage, mean ± SD. (*: p<0.05, ** p <0.01, *** p<0.005, 
**** p<0.001; multiple t-test, corrected by Holm-Sidak method.) 
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3.3.2 IFN-γ treatment of myeloid cells induces antiviral genes that are upregulated in 
17D-infected AB6 mice 
Our data suggest that myeloid cells are responsible for IFN-γ-mediated restriction of 17D. Thus, 
we compared antiviral gene expression in 17D-204-infected animals and myeloid cells. Antiviral 
genes such as Igtp and Ifit2 were selected because they are robustly induced by IFN-γ (350), and 
Ifit2 has been shown to protect mice from WNV infection (351). These genes were upregulated 
similarly in DLN of both AB6 and AGB6 mice; however, in tissues like the spleens Igtp and Ifit2 
are preferentially upregulated the presence of IFN-γ response (Fig. 14A-B). This may be 
attributed to a combination of viral induction and IFN-γ-mediated induction of Igtp and Ifit2. 
IFN-γ treatment in BMMΦ and BMDC derived from C57BL/6, IRF3x5x7-/-, and AB6 mice 
resulted in induction of Igtp and Ifit2 but not from AGB6 mice (Fig. 14C-F). These results 
suggest myeloid cell activation by IFN-γ may contribute to restriction of 17D in vivo. 
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Figure 14: IFN-γ treatment in vitro induces antiviral genes that are upregulated in 17D-infected AB6 
mice.  
(A-B) 6-week-old mice were infected with 17D-204. At 4dpi, tissues were harvested and indicated gene transcripts 
were quantified using qPCR. Data are also presented in Fig. 10. (C-F) Indicated myeloid cells were treated with 
 78 
indicated concentrations of IFN for 12hr. Cells were harvested. RNA was isolated, and indicated transcripts were 
analyzed by qPCR. (*: p<0.05, ** p <0.01; multiple t-test, corrected by Holm-Sidak method.) 
 
3.4 DISCUSSION 
To provide insight into the mechanism for IFN-γ-mediated attenuation of 17D, we 
compared sensitivity of WT and 17D viruses to IFN-γ. We found that 17D-204 is more sensitive 
to the antiviral activities of IFN-γ than wild-type YFV in myeloid, but not non-myeloid, cells in 
vitro. While the role that IFN-γ plays in inducing protective immunity against 17D requires 
further study, our data suggest one mechanism by which IFN-γ controls 17D is through inducing 
a direct antiviral response, especially in macrophages and DCs. Correspondingly, antiviral genes 
upregulated in 17D-204-infected AB6 mice, such as Igtp and Ifit2 are also upregulated in 
myeloid cells treated with IFN-γ. This leads us to speculate that myeloid cells act as a gateway 
for restricting 17D in vivo through an IFN-γ-dependent mechanism. Because IFN-γ induces a 
large network of antiviral genes (350), it is very likely that multiple ISGs are participating in 
inhibition of YFV replication cycle. Since we also observe the lack of viral antigens in the liver 
of 17D-204-infected AB6 mice, genes differentially upregulated in the presence of IFN-γ 
response, such as Igtp, may be important downstream effectors to IFN-γ in attenuation of 17D 
and protection of visceral organs like the liver. 
Cell-type specific effects of IFN-γ have been previously observed. In mice, an IFN-γ-
induced antiviral state inhibits murine cytomegalovirus more robustly in macrophages than in 
MEF (349). IFN-γ induces different gene expression profiles in human DCs and macrophages  
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(352). Furthermore, the maturation state of macrophages affects the binding of STAT1 to IFN-γ-
activated promoter sites (353). Clearly, further work is needed to elucidate the role of specific 
IFN-γ-induced antiviral effectors in suppression of 17D replication. In addition to ISG induction, 
specific innate antiviral activities in myeloid cells have been documented for IFN-γ. IFN-γ-
induced nitric oxide inhibits replication of JEV in macrophages in vitro (145). The function of 
nitric oxide in the context of flavivirus infection is currently unknown. Nitric oxide is a potent 
radical species that modifies biomolecules (306), which may modify viral proteins (354), nucleic 
acid (355), or host factors (356) and interfere the virus replication cycle (145). Pathogens that 
modify host lipid membranes, such as murine norovirus and Toxoplasma gondii, are inhibited by 
IFN-γ-induced GTPases in macrophages (242). As flaviviruses modify the host membrane 
extensively for replication and polyprotein processing, YFV is likely also sensitive to these 
membrane-modulatory GTPases. Myeloid cells derived from mice lacking iNOS and/or immune-
related GTPases can be useful to determine whether these factors attenuate17D. 
In addition to IFN-γ-dependent antiviral activities in the host, the specific mutations in 
17D responsible for the increased IFN-γ sensitivity, and how these mutations increase 
susceptibility to individual antiviral effectors, need to be identified. Other than mutations in E 
protein that confer increased GAGs binding (27), the effects of mutations in 17D have yet to be 
characterized. The mutations M-L36F and NS4B-I95M that differentiate between WT strains and 
attenuated strains (17D substrains and French neurotropic vaccine strain) are possible candidates 
for influencing IFN-γ sensitivity (212). For M-L36F, substitution of the analogous amino acid in 
JEV resulted in a mutant deficient in virion maturation and virus particle production (213). 
NS4B from various flaviviruses is an antagonist of IFN signaling and inhibits STAT1 
translocation (84) and is also critical for usurping the host membrane to generate sites for virus 
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replication and polyprotein processing. The mutation E-G52R is also a potential candidate as it is 
also mutated in cell culture-adapted JEV and contributes to reduction of peripheral virulence and 
altered entry kinetics (213). E-G52R is located at the hinge region important for conformational 
changes during fusion; however, substitution of the analogous mutation in DENV2 does not alter 
fusion kinetics, suggestive of virus-specific role of this residue (220). Another potentially 
important mutation is the poorly characterized NS5-P901L, which is present in the attenuated 
strains 17D and HeLa-p6. This mutation is located at the C-terminus tail of NS5 and does not a 
have known regulatory function in viral replication. It is possible that these mutations, alone or 
in combination with other 17D mutations, could influence sensitivity to IFN-γ.  
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4.0  CONCLUDING REMARKS AND FUTURE DIRECTIONS 
The YFV live attenuated vaccine strain 17D is arguably one of the best LAVs available. 
In addition to offering long-term protection, the genetic backbone of 17D has been used to 
develop vaccine candidates against other pathogens (326–328). However, our understanding of 
the mechanisms of YFV 17D attenuation remains incomplete. Understanding the factors 
contributing to attenuation and immunogenicity will also be valuable for future rational design of 
LAV candidates for other flaviviruses or pathogens. In addition, potentially lethal severe adverse 
events after 17D vaccination and the concerns of YFV re-emergence beyond current 
geographical boundaries highlight the need to further understand attenuation of 17D.  
In contrast to primates, WT mice are highly resistant to peripheral infection of YFV, 
which complicates the studying of YFV pathogenesis and immunology in a pathophysiologically 
relevant context. To understand YFV-host interaction, we used mice lacking the type I IFN 
response (AB6), which are susceptible to s.c. infection of wild-type YFV but resistant to 17D 
infection. Wild-type virus causes viscerotropic disease in AB6 mice while 17D infection results 
in long-term immunity. Such similarity to human-YFV interactions prompted us to investigate 
host factors important in YFV attenuation. In this study, we have characterized the role of the 
host type II IFN system as an attenuation factor against 17D in a pathophysiologically relevant 
mouse model. 
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Our study revealed the importance of IFN-γ in controlling 17D in vivo (summarized in 
Fig. 15). By comparing 17D replication kinetics and pathogenesis in AB6 and AGB6 mice, we 
conclude that IFN-γ restricts 17D replication and dissemination early during infection. In the 
absence of the IFN-γ response, 17D replicated in and caused stress or inflammation in the liver 
and the brain, indicative of both viscerotropic and neurotropic disease. IFN-γ may play a role in 
virus clearance as clearance was observed within eight days in AB6 mice, whereas in AGB6 
mice, virus clearance only occurred in the periphery but in a delayed manner. Deficiency in IFN-
γ signaling resulted in poor cytokine responses and less robust induction of antiviral genes when 
compared to AB6 mice, indicative of a central role for cytokine upregulation and antiviral 
function of IFN-γ against 17D. We also determined that NK cells were a primary source of IFN-
γ early during infection in our model. In vitro, we also demonstrated that, IFN-γ inhibits 
replication of both YFV strains 17D and Angola71 in a dose-dependent manner; however, 17D 
was more robustly inhibited by IFN-γ treatment than the WT strain in myeloid (macrophage and 
DC) but not fibroblastic cells. This prompted us to conclude that one mechanism for 17D 
attenuation is enhanced sensitivity to innate antiviral activities of IFN-γ in myeloid cells. 
One important knowledge gap that should be addressed in future studies is the exact 
molecular mechanism(s) for enhanced sensitivity of 17D to IFN-γ. IFN-γ, like other IFN types, 
can induce a plethora of immune-modulatory genes. Among these gene products, iNOS and 
immune-related GTPases have been demonstrated to inhibit viruses from different families in 
myeloid cells (145, 242). It would be of interest to determine if these genes are also inhibitory to 
YFV replication. For instance, myeloid cells derived from mice deficient in iNOS and specific 
immune-related GTPases can be used to evaluate if these proteins are restricting 17D 
downstream to IFN-γ. In addition, comparative analysis on genes induced in myeloid and non-  
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Figure 15. Model of IFN-γ interaction with 17D in mice. 
17D infection results in early IFN-γ primarily by NK cells. In the presence of IFN-γ receptor (AB6 mice, left), 
myeloid cells are at a heightened antiviral state, leading to effective control of 17D replication and dissemination in 
vivo, and subsequent development of adaptive immunity. In contrast, in the absence of IFN-γ receptor (AGB6 mice, 
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right), myeloid cells possess limited antiviral activity, leading to unrestricted 17D replication and dissemination. The 
virus invades visceral tissues such as the liver and neurologic tissues such as the brain, causing stress and damage, 
eventually leading to death. Our study has highlighted some important questions and future direction (blue) on 
understanding YFV biology, which are discussed in text.  
 
myeloid cells upon IFN-γ treatment can potentially identify factors that restrict 17D in myeloid 
cells at a global level. Alternatively, shRNA-mediated knockdown of host factors can be used to 
screen for the attenuating factors. In addition to identifying host factors contributing to restriction 
of 17D, the specific amino acid and/or nucleotide changes in the 17D genome leading to 
enhanced sensitivity to IFN-γ should be characterized. Chimeric viruses containing parts of 17D 
and parts of WT strains have been used in the literature to understand the role of genetic changes 
in YFV-mosquito interactions (357, 358). By comparing sensitivity of the chimeras to IFN-γ in 
myeloid cells, we can evaluate the contribution of individual or groups of mutation(s) to 
sensitivity to IFN-γ.  
Prior to implementation of the monkey neurovirulence test, enhanced virulence due to 
post-vaccination mutations in 17D has been proposed to cause encephalitis in vaccinees. 17D 
mutants bearing unique mutations not present in the parent stock or in Asibi were isolated from a 
viscerotropic SAE case and were suspected to have enhanced virulence (231). It is possible that 
these unique mutations are compensatory and partially restore virulence of the resulting virus. A 
thorough understanding of how mutations in 17D alter virulence will aid prediction of the 
propensity of an individual vaccine batch to result in SAEs and facilitate informed design of a 
17D vaccine that can accommodate more at-risk populations without sacrificing effectiveness. 
Moreover, 17D-vectored chimeric vaccines (326–328) retain the majority of the 17D genome 
(except structural proteins in the ChimeriVax platform (328)). As a result, these vaccine 
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candidates may retain the ability to cause SAEs and thus stand to benefit from advances in 17D 
safety. 
 Understanding the molecular mechanism of IFN-γ-mediated 17D attenuation can provide 
important insights into the host factors that enhance the risk of SAE. Based on our data, we 
speculate that variation in host IFN-γ response can be a potential risk factor for SAEs; however, 
IFN-γ signaling efficacy can be influenced by factors such as recent infections and on-going 
therapy. A better understanding of the factors upstream and downstream of IFN-γ can provide us 
direction for screening potential high-risk individuals prior to vaccination or closely monitor 
them after vaccination, which may reduce incidence and/or severity of SAEs. 
 Despite the lack of type I and type II IFN responses, virus clearance was also achieved in 
the periphery of 17D-infected AGB6 mice by 8dpi. This suggests alternative mechanisms are 
involved in controlling 17D at a later phase of infection. The role of other innate immunity 
components, such as TLR signaling and proinflammatory cytokines should be evaluated in our 
model because these molecules have been implicated in influencing the outcome of flavivirus 
infection (123, 230, 338). In addition, due to the timing of virus clearance, components of the 
adaptive immune system such as T cells and antibodies likely contribute to peripheral clearance. 
 In our model, 17D invasion and replication in CNS likely contribute to disease and 
ultimate death. However, it remains unclear whether virus and/or host immune responses are 
responsible for the death of AGB6 mice. Because the brain is an immune privileged site, viruses 
that invaded the brain may not be as well controlled when compared to the periphery (359). 
Characterization of the immune response in the brain after neuroinvasion of 17D could provide a 
clearer picture on pathogenesis and aid in development of therapeutic approaches. The role of 
glial cells and immune infiltrating cells, such as T cells, need to be investigated. Microglial cells 
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are resident immune cells that are susceptible to flavivirus infection in vitro (32, 360). 
Interestingly, JEV replicated in primary human microglial cells without secreting infectious 
particles, and infection induced expression of pro-inflammatory cytokines and chemokines (360). 
It will be of interest to determine if microglial cells are critical mediators of anti-17D activities in 
the CNS, or potentially, pathological processes, and whether IFN-γ is important for its these 
activities and whether or not IFN-/ controls whether microglia are protective or disease-
promoting. Lymphocytes, especially CD8+ T cells have been implicated in controlling flavivirus 
infections in the CNS (211, 246). In DENV infected AGB6 mice, adoptive transfer of CD8+ T 
cells from AB6 mice resulted in reduction of virus replication, indicating CD8+ T cells restricts 
DENV in CNS in an IFN-γ-dependent manner (246). As with microglia, it will be of interest to 
determine if T cells are protective or disease-promoting in the absence of IFN-/. 
Our results also suggest that enhanced sensitivity to IFN-γ can lead to attenuation of virus 
and that live attenuated vaccine candidates can be generated by deliberately enhancing viral 
sensitivity to IFN-γ (and reasonably, other host immune mechanisms). In fact, several arbovirus 
LAV candidates have enhanced sensitivity to IFN or particular ISGs (346–348). With the recent 
global emergence of arboviruses such as Chikungunya, Zika, and dengue virus (361–363), a 
rational approach for generating vaccine candidates will likely be beneficial to the public.   
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5.0  MATERIALS AND METHODS 
Ethics Statement 
Animals were maintained and procedures were performed in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Research Council. Protocols 1103456 and 14033545 were approved by the University of 
Pittsburgh's IACUC committee. Approved euthanasia criteria were based on weight loss and 
morbidity. 
 
Cells lines 
Vero (ATCC-CCL-81), Huh7 (Charles M. Rice, The Rockefeller University), PH5CH8 (Michael 
R. Holbrook, NIH) and mouse embryonic fibroblasts (MEFs, derived based on (348)) were 
maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin, 
0.05mg/mL streptomycin, 0.29mg/mL L-glutamine, and 1mM sodium pyruvate unless otherwise 
specified. All cell incubation were performed at 37°C in 5% CO2 unless otherwise specified. 
 
Virus Stocks 
Stocks of 17D-204 and Angola71 were generated from infectious clones by electroporating in 
vitro transcribed RNA into Vero cells as described previously (210). Virus-containing 
supernatant were harvested after incubation for 4 (Angola71) or 7 days (17D-204), followed by 
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clarification by centrifugation at 875g for 30min and stored at -80°C. Brazil75 stocks were 
obtained from Alan T. Barett Virus stock titers were quantified by plaque assay on Huh7. 
Viruses were diluted to appropriate titer using virus diluent – PBS supplemented with 1% donor 
bovine serum, 100U/mL penicillin, and 0.05mg/mL streptomycin. 
 
Mouse experiments 
AB6 and AGB6 mice were bred in-house. C57BL/6 mice were purchased from Charles River. 
Groups of randomized 6-week-old sex-matched mice were infected subcutaneously with 1x104 
PFU or mock at the hind-limb footpad after isoflurane anesthesia. Weight and swelling of 
footpad were monitored daily for at least 21 days. Animal experiments were not blinded. To 
harvest tissues, anesthetized mice were bled at submandibular vein and then sacrificed with 
isoflurane overdose, followed by cardiac perfusion with virus diluent. Blood were collected in 
Microtainer serum separator tube (BD, Cat.: 365967) and serum were obtained by centrifugation 
at 13523g for 5min at 4°C. Tissues were stored in virus diluent or Tri Reagent-LS (Invitrogen) at 
-80°C until further usage. For histology, mice were perfused with virus diluent and 4% 
paraformaldehyde (PFA), followed by 24hr fixation in 4% PFA at 4°C, prior to processing for 
sectioning. For antibody depletion experiments, 3 doses of 75μg of mouse IgG2a (C1.18.4) or 
NK1.1 (PK136, BioXCell) or 3 doses of 150μg of CD4 (GK1.5) or CD8 (2.43) at -3, -1, and 1dpi 
were injected to animals by intraperitoneal route. IgG2a, CD4, and CD8 antibodies were 
generated from the corresponding hybridomas (ATCC) using CELLine bioreactors (Argos 
Technologies) according to manufacture’s protocol and purified with ammonium sulfate 
precipitation as described previously (364). 
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Flow Cytometry 
Popliteal (draining) lymph node were harvested from infected animals at 3dpi, minced, and 
strained through 70μm cell strainer (Falcon). Single cell suspensions were cultured in media – 
RPMI 1640 supplemented with 10% FBS, 100U/mL penicillin, 0.05mg/mL streptomycin, 20μM 
β-mercaptoethanol (Sigma), and 5μg/mL Brefeldin A (Tonbo bioscience) for 6hr. Cells were 
stained as previously described (210). Antibody and dyes used in this study were: Fixable 
Viability dye UV Blue (eBioscience), anti-mouse CD16/32 (93, eBioscience), APC-Cy7-anti-
CD8 (2.43, Tonbo bioscience), PerCP-Cy5.5-anti-CD4 (GK1.5, Tonbo bioscience), APC-anti-
NK1.1 (PK136, Tonbo bioscience), PE-anti-γδTCR (GL3, eBioscience), and FITC-anti-IFN-γ 
(XMG1.2, Tonbo bioscience). FITC-rat IgG1 (MOPC-21, Tonbo bioscience) is used as isotype 
control. Stained cells were fixed in 1% PFA and analyzed using BD LSRFortessa (BD 
Bioscience) and FlowJo software (Tree Star).  
 
Plaque assay 
Huh7 cells were infected with serially diluted inoculum for 1hr. For quantification of virus in 
mouse organs, tissues were homogenized in sterile pestles (Bel-Art), and the virus-containing 
supernatant were clarified by centrifugation at 13523g for 15min at 4°C and used as inoculum. 
Infected Huh7 were overlaid with media supplemented with 0.5% carboxymethocellulose (CMC, 
high viscosity, Sigma). At 4dpi (virus stocks) or 5dpi (tissues), plaques were visualized by 
staining with 0.5% crystal violet in 2% PFA. 
 
Cytokine and gene expression analyses 
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Serum cytokines were quantified by the Cytokine 20-plex Mouse Panel (Invitrogen) according to 
manufacturer protocol. To analyze gene expression in different organs, RNA from tissues was 
isolated using Tri reagent-LS (Invitrogen) following the manufacturer protocol. Polyacryl carrier 
was added to serum and lymph node samples only. Reverse transcription of 100ng of purified 
RNA were performed using random hexamer and TaqMan reverse transcription reagent (AB) 
under the following condition: 25°C for 10min, followed by extension at 48°C for 30min, and 
inactivation of enzymes at 95°C for 5min. Quantitation of 18S cDNA and antiviral genes was 
performed in Maxima Probe qPCR Master Mix (Thermo) and Maxima SYBR Green/Rox qPCR 
mix, respectively. Fluorescent intensity data were collected on a 7900HT Real-Time PCR 
System (AB). Thermocycling conditions were as follow: denaturing and polymerase activation at 
95°C for 10min, followed by 40 cycles of denaturing at 95°C for 15s and extension at 60°C for 
1min with fluorescent intensity data collection. An additional melting curve cycle was added for 
quality controls for antiviral genes. Primers and probes used in PCR were listed in table 2. 
 
Table 2. qPCR primer and probe sequences used in this study. 
Primer/probes Sequence 
18S-S CGCCGCTAGAGGTGAAATTCT 
18S-AS CGAACCTCCGACTTTCGTTCT 
18S probe (HEX) /5HEX/CAA GAC GGA /ZEN/CCA GAG CGA AAG CAT TTG /3IABkFQ/ 
mIFIT1-S GTGGCTCACATAGAGCAGGA 
mIFIT1-AS AGTTTCCTCCAAGCAAAGGA 
mIFIT2-S AGAATTCACCTCTGGATGGG 
mIFIT2-AS GTCAAGCTTCAGTGCCAAGA 
mIGTP-S TCTGAGCAGGTTCTGAAGGA 
mIGTP-AS TCCTCGGCTTCTTTCTTCTC 
mIFNg-S CAAAAGGATGGTGACATGAA 
mIFNg-AS TTGGCAATACTCATGAATGC 
 
 
Histology 
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For Hematoxylin & Eosin (H&E) staining, PBS- and PFA-perfused mouse organs were 
harvested. Sectioning and staining were performed by the Histology Core at the McGowan 
Institute of Regenerative Medicine at the University of Pittsburgh. For Immunostaining, PBS-
perfused mouse organs were harvested fresh, sunk in 30% sucrose at 4°C, and frozen in O.C.T. 
medium. For Angola71-infected mice, PFA perfusion and fixation were performed prior to 
sucrose treatment. Frozen tissues were stored at -80°C until cryosection. 7μm (spleen and liver) 
or 20μm (brain) sections were permeabilized in 100% methanol at -20°C, rehydrated in PBS 
with 0.05% Tween20 (PBST), antigen retrieved by proteinase K digest, and blocked in 2% BSA, 
1:200 anti-CD16/32, 5% normal rat serum and goat serum, followed by incubation in M.O.M. 
reagent (VectorLab). YFV proteins were stained using heat-inactivated immune sera from 
immunized AB6 mice at 21dpi or normal serum as isotype control at 1:50 dilution, followed by 
AlexaFluor488- or AlexaFluor594-conjugated goat-anti-mouse antibody. For staining liver, 
tissues sections were treated with normal mouse serum prior to incubation in M.O.M. reagent. 
Specific cell types were probed with antibodies against F4/80 (BM8, Tonbo Bioscience), CD169 
(MOMA-1, Acris Antibodies, Cat.: SM066B), LYVE-1 (Goat polyclonal, R&D systems, Cat.: 
AF2125), and GFAP (Chicken polyclonal, Abcam, Cat.: Ab4674). Stained slides were mounted 
on DAPI in SlowFade Gold (Invitrogen) and imaged using FluoView 1000 confocal microscope 
(Olympus). 
 
IFN-γ ELISA 
ELISA for IFN-γ was performed using the ELISA Ready-Set-Go kit (eBioscience) according to 
manufacture directions. 
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Generation of bone marrow-derived cells 
Bone marrow-derived macrophages (BMMΦ) and dendritic cells (BMDC) were generated as 
described previously (118). After 6 days of maturation, DCs were collected from supernatant and 
macrophages were scraped from plates. Cells were washed, counted, and seeded on U-bottom 
96-well plates for DC or 24-well plates for macrophages, followed by treatment with IFNs and 
virus infection. 
       
Virus infection 
Mouse embryonic fibroblasts (MEFs), macrophages, and dendritic cells were treated with 
various concentrations of IFN-γ (Peprotech) or IFN-α4/β (made in-house as described previously 
(365)) for 12hr. Media containing IFNs were removed prior to infection with YFVs at designated 
MOI for 1hr. Cells were washed three times after infection. For BMDC, cells were pelleted at 
219g for 5min at 4°C between washes. Infected cells were maintained in their corresponding 
media. Supernatant were harvested daily for focus-forming assay.  
 
Focus-forming assay 
1x104 Vero cells were seeded on 96-well plate, followed by infection with serially diluted virus 
inoculum. After 1hr infection, cells were washed and overlaid with media supplemented with 
0.5% CMC for 96hr. Cell monolayers were washed in PBS and fixed in 4% PFA for 24hr. Fixed 
cells were washed and permeabilized with 100% methanol at -20°C for 10min, followed by 
washes in PBS containing 0.05% tween20 (PBST). Nonspecific protein binding was blocked by 
incubation in PBST with 1% BSA and 5% normal goat serum for 1hr at room temperature. YFV 
proteins were stained using heat-inactivated immune sera from immunized AB6 mice at 21dpi at 
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1:100 dilution for 24hr at 4°C, followed by probing with HRP-goat anti-mouse antibody for 1hr 
at room temperature. Foci were visualized by 3,3’-diaminobenzidine as substrate (ThermoFisher, 
cat.: 34065).  
 
Immunofluorescence staining for STAT proteins 654321 
2x104 PH5CH8 cells were seeded on glass slides (VWR Cat. #48312-003), followed by infection 
with viruses at MOI=2. After 1hr infection, cells were washed and overlaid with media 
supplemented with 20μM zVAD-fmk, zFA-fmk, or an equivalent volume of DMSO. At 48hpi, 
cells were washed and fixed in 4% PFA, followed by immunofluorescence staining using the 
same procedure as focus-forming assay. The following antibodies were used. Primary: STAT1 
(M-22), STAT2 (H-190), and YFV (mouse ascites fluid, ATCC). Secondary: AlexaFluor488-
conjugated donkey anti-mouse and AlexaFluor594-conjugated donkey-anti-rabbit. Stained slides 
were mounted on DAPI in SlowFade Gold (Invitrogen) and imaged using Olympus CKX41 
microscope. 
       
Statistical analysis 
All data were analyzed with GraphPad Prism software. Log-rank test was performed on survival 
studies. Multiple t-test with Holm-Sidak correction was performed whenever appropriate. No 
statistical methods were used to ensure adequate power. Sample sizes were chosen based on 
experience on morbidity and mortality of YFV in mice to achieve statistical significance yet 
utilize fewest animals.  
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APPENDIX A 
PRELIMINARY DATA RELATED TO THIS WORK  
STAT1-degradation may contribute to enhanced virulence of WT YFV 
Experiments in chapter 3 demonstrated that 17D is more sensitive to the antiviral state induced 
by IFN-γ than WT virus strain Angola71. Because virulent virus strains are more capable of 
antagonizing host antiviral activities than attenuated strains (346, 347), we sought to determine if 
WT YFV interferes with signaling molecules downstream of IFN-γ more efficiently than 17D. 
Inhibition of the JAK-STAT pathway is a prominent mechanism employed by virulent viruses to 
dampen IFN signaling. Flavivirus NS5, including that of YFV, suppresses IFN signaling by 
sequestration and/or degradation STAT2 (91, 92, 366). NS5 also inhibits phosphorylation of 
STAT1 (367). To determine if YFV also interferes with STAT1 signaling, we evaluated STAT1 
protein levels in PH5CH8 human hepatocytes. PH5CH8 cells were used because they retain 
functional IFN responses, and different antiviral genes were induced when these cells were 
infected with YFV strains 17D or Asibi (368).  
 Infection in PH5CH8 cells with 17D or Angola71 virus resulted in a loss of STAT2 
staining, as expected. Interestingly, while 17D-infected cells largely remained STAT1-positive, 
STAT1 protein levels were significantly lower in Angola71-infected cells (Fig. 16A-B). 
 95 
Flavivirus infection has been shown to result in activation of caspases and apoptosis in vitro (44, 
369–371). Because of STAT1 has been reported to be cleaved by caspase-3 and -7, leading to its 
degradation (372), we evaluated if caspase inhibition could rescue STAT1 protein levels. 
Treatment of cells with caspase inhibitors or vehicle did not affect virus replication (Fig. 16C). 
However, treatment of Angola71-infected cells with the pan-caspase inhibitor zVAD-fmk 
partially restored STAT1 protein levels (Fig. 16D), indicating caspase activation is involved in 
degradation of STAT1 by WT YFV.   
These preliminary studies suggest that one potential mechanism for enhanced IFN-γ 
sensitivity by 17D is failure to degrade STAT1. However, more detailed and in-depth studies are 
required to elucidate the role of caspase activation in STAT1 degradation and the relative impact 
of differential degradation on 17D and WT YFV replication. Based on our model, IFN-γ 
signaling in myeloid cells, but not non-myeloid cells contributes to attenuation of 17D. The 
effects of caspase inhibition in YFV-infected myeloid cells and the subsequent effects on IFN-γ-
mediated immunity should be evaluated. In addition, the viral factor(s) and the corresponding 
mechanism(s) contributing to caspase-mediated degradation of STAT1 should be identified, as it 
can aid development of pharmacological intervention in YF and/or SAE patients. The C-
terminus of M protein of flaviviruses activates caspases, and M protein from Asibi induces 
apoptosis more robustly than 17D (44). In addition, the E protein, which possesses most of the 
genetic differences between 17D and Asibi, and the viral protease NS3 has also been reported to 
activate caspases (369–371). Thus, it will be of interest to determine if these proteins 
differentially activate caspases to degrade STAT1 and subvert host IFN responses.  
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Figure 16. Wild-type YFV but not 17D-204 downregulates STAT1 in a caspase-dependent manner. 
2x104 PH5CH8 cells were infected at MOI=2 on glass slides. At 48hpi, cells were washed and fixed in 4% 
PFA, followed by immunofluorescence staining. Red=STAT protein and green=virus. (A) representative staining for 
STAT1 and STAT2 in YFV-infected cells. (B) quantified data from (A). (C-D) Experiment was performed as in (A) 
except only Angola71 was used and after infection, cells were incubated in media containing DMSO or 20μM 
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indicated compounds. (C) Virus replication kinetics were not affected by chemical treatments. (D) Pan-caspase 
inhibitor zVAD-fmk partially restored STAT1 level in Angola71-infected cells. (***: p<0.001, multiple t-test 
corrected with Sidak-Holm method. n≥4) 
 
A YEL-AVD clinical isolate, Brazil75 shows enhanced virulence in AGB6 mice 
In addition to host variation in IFN-γ responses, mutations in 17D have been hypothesized to be 
associated with incidence of SAE (231, 232). One YEL-AVD SAE clinical isolate, strain 
Brazil75 (B75) contains two mutations (M-I49L and NS4B-Y240F) when compared to its parent 
strain 17DD (231). These mutations are unique and not reversions to WT residues. Engel et al. 
reported that B75 and 17DD are similarly virulent in immortalized kidney and hepatocyte cell 
lines and the hamster infection model (231); however, in this study, the B75 virus was not 
adapted to hamster prior to infection, which may explain the lack of enhanced virulence. To 
investigate the contribution of viral genetics to SAEs, we evaluated the virulence of B75 in our 
mouse model. In AB6 mice, B75 infection did not result in any discernable disease, including 
footpad swelling (data not shown). However, in AGB6 mice, B75-infected mice succumbed to 
disease significantly earlier (AST 9.17±0.98) than 17D-204-infected animals (11.2±0.45, Fig. 
17A). B75 also resulted in more rapid weigh-loss in infected animals (Fig. 17B). Interestingly, in 
contrast to 17D, no footpad swelling was observed in B75-infected AGB6 mice (Fig. 17C). We 
determined virus replication levels at 8dpi, when B75-infected animals started to succumb to 
infection. Virus titers in most sampled tissues were similar between B75 and 17D-204 except in 
the serum and the brain (Fig. 17D), where viremia remained detectable in B75-infected mice at 
8dpi but not in 17D-204-infected mice, suggesting B75 remained in the circulation longer. Virus 
titer was also significantly higher in the brains of B75-infected AGB6 mice (up to 108 PFU/mg), 
indicative of higher neurovirulence than 17D-204.  
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Figure 17. A YEL-AVD SAE clinical isolate, strain Brazil75 is more virulent than 17D-204 in AGB6 
mice. 
6-week-old AGB6 mice were infected subcutaneously with 1x104 PFU of virus. (A) Survival, (B) weight, and (C) 
footpad swelling were monitored daily. (D) Infected animals were sacrificed on 8dpi. Tissues were harvested and 
virus titers were quantified as described in materials and methods.  (**: p<0.01, Log-rank test in A, *: p<0.05 and 
***: p<0.001 in B and D, multiple t-test with Sidak-Holm correction. n≥6) 
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Our data suggest that mutation(s) in 17D that occur during replication in vaccinees can 
contribute to enhanced virulence. However, some important questions and caveats need to be 
addressed. B75 is derived from the substrain 17DD but not 17D-204 (231). Therefore, 17DD will 
be a better control for future experiments. The observation that B75-infected mice showed no 
footpad swelling is interesting. It remains to be determined if virus mutations are contributing to 
the lack of swelling or local reaction at the site of infection or if it is simply due to differences in 
genetic background of 17DD and 17D-204. A more in-depth analysis of virus replication kinetics 
and immune response are necessary to determine how those genetic changes influence virus 
pathogenicity. It is also intriguing that B75, a YEL-AVD clinical isolate replicated to high titer 
in the brain, suggesting a potential for two mutations (M-I49L and NS4B-Y240F) in causing 
encephalitic disease and/or the AGB6 mice are more prone to experiencing neurologic disease 
after 17D infection. Nevertheless, histological studies are needed to determine the likely cause of 
disease and death. 
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APPENDIX B 
 
TABLE OF ABBREVIATION 
AB6: B6 mice lacking type I interferon receptor 
AGB6: B6 mice lacking type I and type II interferon receptors 
Axl: AXL Receptor Tyrosine Kinase 
BMDC: Bone marrow-derived dendritic cell 
BMMΦ: Bone marrow-derived macrophage 
C: Capsid 
CAPRIN1: Cell cycle associated protein 1 
CCL: CC Chemokine ligand 
cGAS: Cyclic GMP-AMP synthase 
CIITA: class II, major histocompatibility complex, transactivator 
CNS: Central nervous system 
CPE: Cytopathic effects 
CrkL: Crk-like protein 
CS: Circularization sequence 
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DC-SIGN: Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
DENV: Dengue virus 
DNase: Deoxyribonuclease 
Dpi: Day(s) post-infection 
dsRNA: double-stranded RNA 
E: Envelope 
ERK1/2: extracellular signal–regulated kinases 1/2 
FBS: Fetal bovine serum 
G3BP: Ras GTPase-activating protein-binding protein 
GAGs: Glycosaminoglycan 
H&E: Hematoxylin & Eosin 
Hlx: Homeobox Protein HB24 
i.c.: intracerebral 
i.p.: intra-peritoneal 
IFIT: IFN-induced protein with tetratricopeptide repeats 
IFN: Interferon 
IfngCNS: conserved noncoding sequences around Ifng gene locus 
IL: Interleukin 
iNOS: inducible nitric oxide synthases 
IP-10: Interferon gamma-induced protein 10  
IRF: Interferon regulatory factor 
ISG: Interferon-stimulated genes 
ITAM: immunoreceptor tyrosine-based activation motif 
 102 
ITIM: immunoreceptor tyrosine-based inhibition motif 
JAK: Janus Kinase 
JEV: Japanese encephalitis virus 
JNK1: Mitogen-activated protein kinase 8 
LAV: Live attenuated vaccine 
MAPK: mitogen-activated protein kinase 
MAVS: Mitochondrial antiviral-signaling protein 
MDA5: Melanoma Differentiation-Associated protein 5 
MHC: Major histocompatibility complex  
MICA: MHC class I polypeptide-related sequence A 
MTase: Methyltransferase 
mTOR: Mechanistic target of rapamycin 
MVEV: Murray Valley encephalitis virus 
MyD88: Myeloid differentiation primary response 88 
NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NHP: Non-human primate 
NK: Natural killer 
NS1: nonstructural protein 1 
NS2A: nonstructural protein 2A 
NTPase: Nucleoside triphosphatase 
OAS: 2’-5’-oligoadenylate synthetase 
PAMPs: Pathogen-associated molecular patterns 
PBS: Phosphate-buffered saline 
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PFU: Plaque forming unit 
PKC: Protein kinase C 
PMN: Polymorphonuclear leukocyte 
PrM: precursor-membrane 
PRR: Pattern recognition receptor 
qRT-PCR: quantitative real time reverse-transcription-polymerase chain reaction 
RC: Replicative complex 
RI: Replicative intermediate 
RIG-I: retinoic acid-inducible gene I 
RLR: RIG-I-like receptor 
RNase: Ribonuclease 
Runx3: Runt-related transcription factor 3 
s.c.: subcutaneous 
SeV: Sendai virus 
sfRNA: subgenomic flavivirus RNA 
SHP: Src homology region 2 domain-containing phosphatase 
SLA: stem loop A 
SNP: Single nucleotide polymorphism 
SOCS: Suppressor of cytokine signaling 
STAT: Signal transducer and activator of transcription 
STING: Stimulator of Interferon Genes 
Syk: Spleen tyrosin kinase 
T-bet: T-box transcription factor TBX21 
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TBEV: Tick-borne encephalitis virus 
TBK1: TANK-binding kinase 1 
TCM: Central memory T cell 
TEM: Effector memory T cell 
TEMRA: Effector memory T cell re-expressing CD45RA 
TLR: Toll-like receptor 
TNF: Tumor necrosis factor  
UAR: upstream ATG region 
UTR: untranslated region 
WT: wild-type 
WNV: West Nile virus 
XRN1: 5'-3' exoribonuclease 
YFV: Yellow fever virus 
 
APPENDIX B 
 
 105 
BIBLIOGRAPHY 
1.  Kuno G, Chang G-JJ, Tsuchiya KR, Karabatsos N, Cropp CB (1998) Phylogeny of the 
Genus Flavivirus. J Virol 72(1):73–83. 
2.  Cigarroa-Toledo N, et al. (2016) Serologic Evidence of Flavivirus Infections in 
Peridomestic Rodents in Merida, Mexico. J Wildl Dis 52(1):168–172. 
3.  Sf L, et al. (2015) Flavivirus Infection in Wild Birds from Brazilian Amazon. Entomol 
Ornithol Herpetol Curr Res 4(3):1–4. 
4.  Almeida MAB, et al. (2014) Surveillance for Yellow Fever Virus in Non-Human Primates 
in Southern Brazil, 2001–2011: A Tool for Prioritizing Human Populations for 
Vaccination. PLoS Negl Trop Dis 8(3). doi:10.1371/journal.pntd.0002741. 
5.  Morales MA, et al. (2017) Detection of the mosquito-borne flaviviruses, West Nile, 
Dengue, Saint Louis Encephalitis, Ilheus, Bussuquara, and Yellow Fever in free-ranging 
black howlers (Alouatta caraya) of Northeastern Argentina. PLoS Negl Trop Dis 11(2). 
doi:10.1371/journal.pntd.0005351. 
6.  Kading RC, Schountz T (2016) Flavivirus Infections of Bats: Potential Role in Zika Virus 
Ecology. Am J Trop Med Hyg 95(5):993–996. 
7.  Tajima S, Takasaki T, Matsuno S, Nakayama M, Kurane I (2005) Genetic characterization 
of Yokose virus, a flavivirus isolated from the bat in Japan. Virology 332(1):38–44. 
8.  Machain-Williams C, et al. (2013) Serologic Evidence of Flavivirus Infection in Bats in 
the Yucatan Peninsula of Mexico. J Wildl Dis 49(3). doi:10.7589/2012-12-318. 
9.  Nofchissey RA, et al. (2013) Seroprevalence of Powassan virus in New England deer, 
1979-2010. Am J Trop Med Hyg 88(6):1159–1162. 
10.  Lin S-R, et al. (2004) Study of Sequence Variation of Dengue Type 3 Virus in Naturally 
Infected Mosquitoes and Human Hosts: Implications for Transmission and Evolution. J 
Virol 78(22):12717–12721. 
11.  Sim S, et al. (2015) Tracking Dengue Virus Intra-host Genetic Diversity during Human-
to-Mosquito Transmission. PLoS Negl Trop Dis 9(9):e0004052. 
 106 
12.  Ciota AT, et al. (2007) Cell-specific adaptation of two flaviviruses following serial 
passage in mosquito cell culture. Virology 357(2):165–174. 
13.  Billoir F, et al. (2000) Phylogeny of the genus flavivirus using complete coding sequences 
of arthropod-borne viruses and viruses with no known vector. J Gen Virol 81(Pt 3):781–
790. 
14.  Clifford CM, Yunker CE, Thomas LA, Easton ER, Corwin D (1971) Isolation of a Group 
B arbovirus from Ixodes uriae collected on Three Arch Rocks National Wildlife Refuge, 
Oregon. Am J Trop Med Hyg 20(3):461–468. 
15.  Lawrie CH, Uzcátegui NY, Armesto M, Bell-Sakyi L, Gould EA (2004) Susceptibility of 
mosquito and tick cell lines to infection with various flaviviruses. Med Vet Entomol 
18(3):268–274. 
16.  Lawrie CH, Uzcátegui NY, Gould EA, Nuttall PA (2004) Ixodid and argasid tick species 
and west nile virus. Emerg Infect Dis 10(4):653–657. 
17.  Gaunt MW, et al. (2001) Phylogenetic relationships of flaviviruses correlate with their 
epidemiology, disease association and biogeography. J Gen Virol 82(8):1867–1876. 
18.  Calisher CH, et al. (1989) Antigenic Relationships between Flaviviruses as Determined by 
Cross-neutralization Tests with Polyclonal Antisera. J Gen Virol 70(1):37–43. 
19.  Kuhn RJ, et al. (2002) Structure of Dengue Virus: Implications for Flavivirus 
Organization, Maturation, and Fusion. Cell 108(5):717–725. 
20.  Zhang X, et al. (2013) Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. 
Nat Struct Mol Biol 20(1):105–110. 
21.  Allison SL, et al. (2003) Two Distinct Size Classes of Immature and Mature Subviral 
Particles from Tick-Borne Encephalitis Virus. J Virol 77(21):11357–11366. 
22.  Dong H, et al. (2007) Distinct RNA Elements Confer Specificity to Flavivirus RNA Cap 
Methylation Events. J Virol 81(9):4412–4421. 
23.  Asghar N, et al. (2016) The role of the poly(A) tract in the replication and virulence of 
tick-borne encephalitis virus. Sci Rep 6:39265. 
24.  Mandl CW, Kunz C, Heinz FX (1991) Presence of poly(A) in a flavivirus: significant 
differences between the 3’ noncoding regions of the genomic RNAs of tick-borne 
encephalitis virus strains. J Virol 65(8):4070–4077. 
25.  Tassaneetrithep B, et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of 
human dendritic cells. J Exp Med 197(7):823–829. 
 107 
26.  Shimojima M, Takenouchi A, Shimoda H, Kimura N, Maeda K (2014) Distinct usage of 
three C-type lectins by Japanese encephalitis virus: DC-SIGN, DC-SIGNR, and LSECtin. 
Arch Virol 159(8):2023–2031. 
27.  Lee E, Lobigs M (2008) E Protein Domain III Determinants of Yellow Fever Virus 17D 
Vaccine Strain Enhance Binding to Glycosaminoglycans, Impede Virus Spread, and 
Attenuate Virulence. J Virol 82(12):6024–6033. 
28.  Chen S-T, et al. (2008) CLEC5A is critical for dengue-virus-induced lethal disease. 
Nature 453(7195):672–676. 
29.  Chen S-T, et al. (2012) CLEC5A Regulates Japanese Encephalitis Virus-Induced 
Neuroinflammation and Lethality. PLOS Pathog 8(4):e1002655. 
30.  Meertens L, et al. (2012) The TIM and TAM Families of Phosphatidylserine Receptors 
Mediate Dengue Virus Entry. Cell Host Microbe 12(4):544–557. 
31.  Jemielity S, et al. (2013) TIM-family Proteins Promote Infection of Multiple Enveloped 
Viruses through Virion-associated Phosphatidylserine. PLOS Pathog 9(3):e1003232. 
32.  Meertens L, et al. (2017) Axl Mediates ZIKA Virus Entry in Human Glial Cells and 
Modulates Innate Immune Responses. Cell Rep 18(2):324–333. 
33.  Smit JM, Bittman R, Wilschut J (1999) Low-pH-Dependent Fusion of Sindbis Virus with 
Receptor-Free Cholesterol- and Sphingolipid-Containing Liposomes. J Virol 73(10):8476–
8484. 
34.  Randolph VB, Stollar V (1990) Low pH-induced Cell Fusion in Flavivirus-infected Aedes 
Albopictus Cell Cultures. J Gen Virol 71(8):1845–1850. 
35.  Corver J, et al. (2000) Membrane Fusion Activity of Tick-Borne Encephalitis Virus and 
Recombinant Subviral Particles in a Liposomal Model System. Virology 269(1):37–46. 
36.  Gollins SW, Porterfield JS (1986) PH-dependent Fusion between the Flavivirus West Nile 
and Liposomal Model Membranes. J Gen Virol 67(1):157–166. 
37.  Stiasny K, Koessl C, Heinz FX (2003) Involvement of Lipids in Different Steps of the 
Flavivirus Fusion Mechanism. J Virol 77(14):7856–7862. 
38.  Haslwanter D, Blaas D, Heinz FX, Stiasny K (2017) A novel mechanism of antibody-
mediated enhancement of flavivirus infection. PLOS Pathog 13(9):e1006643. 
39.  Dowd KA, Pierson TC (2011) Antibody-mediated neutralization of flaviviruses: A 
reductionist view. Virology 411(2):306–315. 
40.  Assenberg R, et al. (2009) Crystal Structure of a Novel Conformational State of the 
Flavivirus NS3 Protein: Implications for Polyprotein Processing and Viral Replication. J 
Virol 83(24):12895–12906. 
 108 
41.  Jones CT, et al. (2003) Flavivirus Capsid Is a Dimeric Alpha-Helical Protein. J Virol 
77(12):7143–7149. 
42.  Ma L, Jones CT, Groesch TD, Kuhn RJ, Post CB (2004) Solution structure of dengue 
virus capsid protein reveals another fold. Proc Natl Acad Sci U S A 101(10):3414–3419. 
43.  Samuel GH, Wiley MR, Badawi A, Adelman ZN, Myles KM (2016) Yellow fever virus 
capsid protein is a potent suppressor of RNA silencing that binds double-stranded RNA. 
Proc Natl Acad Sci 113(48):13863–13868. 
44.  Catteau A, et al. (2003) Dengue virus M protein contains a proapoptotic sequence referred 
to as ApoptoM. J Gen Virol 84(10):2781–2793. 
45.  Bhardwaj S, Holbrook M, Shope RE, Barrett AD, Watowich SJ (2001) Biophysical 
characterization and vector-specific antagonist activity of domain III of the tick-borne 
flavivirus envelope protein. J Virol 75(8):4002–4007. 
46.  Thullier P, et al. (2001) Mapping of a dengue virus neutralizing epitope critical for the 
infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82(Pt 
8):1885–1892. 
47.  Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of dengue 
virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J 
Virol 75(16):7769–7773. 
48.  Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC (1995) The envelope glycoprotein 
from tick-borne encephalitis virus at 2 A resolution. Nature 375(6529):291–298. 
49.  Adams SC, et al. (1995) Glycosylation and antigenic variation among Kunjin virus 
isolates. Virology 206(1):49–56. 
50.  Chambers TJ, Halevy M, Nestorowicz A, Rice CM, Lustig S (1998) West Nile virus 
envelope proteins: nucleotide sequence analysis of strains differing in mouse 
neuroinvasiveness. J Gen Virol 79 ( Pt 10):2375–2380. 
51.  Post PR, et al. (1992) Heterogeneity in envelope protein sequence and N-linked 
glycosylation among yellow fever virus vaccine strains. Virology 188(1):160–167. 
52.  Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal Antibody Mapping of the Envelope 
Glycoprotein of the Dengue 2 Virus, Jamaica. Virology 246(2):317–328. 
53.  Crill WD, Chang G-JJ (2004) Localization and Characterization of Flavivirus Envelope 
Glycoprotein Cross-Reactive Epitopes. J Virol 78(24):13975–13986. 
54.  Goncalvez AP, Men R, Wernly C, Purcell RH, Lai C-J (2004) Chimpanzee Fab Fragments 
and a Derived Humanized Immunoglobulin G1 Antibody That Efficiently Cross-
Neutralize Dengue Type 1 and Type 2 Viruses. J Virol 78(23):12910–12918. 
 109 
55.  Chambers TJ, Nickells M (2001) Neuroadapted Yellow Fever Virus 17D: Genetic and 
Biological Characterization of a Highly Mouse-Neurovirulent Virus and Its Infectious 
Molecular Clone. J Virol 75(22):10912–10922. 
56.  Nickells M, Chambers TJ (2003) Neuroadapted Yellow Fever Virus 17D: Determinants in 
the Envelope Protein Govern Neuroinvasiveness for SCID Mice. J Virol 77(22):12232–
12242. 
57.  van der Most RG, Corver J, Strauss JH (1999) Mutagenesis of the RGD Motif in the 
Yellow Fever Virus 17D Envelope Protein. Virology 265(1):83–95. 
58.  Hung J-J, et al. (2004) An External Loop Region of Domain III of Dengue Virus Type 2 
Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not 
Mammalian Cells. J Virol 78(1):378–388. 
59.  Chu JJ, Ng M-L (2004) Interaction of West Nile Virus with αvβ3 Integrin Mediates Virus 
Entry into Cells. J Biol Chem 279(52):54533–54541. 
60.  Lindenbach BD, Rice CM (1997) trans-Complementation of yellow fever virus NS1 
reveals a role in early RNA replication. J Virol 71(12):9608–9617. 
61.  Lindenbach BD, Rice CM (1999) Genetic Interaction of Flavivirus Nonstructural Proteins 
NS1 and NS4A as a Determinant of Replicase Function. J Virol 73(6):4611–4621. 
62.  Muylaert IR, Chambers TJ, Galler R, Rice CM (1996) Mutagenesis of the N-linked 
glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and 
mouse neurovirulence. Virology 222(1):159–168. 
63.  Youn S, Cho H, Fremont DH, Diamond MS (2010) A Short N-Terminal Peptide Motif on 
Flavivirus Nonstructural Protein NS1 Modulates Cellular Targeting and Immune 
Recognition. J Virol 84(18):9516–9532. 
64.  Avirutnan P, et al. (2010) Antagonism of the complement component C4 by flavivirus 
nonstructural protein NS1. J Exp Med 207(4):793–806. 
65.  Chung KM, et al. (2006) West Nile virus nonstructural protein NS1 inhibits complement 
activation by binding the regulatory protein factor H. Proc Natl Acad Sci 103(50):19111–
19116. 
66.  Puerta-Guardo H, Glasner DR, Harris E (2016) Dengue Virus NS1 Disrupts the 
Endothelial Glycocalyx, Leading to Hyperpermeability. PLOS Pathog 12(7):e1005738. 
67.  Henchal EA, Henchal LS, Schlesinger JJ (1988) Synergistic Interactions of Anti-NS1 
Monoclonal Antibodies Protect Passively Immunized Mice from Lethal Challenge with 
Dengue 2 Virus. J Gen Virol 69(8):2101–2107. 
 110 
68.  Schlesinger JJ, Brandriss MW, Cropp CB, Monath TP (1986) Protection against yellow 
fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J 
Virol 60(3):1153–1155. 
69.  Schlesinger JJ, Foltzer M, Chapman S (1993) The Fc Portion of Antibody to Yellow Fever 
Virus NS1 Is a Determinant of Protection against YF Encephalitis in Mice. Virology 
192(1):132–141. 
70.  Xie X, Zou J, Puttikhunt C, Yuan Z, Shi P-Y (2015) Two Distinct Sets of NS2A 
Molecules Are Responsible for Dengue Virus RNA Synthesis and Virion Assembly. J 
Virol 89(2):1298–1313. 
71.  Kümmerer BM, Rice CM (2002) Mutations in the yellow fever virus nonstructural protein 
NS2A selectively block production of infectious particles. J Virol 76(10):4773–4784. 
72.  Muñoz-Jordan JL, Sánchez-Burgos GG, Laurent-Rolle M, García-Sastre A (2003) 
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 
100(24):14333–14338. 
73.  Liu WJ, et al. (2006) A single amino acid substitution in the West Nile virus nonstructural 
protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates 
virus virulence in mice. J Virol 80(5):2396–2404. 
74.  Chang Y-S, et al. (1999) Membrane Permeabilization by Small Hydrophobic 
Nonstructural Proteins of Japanese Encephalitis Virus. J Virol 73(8):6257–6264. 
75.  León-Juárez M, et al. (2016) Recombinant Dengue virus protein NS2B alters membrane 
permeability in different membrane models. Virol J 13. doi:10.1186/s12985-015-0456-4. 
76.  Aguirre S, et al. (2017) Dengue virus NS2B protein targets cGAS for degradation and 
prevents mitochondrial DNA sensing during infection. Nat Microbiol 
2(5):nmicrobiol201737. 
77.  Chambers TJ, et al. (1990) Evidence that the N-terminal domain of nonstructural protein 
NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in 
the viral polyprotein. Proc Natl Acad Sci U S A 87(22):8898–8902. 
78.  Aguirre S, et al. (2012) DENV Inhibits Type I IFN Production in Infected Cells by 
Cleaving Human STING. PLOS Pathog 8(10):e1002934. 
79.  Nunes Duarte dos Santos C, et al. (2000) Determinants in the Envelope E Protein and 
Viral RNA Helicase NS3 That Influence the Induction of Apoptosis in Response to 
Infection with Dengue Type 1 Virus. Virology 274(2):292–308. 
80.  Mackenzie JM, Khromykh AA, Jones MK, Westaway EG (1998) Subcellular localization 
and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and 
NS4A. Virology 245(2):203–215. 
 111 
81.  Bartenschlager R, Lohmann V, Wilkinson T, Koch JO (1995) Complex formation between 
the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for 
polyprotein maturation. J Virol 69(12):7519–7528. 
82.  Shiryaev SA, Chernov AV, Aleshin AE, Shiryaeva TN, Strongin AY (2009) NS4A 
regulates the ATPase activity of the NS3 helicase: a novel cofactor role of the non-
structural protein NS4A from West Nile virus. J Gen Virol 90(9):2081–2085. 
83.  Miller S, Sparacio S, Bartenschlager R (2006) Subcellular localization and membrane 
topology of the Dengue virus type 2 Non-structural protein 4B. J Biol Chem 
281(13):8854–8863. 
84.  Muñoz-Jordán JL, et al. (2005) Inhibition of alpha/beta interferon signaling by the NS4B 
protein of flaviviruses. J Virol 79(13):8004–8013. 
85.  Lee Y-R, et al. (2008) Autophagic machinery activated by dengue virus enhances virus 
replication. Virology 374(2):240–248. 
86.  Liang Q, et al. (2016) Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR 
Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce 
Autophagy. Cell Stem Cell 19(5):663–671. 
87.  McLean JE, Wudzinska A, Datan E, Quaglino D, Zakeri Z (2011) Flavivirus NS4A-
induced Autophagy Protects Cells against Death and Enhances Virus Replication. J Biol 
Chem 286(25):22147–22159. 
88.  Zou G, et al. (2009) A single-amino acid substitution in West Nile virus 2K peptide 
between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 
384(1):242–252. 
89.  Egloff M-P, Benarroch D, Selisko B, Romette J-L, Canard B (2002) An RNA cap 
(nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal 
structure and functional characterization. EMBO J 21(11):2757–2768. 
90.  Yap TL, et al. (2007) Crystal Structure of the Dengue Virus RNA-Dependent RNA 
Polymerase Catalytic Domain at 1.85-Angstrom Resolution. J Virol 81(9):4753–4765. 
91.  Ashour J, et al. (2010) Mouse STAT2 Restricts Early Dengue Virus Replication. Cell Host 
Microbe 8(5):410–421. 
92.  Grant A, et al. (2016) Zika Virus Targets Human STAT2 to Inhibit Type I Interferon 
Signaling. Cell Host Microbe 19(6):882–890. 
93.  Pijlman GP, Kondratieva N, Khromykh AA (2006) Translation of the flavivirus kunjin 
NS3 gene in cis but not its RNA sequence or secondary structure is essential for efficient 
RNA packaging. J Virol 80(22):11255–11264. 
 112 
94.  Sun M, et al. (2013) Global Analysis of Eukaryotic mRNA Degradation Reveals Xrn1-
Dependent Buffering of Transcript Levels. Mol Cell 52(1):52–62. 
95.  Chapman EG, Moon SL, Wilusz J, Kieft JS (2014) RNA structures that resist degradation 
by Xrn1 produce a pathogenic Dengue virus RNA. eLife 3:e01892. 
96.  Moon SL, et al. (2012) A noncoding RNA produced by arthropod-borne flaviviruses 
inhibits the cellular exoribonuclease XRN1 and alters host mRNA stability. RNA N Y N 
18(11):2029–2040. 
97.  Silva ML, et al. (2010) Clinical and Immunological Insights on Severe, Adverse 
Neurotropic and Viscerotropic Disease following 17D Yellow Fever Vaccination. Clin 
Vaccine Immunol CVI 17(1):118–126. 
98.  Funk A, et al. (2010) RNA Structures Required for Production of Subgenomic Flavivirus 
RNA. J Virol 84(21):11407–11417. 
99.  Schuessler A, et al. (2012) West Nile Virus Noncoding Subgenomic RNA Contributes to 
Viral Evasion of the Type I Interferon-Mediated Antiviral Response. J Virol 86(10):5708–
5718. 
100.  Donald CL, et al. (2016) Full Genome Sequence and sfRNA Interferon Antagonist 
Activity of Zika Virus from Recife, Brazil. PLoS Negl Trop Dis 10(10):e0005048. 
101.  Manokaran G, et al. (2015) Dengue subgenomic RNA binds TRIM25 to inhibit interferon 
expression for epidemiological fitness. Science 350(6257):217–221. 
102.  Bidet K, Dadlani D, Garcia-Blanco MA (2014) G3BP1, G3BP2 and CAPRIN1 Are 
Required for Translation of Interferon Stimulated mRNAs and Are Targeted by a Dengue 
Virus Non-coding RNA. PLOS Pathog 10(7):e1004242. 
103.  Chu PWG, Westaway EG (1992) Molecular and ultrastructural analysis of heavy 
membrane fractions associated with the replication of Kunjin virus RNA. Arch Virol 
125(1–4):177–191. 
104.  Zou J, et al. (2015) Mapping the Interactions between the NS4B and NS3 Proteins of 
Dengue Virus. J Virol 89(7):3471–3483. 
105.  Tay MYF, et al. (2014) The C-terminal 50 amino acid residues of Dengue NS3 protein are 
important for NS3-NS5 interaction and viral replication. J Biol Chem:jbc.M114.607341. 
106.  Klema VJ, Padmanabhan R, Choi KH (2015) Flaviviral Replication Complex: 
Coordination between RNA Synthesis and 5′-RNA Capping. Viruses 7(8):4640–4656. 
107.  Cleaves GR, Ryan TE, Schlesinger RW (1981) Identification and characterization of type 
2 dengue virus replicative intermediate and replicative form RNAs. Virology 111(1):73–
83. 
 113 
108.  Fan Y-H, et al. (2011) Small noncoding RNA modulates japanese encephalitis virus 
replication and translation in trans. Virol J 8:492. 
109.  Filomatori CV, et al. (2006) A 5′ RNA element promotes dengue virus RNA synthesis on 
a circular genome. Genes Dev 20(16):2238–2249. 
110.  Selisko B, et al. (2012) Molecular Basis for Nucleotide Conservation at the Ends of the 
Dengue Virus Genome. PLOS Pathog 8(9):e1002912. 
111.  Selisko B, Wang C, Harris E, Canard B (2014) Regulation of Flavivirus RNA synthesis 
and replication. Curr Opin Virol 9:74–83. 
112.  Leung JY, et al. (2008) Role of Nonstructural Protein NS2A in Flavivirus Assembly. J 
Virol 82(10):4731–4741. 
113.  Plevka P, et al. (2011) Maturation of flaviviruses starts from one or more icosahedrally 
independent nucleation centres. EMBO Rep 12(6):602–606. 
114.  Wu B, et al. (2013) Structural basis for dsRNA recognition, filament formation, and 
antiviral signal activation by MDA5. Cell 152(1–2):276–289. 
115.  Dixit E, et al. (2010) Peroxisomes Are Signaling Platforms for Antiviral Innate Immunity. 
Cell 141(4):668–681. 
116.  Devarkar SC, et al. (2016) Structural basis for m7G recognition and 2’-O-methyl 
discrimination in capped RNAs by the innate immune receptor RIG-I. Proc Natl Acad Sci 
U S A 113(3):596–601. 
117.  Kato H, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of 
RNA viruses. Nature 441(7089):101–105. 
118.  Kato H, et al. (2008) Length-dependent recognition of double-stranded ribonucleic acids 
by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp 
Med 205(7):1601–1610. 
119.  Gitlin L, et al. (2006) Essential role of mda-5 in type I IFN responses to 
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl 
Acad Sci U S A 103(22):8459–8464. 
120.  Sato M, et al. (2000) Distinct and essential roles of transcription factors IRF-3 and IRF-7 
in response to viruses for IFN-alpha/beta gene induction. Immunity 13(4):539–548. 
121.  Fredericksen BL, Gale M (2006) West Nile virus evades activation of interferon 
regulatory factor 3 through RIG-I-dependent and -independent pathways without 
antagonizing host defense signaling. J Virol 80(6):2913–2923. 
 114 
122.  Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M (2008) Establishment and 
maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and 
MDA5 signaling through IPS-1. J Virol 82(2):609–616. 
123.  Nasirudeen AMA, et al. (2011) RIG-I, MDA5 and TLR3 Synergistically Play an 
Important Role in Restriction of Dengue Virus Infection. PLoS Negl Trop Dis 5(1):e926. 
124.  Errett JS, Suthar MS, McMillan A, Diamond MS, Gale M (2013) The Essential, 
Nonredundant Roles of RIG-I and MDA5 in Detecting and Controlling West Nile Virus 
Infection. J Virol 87(21):11416–11425. 
125.  Bruni D, et al. (2015) Viral entry route determines how human plasmacytoid dendritic 
cells produce type I interferons. Sci Signal 8(366):ra25. 
126.  Parthiban P, Mahendra J (2015) Toll-Like Receptors: A Key Marker for Periodontal 
Disease and Preterm Birth – A Contemporary Review. J Clin Diagn Res JCDR 9(9):ZE14-
ZE17. 
127.  Tsai Y-T, Chang S-Y, Lee C-N, Kao C-L (2009) Human TLR3 recognizes dengue virus 
and modulates viral replication in vitro. Cell Microbiol 11(4):604–615. 
128.  Wang JP, et al. (2006) Flavivirus activation of plasmacytoid dendritic cells delineates key 
elements of TLR7 signaling beyond endosomal recognition. J Immunol Baltim Md 1950 
177(10):7114–7121. 
129.  Querec T, et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell 
subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203(2):413–
424. 
130.  Wang T, et al. (2004) Toll-like receptor 3 mediates West Nile virus entry into the brain 
causing lethal encephalitis. Nat Med 10(12):1366–1373. 
131.  Daffis S, Samuel MA, Suthar MS, Gale M, Diamond MS (2008) Toll-Like Receptor 3 Has 
a Protective Role against West Nile Virus Infection. J Virol 82(21):10349–10358. 
132.  Szretter KJ, et al. (2010) The Innate Immune Adaptor Molecule MyD88 Restricts West 
Nile Virus Replication and Spread in Neurons of the Central Nervous System. J Virol 
84(23):12125–12138. 
133.  Shipley JG, Vandergaast R, Deng L, Mariuzza RA, Fredericksen BL (2012) Identification 
of multiple RIG-I-specific pathogen associated molecular patterns within the West Nile 
virus genome and antigenome. Virology 432(1):232–238. 
134.  Chan YK, Gack MU (2016) A phosphomimetic-based mechanism of dengue virus to 
antagonize innate immunity. Nat Immunol 17(5):523–530. 
135.  Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. 
Nat Rev Immunol 5(5):nri1604. 
 115 
136.  Leyssen P, et al. (2003) Interferons, Interferon Inducers, and Interferon-Ribavirin in 
Treatment of Flavivirus-Induced Encephalitis in Mice. Antimicrob Agents Chemother 
47(2):777–782. 
137.  Govero J, et al. (2016) Zika virus infection damages the testes in mice. Nature 
540(7633):438. 
138.  Sheehan KCF, Lazear HM, Diamond MS, Schreiber RD (2015) Selective Blockade of 
Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West 
Nile Virus Infection. PLoS ONE 10(5). doi:10.1371/journal.pone.0128636. 
139.  Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD (2009) A Mouse 
Model for Studying Viscerotropic Disease Caused by Yellow Fever Virus Infection. PLOS 
Pathog 5(10):e1000614. 
140.  Lobigs M, Mullbacher A, Wang Y, Pavy M, Lee E (2003) Role of type I and type II 
interferon responses in recovery from infection with an encephalitic flavivirus. J Gen 
Virol. doi:10.1099/vir.0.18654-0. 
141.  Weber E, et al. (2014) Type I Interferon Protects Mice from Fatal Neurotropic Infection 
with Langat Virus by Systemic and Local Antiviral Responses. J Virol 88(21):12202–
12212. 
142.  Pinto AK, et al. (2011) A Temporal Role Of Type I Interferon Signaling in CD8+ T Cell 
Maturation during Acute West Nile Virus Infection. PLOS Pathog 7(12):e1002407. 
143.  Diamond MS, et al. (2000) Modulation of Dengue Virus Infection in Human Cells by 
Alpha, Beta, and Gamma Interferons. J Virol 74(11):4957–4966. 
144.  Best SM, et al. (2005) Inhibition of Interferon-Stimulated JAK-STAT Signaling by a Tick-
Borne Flavivirus and Identification of NS5 as an Interferon Antagonist. J Virol 
79(20):12828–12839. 
145.  Lin YL, et al. (1997) Inhibition of Japanese encephalitis virus infection by nitric oxide: 
antiviral effect of nitric oxide on RNA virus replication. J Virol 71(7):5227–5235. 
146.  Shrestha B, et al. (2006) Gamma Interferon Plays a Crucial Early Antiviral Role in 
Protection against West Nile Virus Infection. J Virol 80(11):5338–5348. 
147.  Arroyo JI, et al. (1988) Effect of human gamma interferon on yellow fever virus infection. 
Am J Trop Med Hyg 38(3):647–650. 
148.  Ma D, et al. (2009) Antiviral effect of interferon lambda against West Nile virus. Antiviral 
Res 83(1):53–60. 
149.  Lazear HM, et al. (2015) Interferon-λ restricts West Nile virus neuroinvasion by 
tightening the blood-brain barrier. Sci Transl Med 7(284):284ra59. 
 116 
150.  Corry J, Arora N, Good CA, Sadovsky Y, Coyne CB (2017) Organotypic models of type 
III interferon-mediated protection from Zika virus infections at the maternal-fetal 
interface. Proc Natl Acad Sci U S A 114(35):9433–9438. 
151.  Douam F, et al. (2017) Type III Interferon-Mediated Signaling Is Critical for Controlling 
Live Attenuated Yellow Fever Virus Infection In Vivo. mBio 8(4):e00819-17. 
152.  Silverman RH (2007) Viral Encounters with 2′,5′-Oligoadenylate Synthetase and RNase L 
during the Interferon Antiviral Response. J Virol 81(23):12720–12729. 
153.  Elbahesh H, Jha BK, Silverman RH, Scherbik SV, Brinton MA (2011) The Flvr-encoded 
murine oligoadenylate synthetase 1b (Oas1b) suppresses 2-5A synthesis in intact cells. 
Virology 409(2):262–270. 
154.  Mertens E, et al. (2010) Viral determinants in the NS3 helicase and 2K peptide that 
promote West Nile virus resistance to antiviral action of 2′,5′-oligoadenylate synthetase 
1b. Virology 399(1):176–185. 
155.  Lin R-J, et al. (2009) Distinct Antiviral Roles for Human 2′,5′-Oligoadenylate Synthetase 
Family Members against Dengue Virus Infection. J Immunol 183(12):8035–8043. 
156.  Kurane I, Hebblewaite D, Brandt WE, Ennis FA (1984) Lysis of dengue virus-infected 
cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated 
cytotoxicity. J Virol 52(1):223–230. 
157.  Reefman E, et al. (2010) Cytokine Secretion Is Distinct from Secretion of Cytotoxic 
Granules in NK Cells. J Immunol 184(9):4852–4862. 
158.  Mariani E, et al. (2002) RANTES and MIP-1α production by T lymphocytes, monocytes 
and NK cells from nonagenarian subjects. Exp Gerontol 37(2):219–226. 
159.  Marquardt N, et al. (2015) The Human NK Cell Response to Yellow Fever Virus 17D Is 
Primarily Governed by NK Cell Differentiation Independently of NK Cell Education. J 
Immunol Baltim Md 1950 195(7):3262–3272. 
160.  Neves PCC, Santos JR, Tubarão LN, Bonaldo MC, Galler R (2013) Early IFN-Gamma 
Production after YF 17D Vaccine Virus Immunization in Mice and Its Association with 
Adaptive Immune Responses. PLoS ONE 8(12):e81953. 
161.  Shresta S, et al. (2004) Interferon-Dependent Immunity Is Essential for Resistance to 
Primary Dengue Virus Infection in Mice, Whereas T- and B-Cell-Dependent Immunity 
Are Less Critical. J Virol 78(6):2701–2710. 
162.  Blom K, et al. (2016) NK Cell Responses to Human Tick-Borne Encephalitis Virus 
Infection. J Immunol 197(7):2762–2771. 
 117 
163.  Cheng Y, King NJC, Kesson AM Major Histocompatibility Complex Class I (MHC-I) 
Induction by West Nile Virus: Involvement of 2 Signaling Pathways in MHC-I Up-
Regulation. J Infect Dis:658–668. 
164.  Müllbacher A, Lobigs M (1995) Up-regulation of MHC class I by flavivirus-induced 
peptide translocation into the endoplasmic reticulum. Immunity 3(2):207–214. 
165.  Lobigs M, Müllbacher A, Lee E (2004) Evidence that a mechanism for efficient flavivirus 
budding upregulates MHC class I. Immunol Cell Biol. Available at: 
https://www.nature.com/articles/icb200429 [Accessed January 4, 2018]. 
166.  Hershkovitz O, et al. (2008) Dengue Virus Replicon Expressing the Nonstructural Proteins 
Suffices To Enhance Membrane Expression of HLA Class I and Inhibit Lysis by Human 
NK Cells. J Virol 82(15):7666–7676. 
167.  Hershkovitz O, et al. (2009) NKp44 Receptor Mediates Interaction of the Envelope 
Glycoproteins from the West Nile and Dengue Viruses with NK Cells. J Immunol 
183(4):2610–2621. 
168.  García G, et al. (2006) Antibodies from patients with dengue viral infection mediate 
cellular cytotoxicity. J Clin Virol 37(1):53–57. 
169.  Gardner CL, Ryman KD (2010) Yellow Fever: A Reemerging Threat. Clin Lab Med 
30(1):237–260. 
170.  Huang Y-JS, Higgs S, Horne KM, Vanlandingham DL (2014) Flavivirus-Mosquito 
Interactions. Viruses 6(11):4703–4730. 
171.  Wee LK, et al. (2013) Relationship between rainfall and Aedes larval population at two 
insular sites in Pulau Ketam, Selangor, Malaysia. Southeast Asian J Trop Med Public 
Health 44(2):157–166. 
172.  Nasir S, Jabeen F, Abbas S, Nasir I, Debboun M (2017) Effect of Climatic Conditions and 
Water Bodies on Population Dynamics of the Dengue Vector, Aedes aegypti (Diptera: 
Culicidae). J Arthropod-Borne Dis 11(1):50–59. 
173.  Black WC, Rai KS, Turco BJ, Arroyo DC (1989) Laboratory study of competition 
between United States strains of Aedes albopictus and Aedes aegypti (Diptera: Culicidae). 
J Med Entomol 26(4):260–271. 
174.  World Health Organization (2011) Yellow fever in Africa and Central and South America, 
2008–2009. Releve Epidemiol Hebd 86(4):25–36. 
175.  World Health Organization (2013) Yellow fever in Africa and South America, 2011–2012. 
Releve Epidemiol Hebd 88(28):285–296. 
176.  World Health Organization (2014) Yellow fever in Africa and South America, 2013. 
Releve Epidemiol Hebd 89(27):297–306. 
 118 
177.  World Health Organization (2016) Yellow fever in Africa and South America, 2015. 
Releve Epidemiol Hebd 91(32):381–388. 
178.  World Health Organization WHO | Yellow fever – Brazil. WHO. Available at: 
http://www.who.int/csr/don/27-january-2017-yellow-fever-brazil/en/ [Accessed November 
1, 2017]. 
179.  Romano APM, et al. (2014) Yellow Fever outbreaks in unvaccinated populations, Brazil, 
2008-2009. PLoS Negl Trop Dis 8(3):e2740. 
180.  Wasserman S, Tambyah PA, Lim PL (2016) Yellow fever cases in Asia: primed for an 
epidemic. Int J Infect Dis 48:98–103. 
181.  Agampodi SB, Wickramage K (2013) Is There a Risk of Yellow Fever Virus 
Transmission in South Asian Countries with Hyperendemic Dengue? BioMed Res Int 
2013:e905043. 
182.  Johansson MA, Vasconcelos PFC, Staples JE (2014) The whole iceberg: estimating the 
incidence of yellow fever virus infection from the number of severe cases. Trans R Soc 
Trop Med Hyg 108(8):482–487. 
183.  Monath TP, et al. (1980) Yellow fever in the Gambia, 1978--1979: epidemiologic aspects 
with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg 
29(5):912–928. 
184.  Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC) 
(2010) Yellow fever vaccine: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep Morb Mortal Wkly Rep Recomm 
Rep 59(RR-7):1–27. 
185.  Stokes A, Bauer JH, Hudson NP (1928) THE TRANSMISSION OF YELLOW FEVER 
TO MACACUS RHESUS: PRELIMINARY NOTE. J Am Med Assoc 90(4):253–254. 
186.  Sellards AW, Hindle E (1928) THE PRESERVATION OF YELLOW FEVER VIRUS. Br 
Med J 1(3512):713–714. 
187.  Berry GP, Kitchen SF (1931) Yellow Fever Accidentally Contracted in the Laboratory. 
Am J Trop Med Hyg s1-11(6):365–434. 
188.  Lloyd W, Theiler M, Ricci NI (1936) Modification of the virulence of yellow fever virus 
by cultivation in tissues in vitro. Trans R Soc Trop Med Hyg 29(5):481–529. 
189.  Barrett ADT (1987) Yellow Fever Vaccines. Bull Inst Pasteur 85:103–124. 
190.  World Health Organization (1998) Requirements for yellow fever vaccine, Annex 2. WHO 
Tech Rep Ser 872. 
 119 
191.  Campi-Azevedo AC, et al. (2014) Subdoses of 17DD yellow fever vaccine elicit 
equivalent virological/immunological kinetics timeline. BMC Infect Dis 14:391. 
192.  Barba-Spaeth G, Longman RS, Albert ML, Rice CM (2005) Live attenuated yellow fever 
17D infects human DCs and allows for presentation of endogenous and recombinant T cell 
epitopes. J Exp Med 202(9):1179–1184. 
193.  Querec TD, et al. (2009) Systems biology approach predicts immunogenicity of the yellow 
fever vaccine in humans. Nat Immunol 10(1):116–125. 
194.  Kohler S, et al. (2012) The early cellular signatures of protective immunity induced by 
live viral vaccination. Eur J Immunol 42(9):2363–2373. 
195.  Gibney KB, et al. (2012) Detection of Anti-Yellow Fever Virus Immunoglobulin M 
Antibodies at 3–4 Years Following Yellow Fever Vaccination. Am J Trop Med Hyg 
87(6):1112–1115. 
196.  Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K (1981) Persistence of 
neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull 
World Health Organ 59(6):895–900. 
197.  Niedrig M, Lademann M, Emmerich P, Lafrenz M (1999) Assessment of IgG antibodies 
against yellow fever virus after vaccination with 17D by different assays: neutralization 
test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med 
Int Health 4(12):867–871. 
198.  Wieten RW, et al. (2016) A Single 17D Yellow Fever Vaccination Provides Lifelong 
Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell 
Responses after Vaccination. PLOS ONE 11(3):e0149871. 
199.  Hepburn MJ, et al. (2006) Neutralizing antibody response to booster vaccination with the 
17d yellow fever vaccine. Vaccine 24(15):2843–2849. 
200.  Hayakawa K, et al. (2015) Persistent seropositivity for yellow fever in a previously 
vaccinated autologous hematopoietic stem cell transplantation recipient. Int J Infect Dis 
37(Supplement C):9–10. 
201.  Avelino-Silva VI, et al. (2015) Persistence of Yellow Fever vaccine-induced antibodies 
after cord blood stem cell transplant. Hum Vaccines Immunother 12(4):937–938. 
202.  Martínez MJ, et al. (2011) Persistence of yellow fever vaccine RNA in urine. Vaccine 
29(18):3374–3376. 
203.  Blom K, et al. (2013) Temporal Dynamics of the Primary Human T Cell Response to 
Yellow Fever Virus 17D As It Matures from an Effector- to a Memory-Type Response. J 
Immunol 190(5):2150–2158. 
 120 
204.  Akondy RS, et al. (2015) Initial viral load determines the magnitude of the human CD8 T 
cell response to yellow fever vaccination. Proc Natl Acad Sci 112(10):3050–3055. 
205.  Miller JD, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox 
and yellow fever vaccines. Immunity 28(5):710–722. 
206.  Silva ML, et al. (2011) Characterization of main cytokine sources from the innate and 
adaptive immune responses following primary 17DD yellow fever vaccination in adults. 
Vaccine 29(3):583–592. 
207.  Campi-Azevedo AC, et al. (2012) 17DD and 17D-213/77 Yellow Fever Substrains Trigger 
a Balanced Cytokine Profile in Primary Vaccinated Children. PLOS ONE 7(12):e49828. 
208.  James EA, et al. (2013) Yellow Fever Vaccination Elicits Broad Functional CD4+ T Cell 
Responses That Recognize Structural and Nonstructural Proteins. J Virol 87(23):12794–
12804. 
209.  Santos AP, Matos DCS, Bertho AL, Mendonça SCF, Marcovistz R (2008) Detection of 
TH1/TH2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot 
assay. Cytokine 42(2):152–155. 
210.  Watson AM, Lam LKM, Klimstra WB, Ryman KD (2016) The 17D-204 Vaccine Strain-
Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral 
Immunity and CD4+ but not CD8+ T Cells. PLOS Pathog 12(7):e1005786. 
211.  Bassi MR, et al. (2015) CD8+ T Cells Complement Antibodies in Protecting against 
Yellow Fever Virus. J Immunol 194(3):1141–1153. 
212.  Beck AS, Barrett ADT (2015) Current status and future prospects of yellow fever 
vaccines. Expert Rev Vaccines 14(11):1479–1492. 
213.  de Wispelaere M, Khou C, Frenkiel M-P, Desprès P, Pardigon N (2016) A Single Amino 
Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian 
Hosts. J Virol 90(5):2676–2689. 
214.  Zmurko J, Neyts J, Dallmeier K (2015) Flaviviral NS4b, chameleon and jack‐in‐the‐box 
roles in viral replication and pathogenesis, and a molecular target for antiviral 
intervention. Rev Med Virol 25(4):205–223. 
215.  Dunster LM, et al. (1999) Molecular and Biological Changes Associated with HeLa Cell 
Attenuation of Wild-Type Yellow Fever Virus. Virology 261(2):309–318. 
216.  McArthur MA, Suderman MT, Mutebi J-P, Xiao S-Y, Barrett ADT (2003) Molecular 
Characterization of a Hamster Viscerotropic Strain of Yellow Fever Virus. J Virol 
77(2):1462–1468. 
 121 
217.  Fernandez-Garcia MD, et al. (2016) Vaccine and Wild-Type Strains of Yellow Fever 
Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune 
Responses. mBio 7(1):e01956-15. 
218.  Hasegawa H, Yoshida M, Shiosaka T, Fujita S, Kobayashi Y (1992) Mutations in the 
envelope protein of Japanese encephalitis virus affect entry into cultured cells and 
virulence in mice. Virology 191(1):158–165. 
219.  Morita K, et al. (2001) Locus of a Virus Neutralization Epitope on the Japanese 
Encephalitis Virus Envelope Protein Determined by Use of Long PCR-Based Region-
Specific Random Mutagenesis. Virology 287(2):417–426. 
220.  Butrapet S, et al. (2011) Amino acid changes within the E protein hinge region that affect 
dengue virus type 2 infectivity and fusion. Virology 413(1):118–127. 
221.  Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE (2016) Adverse event reports 
following yellow fever vaccination, 2007–13. J Travel Med 23(5):taw045. 
222.  Merlo C, Steffen R, Landis T, Tsai T, Karabatsos N (1993) Possible association of 
encephalitis and 17D yellow fever vaccination in a 29-year-old traveller. Vaccine 
11(6):691. 
223.  Kengsakul K, Sathirapongsasuti K, Punyagupta S (2002) Fatal myeloencephalitis 
following yellow fever vaccination in a case with HIV infection. J Med Assoc Thail 
Chotmaihet Thangphaet 85(1):131–134. 
224.  Monath TP, Barrett AD (2003) Pathogenesis and pathophysiology of yellow fever. Adv 
Virus Res 60:343–395. 
225.  Martin M, et al. (2001) Fever and multisystem organ failure associated with 17D-204 
yellow fever vaccination: a report of four cases. The Lancet 358(9276):98–104. 
226.  Chan RC, et al. (2001) Hepatitis and death following vaccination with 17D-204 yellow 
fever vaccine. The Lancet 358(9276):121–122. 
227.  Vasconcelos PF, et al. (2001) Serious adverse events associated with yellow fever 17DD 
vaccine in Brazil: a report of two cases. The Lancet 358(9276):91–97. 
228.  Whittembury A, et al. (2009) Viscerotropic disease following yellow fever vaccination in 
Peru. Vaccine 27(43):5974–5981. 
229.  Seligman SJ, Cohen JE, Itan Y, Casanova J-L, Pezzullo JC (2014) Defining Risk Groups 
to Yellow Fever Vaccine-Associated Viscerotropic Disease in the Absence of 
Denominator Data. Am J Trop Med Hyg 90(2):267–271. 
230.  Pulendran B, et al. (2008) Case of Yellow Fever Vaccine-associated Viscerotropic Disease 
with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in 
CCR5 and RANTES Genes. J Infect Dis 198(4):500–507. 
 122 
231.  Engel AR, C Vasconcelos PF, McArthur MA, T. Barrett AD (2006) Characterization of a 
viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 24(15):2803–
2809. 
232.  Galler R, et al. (2001) Phenotypic and Molecular Analyses of Yellow Fever 17DD 
Vaccine Viruses Associated with Serious Adverse Events in Brazil. Virology 290(2):309–
319. 
233.  Nascimento Silva JR, et al. (2011) Mutual interference on the immune response to yellow 
fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 
29(37):6327–6334. 
234.  Lieberman LA, Hunter CA (2002) Regulatory pathways involved in the infection-induced 
production of IFN-gamma by NK cells. Microbes Infect 4(15):1531–1538. 
235.  Tato CM, et al. (2004) Cutting Edge: Innate Production of IFN-γ by NK Cells Is 
Independent of Epigenetic Modification of the IFN-γ Promoter. J Immunol 173(3):1514–
1517. 
236.  Eberl G, Colonna M, Santo JPD, McKenzie ANJ (2015) Innate lymphoid cells: A new 
paradigm in immunology. Science 348(6237):aaa6566. 
237.  Darwich L, et al. (2009) Secretion of interferon-γ by human macrophages demonstrated at 
the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 
126(3):386–393. 
238.  Pan J, et al. (2004) Interferon-γ is an autocrine mediator for dendritic cell maturation. 
Immunol Lett 94(1):141–151. 
239.  Moretto MM, Weiss LM, Combe CL, Khan IA (2007) IFN-γ-Producing Dendritic Cells 
Are Important for Priming of Gut Intraepithelial Lymphocyte Response Against 
Intracellular Parasitic Infection. J Immunol 179(4):2485–2492. 
240.  Ethuin F, et al. (2004) Human neutrophils produce interferon gamma upon stimulation by 
interleukin-12. Lab Invest 84(10):1363–1371. 
241.  Bao Y, et al. (2014) Identification of IFN-γ-producing innate B cells. Cell Res 24(2):161–
176. 
242.  Biering SB, et al. (2017) Viral Replication Complexes Are Targeted by LC3-Guided 
Interferon-Inducible GTPases. Cell Host Microbe 22(1):74–85.e7. 
243.  Herrero C, Marqués L, Lloberas J, Celada A (2001) IFN-γ–dependent transcription of 
MHC class II IA is impaired in macrophages from aged mice. J Clin Invest 107(4):485–
493. 
244.  Flynn JL, et al. (1993) An essential role for interferon gamma in resistance to 
Mycobacterium tuberculosis infection. J Exp Med 178(6):2249–2254. 
 123 
245.  Lane TE, Wu-Hsieh BA, Howard DH (1991) Iron limitation and the gamma interferon-
mediated antihistoplasma state of murine macrophages. Infect Immun 59(7):2274–2278. 
246.  Prestwood TR, et al. (2012) Gamma Interferon (IFN-γ) Receptor Restricts Systemic 
Dengue Virus Replication and Prevents Paralysis in IFN-α/β Receptor-Deficient Mice. J 
Virol 86(23):12561–12570. 
247.  Takács AC, Swierzy IJ, Lüder CGK (2012) Interferon-γ Restricts Toxoplasma gondii 
Development in Murine Skeletal Muscle Cells via Nitric Oxide Production and Immunity-
Related GTPases. PLOS ONE 7(9):e45440. 
248.  Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and 
adaptive immune responses. Adv Immunol 96:41–101. 
249.  Collier SP, Collins PL, Williams CL, Boothby MR, Aune TM (2012) Cutting Edge: 
Influence of Tmevpg1, a Long Intergenic Noncoding RNA, on the Expression of Ifng by 
Th1 Cells. J Immunol 189(5):2084–2088. 
250.  Schoenborn JR, et al. (2007) Comprehensive epigenetic profiling identifies multiple distal 
regulatory elements directing transcription of the gene encoding interferon-γ. Nat Immunol 
8(7):ni1474. 
251.  Winders BR, Schwartz RH, Bruniquel D (2004) A Distinct Region of the Murine IFN-γ 
Promoter Is Hypomethylated from Early T Cell Development through Mature Naive and 
Th1 Cell Differentiation, but Is Hypermethylated in Th2 Cells. J Immunol 173(12):7377–
7384. 
252.  Szabo SJ, et al. (2000) A Novel Transcription Factor, T-bet, Directs Th1 Lineage 
Commitment. Cell 100(6):655–669. 
253.  Tato CM, et al. (2006) Opposing roles of NF-κB family members in the regulation of NK 
cell proliferation and production of IFN-γ. Int Immunol 18(4):505–513. 
254.  Rahman MM, McFadden G (2011) Modulation of NF-κB signalling by microbial 
pathogens. Nat Rev Microbiol 9(4):291–306. 
255.  Corn RA, et al. (2003) T Cell-Intrinsic Requirement for NF-κB Induction in 
Postdifferentiation IFN-γ Production and Clonal Expansion in a Th1 Response. J Immunol 
171(4):1816–1824. 
256.  Tato CM, Villarino A, Caamaño JH, Boothby M, Hunter CA (2003) Inhibition of NF-κB 
Activity in T and NK Cells Results in Defective Effector Cell Expansion and Production 
of IFN-γ Required for Resistance to Toxoplasma gondii. J Immunol 170(6):3139–3146. 
257.  Corn RA, Hunter C, Liou H-C, Siebenlist U, Boothby MR (2005) Opposing Roles for 
RelB and Bcl-3 in Regulation of T-Box Expressed in T Cells, GATA-3, and Th Effector 
Differentiation. J Immunol 175(4):2102–2110. 
 124 
258.  Gomez JA, et al. (2013) NeST, a long noncoding RNA, controls microbial susceptibility 
and epigenetic activation of the Ifng locus. Cell 152(4):743–754. 
259.  Collier SP, Henderson MA, Tossberg JT, Aune TM (2014) Regulation of the Th1 
Genomic Locus from Ifng through Tmevpg1 by T-bet. J Immunol 193(8):3959–3965. 
260.  Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013) Controlling NK Cell 
Responses: Integration of Signals for Activation and Inhibition. Annu Rev Immunol 31. 
doi:10.1146/annurev-immunol-020711-075005. 
261.  Ma X, et al. (2015) Regulation of IL-10 and IL-12 production and function in 
macrophages and dendritic cells. F1000Research 4. doi:10.12688/f1000research.7010.1. 
262.  de Groen RA, et al. (2015) IFN-λ-mediated IL-12 production in macrophages induces 
IFN-γ production in human NK cells. Eur J Immunol 45(1):250–259. 
263.  Xing Z, Zganiacz A, Santosuosso M (2000) Role of IL-12 in macrophage activation 
during intracellular infection: IL-12 and mycobacteria synergistically release TNF-α and 
nitric oxide from macrophages via IFN-γ induction. J Leukoc Biol 68(6):897–902. 
264.  Heufler C, et al. (1996) Interleukin-12 is produced by dendritic cells and mediates T 
helper 1 development as well as interferon-γ production by T helper 1 cells. Eur J 
Immunol 26(3):659–668. 
265.  Henry CJ, Ornelles DA, Mitchell LM, Brzoza-Lewis KL, Hiltbold EM (2008) IL-12 
Produced by Dendritic Cells Augments CD8+ T cell Activation through the Production of 
the Chemokines CCL1 and CCL17. J Immunol Baltim Md 1950 181(12):8576–8584. 
266.  Bliss SK, Marshall AJ, Zhang Y, Denkers EY (1999) Human polymorphonuclear 
leukocytes produce IL-12, TNF-alpha, and the chemokines macrophage-inflammatory 
protein-1 alpha and -1 beta in response to Toxoplasma gondii antigens. J Immunol Baltim 
Md 1950 162(12):7369–7375. 
267.  Cassatella MA, et al. (1995) Interleukin-12 production by human polymorphonuclear 
leukocytes. Eur J Immunol 25(1):1–5. 
268.  Luque I, Reyburn H, Strominger JL (2000) Expression of the CD80 and CD86 molecules 
enhances cytotoxicity by human natural killer cells. Hum Immunol 61(8):721–728. 
269.  Wilson JL, et al. (1999) NK Cell Triggering by the Human Costimulatory Molecules 
CD80 and CD86. J Immunol 163(8):4207–4212. 
270.  Wang KS, Ritz J, Frank DA (1999) IL-2 Induces STAT4 Activation in Primary NK Cells 
and NK Cell Lines, But Not in T Cells. J Immunol 162(1):299–304. 
271.  Hunter CA, Gabriel KE, Radzanowski T, Neyer LE, Remington JS (1997) Type I 
interferons enhance production of IFN-gamma by NK cells. Immunol Lett 59(1):1–5. 
 125 
272.  Hunter CA, et al. (1997) Comparison of the effects of interleukin-1α, interleukin-lβ and 
interferon-γ-inducing factor on the production of interferon-γ by natural killer. Eur J 
Immunol 27(11):2787–2792. 
273.  Okamura H, et al. (1995) Cloning of a new cytokine that induces IFN-gamma production 
by T cells. Nature 378(6552):88–91. 
274.  Cooper MA, et al. (2002) In vivo evidence for a dependence on interleukin 15 for survival 
of natural killer cells. Blood 100(10):3633–3638. 
275.  Koka R, et al. (2003) Interleukin (IL)-15Rα–deficient Natural Killer Cells Survive in 
Normal but Not IL-15Rα–deficient Mice. J Exp Med 197(8):977–984. 
276.  Carson WE, et al. (1995) The functional characterization of interleukin-10 receptor 
expression on human natural killer cells. Blood 85(12):3577–3585. 
277.  D’Andrea A, et al. (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon 
gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in 
accessory cells. J Exp Med 178(3):1041–1048. 
278.  Yu J, et al. (2006) Pro- and antiinflammatory cytokine signaling: reciprocal antagonism 
regulates interferon-gamma production by human natural killer cells. Immunity 24(5):575–
590. 
279.  Trotta R, et al. (2008) TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma 
production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 
Baltim Md 1950 181(6):3784–3792. 
280.  Afkarian M, et al. (2002) T-bet is a STAT1-induced regulator of IL-12R expression in 
naïve CD4+ T cells. Nat Immunol 3(6):549–557. 
281.  Agarwal S, Rao A (1998) Modulation of Chromatin Structure Regulates Cytokine Gene 
Expression during T Cell Differentiation. Immunity 9(6):765–775. 
282.  Mullen AC, et al. (2002) Hlx is induced by and genetically interacts with T-bet to promote 
heritable TH1 gene induction. Nat Immunol 3(7):652. 
283.  Djuretic IM, et al. (2007) Transcription factors T-bet and Runx3 cooperate to activate Ifng 
and silence Il4 in T helper type 1 cells. Nat Immunol 8(2):145–153. 
284.  Cho BK, Wang C, Sugawa S, Eisen HN, Chen J (1999) Functional differences between 
memory and naive CD8 T cells. Proc Natl Acad Sci 96(6):2976–2981. 
285.  Krämer OH, et al. (2009) A phosphorylation-acetylation switch regulates STAT1 
signaling. Genes Dev 23(2):223–235. 
286.  Choudhury GG (2004) A Linear Signal Transduction Pathway Involving 
Phosphatidylinositol 3-Kinase, Protein Kinase Cϵ, and MAPK in Mesangial Cells 
 126 
Regulates Interferon-γ-induced STAT1α Transcriptional Activation. J Biol Chem 
279(26):27399–27409. 
287.  Uddin S, et al. (2002) Protein Kinase C-δ (PKC-δ) Is Activated by Type I Interferons and 
Mediates Phosphorylation of Stat1 on Serine 727. J Biol Chem 277(17):14408–14416. 
288.  Wen Z, Zhong Z, Darnell JE (1995) Maximal activation of transcription by statl and stat3 
requires both tyrosine and serine phosphorylation. Cell 82(2):241–250. 
289.  Beurel E, Jope RS (2009) Glycogen synthase kinase-3 promotes the synergistic action of 
interferon-γ on lipopolysaccharide-induced IL-6 production in RAW264.7 cells1. Cell 
Signal 21(6):978–985. 
290.  Valledor AF, et al. (2008) Selective Roles of MAPKs during the Macrophage Response to 
IFN-γ. J Immunol 180(7):4523–4529. 
291.  Wang Z, et al. (2015) Interferon-γ Inhibits Nonopsonized Phagocytosis of Macrophages 
via an mTORC1-c/EBPβ Pathway. J Innate Immun 7(2):165–176. 
292.  Su X, et al. (2015) Interferon-γ regulates cellular metabolism and mRNA translation to 
potentiate macrophage activation. Nat Immunol 16(8):838. 
293.  Kroczynska B, et al. (2016) Interferon γ (IFNγ) Signaling via Mechanistic Target of 
Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II 
Interferon Biological Responses. J Biol Chem 291(5):2389–2396. 
294.  Alsayed Y, et al. (2000) IFN-γ Activates the C3G/Rap1 Signaling Pathway. J Immunol 
164(4):1800–1806. 
295.  Gatto L, et al. (2004) Analysis of SOCS-3 Promoter Responses to Interferon γ. J Biol 
Chem 279(14):13746–13754. 
296.  Lesinski GB, et al. (2010) Modulation of SOCS protein expression influences the 
interferon responsiveness of human melanoma cells. BMC Cancer 10:142. 
297.  Liang Y, Xu W-D, Peng H, Pan H-F, Ye D-Q (2014) SOCS signaling in autoimmune 
diseases: Molecular mechanisms and therapeutic implications. Eur J Immunol 44(5):1265–
1275. 
298.  Chong MMW, Thomas HE, Kay TWH (2001) γ-Interferon Signaling in Pancreatic β-Cells 
Is Persistent but Can Be Terminated by Overexpression of Suppressor of Cytokine 
Signaling-1. Diabetes 50(12):2744–2751. 
299.  Haspel RL, Salditt-Georgieff M, Darnell JE (1996) The rapid inactivation of nuclear 
tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 
15(22):6262–6268. 
 127 
300.  Endo TA, et al. (1997) A new protein containing an SH2 domain that inhibits JAK 
kinases. Nature 387(6636):921–924. 
301.  Sakamoto H, Kinjyo I, Yoshimura A (2000) The Janus Kinase Inhibitor, JAB/SOCS-1, Is 
an Interferon-γ Inducible Gene and Determines the Sensitivity to Interferons. Leuk 
Lymphoma 38(1–2):49–58. 
302.  Wormald S, et al. (2006) The comparative roles of suppressor of cytokine signaling-1 and 
-3 in the inhibition and desensitization of cytokine signaling. J Biol Chem 281(16):11135–
11143. 
303.  Zhang J-G, et al. (1999) The conserved SOCS box motif in suppressors of cytokine 
signaling binds to elongins B and C and may couple bound proteins to proteasomal 
degradation. Proc Natl Acad Sci 96(5):2071–2076. 
304.  Jasmin J-F, Mercier I, Sotgia F, Lisanti MP (2006) SOCS proteins and caveolin-1 as 
negative regulators of endocrine signaling. Trends Endocrinol Metab 17(4):150–158. 
305.  Zhang X, Mosser D (2008) Macrophage activation by endogenous danger signals. J 
Pathol 214(2):161–178. 
306.  Eiserich JP, Patel RP, O’Donnell VB (1998) Pathophysiology of nitric oxide and related 
species: free radical reactions and modification of biomolecules. Mol Aspects Med 19(4–
5):221–357. 
307.  Larena M, Regner M, Lobigs M (2013) Cytolytic effector pathways and IFN-γ help 
protect against Japanese encephalitis. Eur J Immunol 43(7):1789–1798. 
308.  Liu T, Chambers TJ (2001) Yellow Fever Virus Encephalitis: Properties of the Brain-
Associated T-Cell Response during Virus Clearance in  Normal and Gamma Interferon-
Deficient Mice and Requirement for CD4+ Lymphocytes. J Virol 75(5):2107–2118. 
309.  Engelmann F, et al. (2014) Pathophysiologic and Transcriptomic Analyses of 
Viscerotropic Yellow Fever in a Rhesus Macaque Model. PLoS Negl Trop Dis 
8(11):e3295. 
310.  Rosen L (1958) Experimental infection of New World monkeys with dengue and yellow 
fever viruses. Am J Trop Med Hyg 7(4):406–410. 
311.  Tesh RB, et al. (2001) Experimental Yellow Fever Virus Infection in the Golden Hamster 
(Mesocricetus auratus). I. Virologic, Biochemical, and Immunologic Studies. J Infect Dis 
183(10):1431–1436. 
312.  Xiao S-Y, Zhang H, Guzman H, Tesh RB (2001) Experimental Yellow Fever Virus 
Infection in the Golden Hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 
183(10):1437–1444. 
 128 
313.  Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y (2009) Activity of T-705 in a 
Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically 
Related Compound, T-1106. Antimicrob Agents Chemother 53(1):202–209. 
314.  Julander JG, et al. (2014) BCX4430, a Novel Nucleoside Analog, Effectively Treats 
Yellow Fever in a Hamster Model. Antimicrob Agents Chemother 58(11):6607–6614. 
315.  Julander JG, Ennis J, Turner J, Morrey JD (2011) Treatment of Yellow Fever Virus with 
an Adenovirus-Vectored Interferon, DEF201, in a Hamster Model▿. Antimicrob Agents 
Chemother 55(5):2067–2073. 
316.  Fitzgeorge R, Bradish CJ (1980) Differentiation of Strains of Yellow Fever Virus in γ-
irradiated mice. J Gen Virol 50(2):345–356. 
317.  Fitzgeorge R, Bradish CJ (1980) The In Vivo Differentiation of Strains of Yellow Fever 
Virus in Mice. J Gen Virol 46(1):1–13. 
318.  Thibodeaux BA, et al. (2012) A small animal peripheral challenge model of yellow fever 
using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 
30(21):3180–3187. 
319.  Green A (2016) Yellow fever continues to spread in Angola. The Lancet 
387(10037):2493. 
320.  Woodall JP, Yuill TM (2016) Why is the yellow fever outbreak in Angola a ‘threat to the 
entire world’? Int J Infect Dis 48:96–97. 
321.  Lucey D, Gostin LO (2016) A yellow fever epidemic: A new global health emergency? 
JAMA 315(24):2661–2662. 
322.  Vasconcelos PFC, Monath TP (2016) Yellow Fever Remains a Potential Threat to Public 
Health. Vector-Borne Zoonotic Dis 16(8):566–567. 
323.  Gotuzzo E, Yactayo S, Córdova E (2013) Efficacy and Duration of Immunity after Yellow 
Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years. Am J 
Trop Med Hyg 89(3):434–444. 
324.  Barrett AD, Teuwen DE (2009) Yellow fever vaccine — how does it work and why do 
rare cases of serious adverse events take place? Curr Opin Immunol 21(3):308–313. 
325.  Breugelmans JG, et al. (2013) Adverse events following yellow fever preventive 
vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 
31(14):1819–1829. 
326.  Tao D, et al. (2005) Yellow fever 17D as a vaccine vector for microbial CTL epitopes 
protection in a rodent malaria model. J Exp Med 201(2):201–209. 
 129 
327.  Martins MA, et al. (2013) Immunogenicity of Seven New Recombinant Yellow Fever 
Viruses 17D Expressing Fragments of SIVmac239 Gag, Nef, and Vif in Indian Rhesus 
Macaques. PLOS ONE 8(1):e54434. 
328.  Monath TP, et al. (2002) Clinical proof of principle for ChimeriVaxTM: recombinant live, 
attenuated vaccines against flavivirus infections. Vaccine 20(7–8):1004–1018. 
329.  Guirakhoo F, et al. (2002) Viremia and Immunogenicity in Nonhuman Primates of a 
Tetravalent Yellow Fever–Dengue Chimeric Vaccine: Genetic Reconstructions, Dose 
Adjustment, and Antibody Responses against Wild-type Dengue Virus Isolates. Virology 
298(1):146–159. 
330.  Theiler M, Smith HH (1937) The Effect of Prolonged Cultivation in Vitro Upon the 
Pathogenicity of Yellow Fever Virus. J Exp Med 65(6):767–786. 
331.  Galler R, Freire M da S, Jabor AV, Mann GF (1997) The yellow fever 17D vaccine virus: 
molecular basis of viral attenuation and its use as an expression vector. Braz J Med Biol 
Res 30(2):157–168. 
332.  Camacho LAB, et al. (2004) Immunogenicity of WHO-17D and Brazilian 17DD yellow 
fever vaccines: a randomized trial. Rev Saúde Pública 38(5):671–678. 
333.  Jennings AD, Whitby JE, Minor PD, Barrett ADT (1993) Comparison of the nucleotide 
and deduced amino acid sequences of the structural protein genes of the yellow fever 
17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses. 
Vaccine 11(6):679–681. 
334.  Hahn CS, Dalrymple JM, Strauss JH, Rice CM (1987) Comparison of the virulent Asibi 
strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad 
Sci U S A 84(7):2019–2023. 
335.  Douam F, et al. (2017) Single-cell tracking of flavivirus RNA uncovers species-specific 
interactions with the immune system dictating disease outcome. Nat Commun 8:14781. 
336.  Belsher JL, et al. (2007) Fatal multiorgan failure due to yellow fever vaccine-associated 
viscerotropic disease. Vaccine 25(50):8480–8485. 
337.  Neves PCC, et al. (2010) CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-γ at 
5–7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of 
classical antigen-specific T cell responses. Vaccine 28(51):8183–8188. 
338.  Mandl JN, et al. (2011) Distinctive TLR7 Signaling, Type I IFN Production, and 
Attenuated Innate and Adaptive Immune Responses to Yellow Fever Virus in a Primate 
Reservoir Host. J Immunol 186(11):6406–6416. 
339.  Bayer A, et al. (2016) Type III Interferons Produced by Human Placental Trophoblasts 
Confer Protection against Zika Virus Infection. Cell Host Microbe 19(5):705–712. 
 130 
340.  Gaucher D, et al. (2008) Yellow fever vaccine induces integrated multilineage and 
polyfunctional immune responses. J Exp Med 205(13):3119–3131. 
341.  Jennings AD, et al. (1994) Analysis of a Yellow Fever Virus Isolated from a Fatal Case of 
Vaccine-Associated Human Encephalitis. J Infect Dis 169(3):512–518. 
342.  Jong R de, et al. (1998) Severe Mycobacterial and Salmonella Infections in Interleukin-12 
Receptor-Deficient Patients. Science 280(5368):1435–1438. 
343.  Jouanguy E, et al. (1997) Partial interferon-gamma receptor 1 deficiency in a child with 
tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. J 
Clin Invest 100(11):2658–2664. 
344.  Ramirez-Alejo N, Santos-Argumedo L (2014) Innate Defects of the IL-12/IFN-γ Axis in 
Susceptibility to Infections by Mycobacteria and Salmonella. J Interferon Cytokine Res 
34(5):307–317. 
345.  Yossef R, Rosental B, Appel MY, Hershkovitz O, Porgador A (2012) Upregulation of 
MHC class I expression following dengue virus infection: the mechanism at the promoter 
level. Expert Rev Anti Infect Ther 10(3):285–287. 
346.  Gardner CL, Burke CW, Higgs ST, Klimstra WB, Ryman KD (2012) Interferon-
alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-
type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 
vaccine candidate. Virology 425(2):103–112. 
347.  Liang J-J, Liao C-L, Liao J-T, Lee Y-L, Lin Y-L (2009) A Japanese encephalitis virus 
vaccine candidate strain is attenuated by decreasing its interferon antagonistic ability. 
Vaccine 27(21):2746–2754. 
348.  White LJ, Wang J-G, Davis NL, Johnston RE (2001) Role of Alpha/Beta Interferon in 
Venezuelan Equine Encephalitis Virus Pathogenesis: Effect of an Attenuating Mutation in 
the 5′ Untranslated Region. J Virol 75(8):3706–3718. 
349.  Presti RM, Popkin DL, Connick M, Paetzold S, Virgin HW (2001) Novel Cell Type–
Specific Antiviral Mechanism of Interferon γ Action in Macrophages. J Exp Med 
193(4):483–496. 
350.  Liu S-Y, Sanchez DJ, Aliyari R, Lu S, Cheng G (2012) Systematic identification of type I 
and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A 109(11):4239–
4244. 
351.  Cho H, Shrestha B, Sen GC, Diamond MS (2013) A Role for Ifit2 in Restricting West Nile 
Virus Infection in the Brain. J Virol 87(15):8363–8371. 
352.  Riquelme P, et al. (2013) IFN-γ-induced iNOS Expression in Mouse Regulatory 
Macrophages Prolongs Allograft Survival in Fully Immunocompetent Recipients. Mol 
Ther 21(2):409–422. 
 131 
353.  Coccia EM, et al. (2002) Protein inhibitor of activated signal transducer and activator of 
transcription (STAT)-1 (PIAS-1) regulates the IFN-γ response in macrophage cell lines. 
Cell Signal 14(6):537–545. 
354.  Colasanti M, Persichini T, Venturini G, Ascenzi P (1999) S-nitrosylation of viral proteins: 
molecular bases for antiviral effect of nitric oxide. IUBMB Life 48(1):25–31. 
355.  Akaike T, et al. (2000) Viral mutation accelerated by nitric oxide production during 
infection in vivo. FASEB J 14(10):1447–1454. 
356.  Dunne KA, et al. (2013) Increased S-Nitrosylation and Proteasomal Degradation of 
Caspase-3 during Infection Contribute to the Persistence of Adherent Invasive Escherichia 
coli (AIEC) in Immune Cells. PLOS ONE 8(7):e68386. 
357.  McElroy KL, Tsetsarkin KA, Vanlandingham DL, Higgs S (2006) Manipulation of the 
yellow fever virus non-structural genes 2A and 4B and the 3’non-coding region to 
evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut. Am J 
Trop Med Hyg 75(6):1158–1164. 
358.  McElroy KL, Tsetsarkin KA, Vanlandingham DL, Higgs S (2006) Role of the yellow 
fever virus structural protein genes in viral dissemination from the Aedes aegypti 
mosquito midgut. J Gen Virol 87(10):2993–3001. 
359.  Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC (2006) CNS immune privilege: 
hiding in plain sight. Immunol Rev 213:48–65. 
360.  Lannes N, et al. (2017) Interactions of human microglia cells with Japanese encephalitis 
virus. Virol J 14:8. 
361.  Weaver SC (2014) Arrival of Chikungunya Virus in the New World: Prospects for Spread 
and Impact on Public Health. PLoS Negl Trop Dis 8(6). 
doi:10.1371/journal.pntd.0002921. 
362.  Gubler DJ, Vasilakis N, Musso D (2017) History and Emergence of Zika Virus. J Infect 
Dis 216(suppl_10):S860–S867. 
363.  Vasilakis N, Cardosa J, Hanley KA, Holmes EC, Weaver SC (2011) Fever from the forest: 
prospects for the continued emergence of sylvatic dengue virus and its impact on public 
health. Nat Rev Microbiol 9(7):532–541. 
364.  Cooper HM, Paterson Y (2001) Purification of immunoglobulin G fraction from 
antiserum, ascites fluid, or hybridoma supernatant. Curr Protoc Mol Biol Chapter 
11:Unit11.14. 
365.  Yin J, Gardner CL, Burke CW, Ryman KD, Klimstra WB (2009) Similarities and 
Differences in Antagonism of Neuron Alpha/Beta Interferon Responses by Venezuelan 
Equine Encephalitis and Sindbis Alphaviruses. J Virol 83(19):10036–10047. 
 132 
366.  Laurent-Rolle M, et al. (2014) The Interferon Signaling Antagonist Function of Yellow 
Fever Virus NS5 Protein Is Activated by Type I Interferon. Cell Host Microbe 16(3):314–
327. 
367.  Laurent-Rolle M, et al. (2010) The NS5 protein of the virulent West Nile virus NY99 
strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol 
84(7):3503–3515. 
368.  Woodson SE, Holbrook MR (2011) Infection of hepatocytes with 17-D vaccine-strain 
yellow fever virus induces a strong pro-inflammatory host response. J Gen Virol 
92(10):2262–2271. 
369.  Yang T-C, et al. (2009) Japanese encephalitis virus NS2B-NS3 protease induces caspase 3 
activation and mitochondria-mediated apoptosis in human medulloblastoma cells. Virus 
Res 143(1):77–85. 
370.  Prikhod’ko GG, Prikhod’ko EA, Pletnev AG, Cohen JI (2002) Langat Flavivirus Protease 
NS3 Binds Caspase-8 and Induces Apoptosis. J Virol 76(11):5701–5710. 
371.  Prikhod’ko GG, Prikhod’ko EA, Cohen JI, Pletnev AG (2001) Infection with Langat 
Flavivirus or expression of the envelope protein induces apoptotic cell death. Virology 
286(2):328–335. 
372.  King P, Goodbourn S (1998) STAT1 Is Inactivated by a Caspase. J Biol Chem 
273(15):8699–8704. 
 
